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Abbreviations of recruited proteins described in Chapter 4 are explained in the 
corresponding tables in the same chapter. 
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1.1 PHYSIOLOGY OF ANDROGEN ACTION 
Androgens play important roles during fetal male sexual differentiation, but also in 
development and maintenance of secondary male characteristics, and during 
initiation and maintenance of spermatogenesis (George and Wilson, 1994). In 
addition, androgens have a role in female physiology. Androgen action is primarily 
exerted by testosterone (T), but also by its more active metabolite 5α-
dihydrotestosterone (DHT). The conversion of T to DHT occurs in some androgen 
target tissues (e.g. prostate) by the enzyme 5α-reductase type 2. Although both 
hormones act via binding to the same androgen receptor (AR), T and DHT have 
quite separate roles during male sexual differentiation. T acts on development of 
muscles, the larynx (male voice), the Wolffian duct and its derived structures 
(epididymides, vasa deferentia, seminal vesicles and ejaculatory ducts). DHT plays 
a role in other androgen target tissues, like the skin, hair follicles, the urogenital 
sinus, the urogenital tubercle, the urogenital fold, the urogenital swelling and their 
derived structures (prostate gland, scrotum, urethra, glans, shaft, penis) (Fig. 1-1). 
Both hormones act on spermatogenesis and can influence sex drive and behaviour 
(McLachlan et al., 2002; Wilson, 2001; Gooren and Kruijver, 2002). The precise 
reasons for the different roles of DHT and T are not understood. Although T and 
DHT bind the AR with similar high affinity, DHT can induce a higher AR 
transcriptional activation compared to T (Wilson and French, 1976; Askew et al., 
2007). The higher AR activity is likely caused by the twofold higher affinity for co-
factors when the AR is bound to DHT instead of T (Askew et al., 2007). In addition, 
the lower affinity for co-factors of T liganded AR accounts for a three to four times 
faster dissociation of T compared to DHT (Askew et al., 2007). 
T and DHT are often rapidly converted in vitro into inactive metabolites during 
androgen-responsive reporter gene assays performed in cell lines. Therefore, stable 
synthetic androgenic agonists such as methyltrienolone (RU1881; 17β-hydroxy-17α-
methyl 4,9,11,-estratrien-3-one) and mibolerone (7α,17α-dimethyl-19 
nortestosterone) are predominantly being used in such assays. 
An important tool in studying androgen action are anti-androgens. These 
compounds act by binding to the AR and inducing a conformational change resulting 
in an inactive or in a partially inactive receptor. Two anti-androgens with partial 
agonistic and partial antagonistic properties are cyproterone acetate (CPA) and 
mifepristone (RU38486), whereas hydroxyflutamide (OH-F), nilutamide and 
bicalutamide are pure anti-androgens (Neumann and Topert, 1986; Raynaud and 
Ojasoo, 1986; Furr et al., 1987). Because of their inhibitory action, anti-androgens 
are used extensively in the treatment of several diseases and disorders, such as 
prostate cancer, and hypervirilisation syndromes. 
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Figure 1-1 
Schematic overview of androgen dependent development of different target tissues initiated by 
testosterone (T) and/or dihydrotestosterone (DHT). Adapted from Berne and Levy; Principles of 
human physiology, 3rd Ed., 2000, Mosby Inc., St. Louis, USA, Chapter 49, Figure 49-5.
1.2 THE ANDROGEN RECEPTOR (AR): CLONING, GENOMIC
ORGANISATION, mRNA, PROTEIN AND FUNCTIONAL DOMAIN 
STRUCTURE
The AR belongs, together with progesterone (PR), glucocorticoid (GR), estrogen 
(ER) and mineralocorticoid (MR) receptors, to the steroid hormone receptor (SHR)
family. This family in turn belongs to the superfamily of nuclear receptors (NRs). As
the name nuclear receptor indicates, these receptors, play a role in the nucleus and 
once activated they act as transcription factors to regulate genes positively or 
negatively.
The human AR cDNA was cloned in 1988 by several groups just a few years 
after cloning of the GR, ERĮ, MR and PR cDNAs (Chang et al., 1988; Lubahn et al., 
1988; Trapman et al., 1988). The AR gene is located on the human X chromosome 
at q11.1-q12 and consists of 8 exons (Fig. 1-2). The gene expands 186,587 kilo 
bases (kb) in total (Brown et al., 1989; Kuiper et al., 1989; www.genecards.org).
Two mRNAs of 10.6 and 8.5 kb respectively, are transcribed from the AR gene and 
both contain a 1.1 kb 5’-untranslated region (UTR) and a 2.7 kb open reading frame 
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(ORF) (Faber et al., 1991; Tilley et al., 1990; Trapman et al., 1988). Furthermore, 
the 10.6 kb transcript contains a 3’-UTR of 6.8 kb, whereas the 8.5 kb transcript 
lacks part of the 3’-UTR (Faber et al., 1991). There are no indications for any
preferential use of either one of the two transcripts and neither for a specific function.
In the human prostate and in genital skin fibroblasts predominantly the 10.6 kb 
mRNA is being expressed. 
Xq11-12
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Figure 1-2 
Genomic organization and protein domain structure of the human androgen receptor
The AR gene is located on the human X chromosome at Xq11-12 and spans more than 186 kb. The
gene encodes a protein of approximately 919 amino acids depending on the length of the variable
polyglutamine and polyglycine stretches in the NH2-terminal domain (NTD). The NTD, the DNA
binding domain (DBD), the hinge region, the ligand-binding domain (LBD), activation functions (AF),
and polyglutamine and polyglycine repeats are indicated in the figure.
The number of amino acid residues in the AR protein varies between individuals
due to the polymorphic polyglutamine stretch and the less variable polyglycine
stretch in the NH2-terminal domain (NTD) (Faber et al., 1989; Sleddens et al., 1993). 
Throughout this thesis the numbering of the AR is based on 919 amino acid 
residues according to the AR-data base (www.mcgill.ca/androgendb; Gottlieb et al., 
2004b). On SDS-PAGE the AR appears as a 110 - 112 kilo Dalton (kDa) doublet. 
However, in the presence of androgens a 114 kDa band also appears. Those three 
bands represent different phosphorylated isoforms (Kuiper and Brinkmann, 1995; 
Jenster et al., 1994; Kuiper et al., 1991; Wong et al., 2004). The AR protein is
expressed in the male as well as in the female reproductive tract and in tissues not 
involved in reproductive functions (Quigley et al., 1995). In these tissues the 
expression of the AR protein is regulated by androgens at the transcriptional and 
post-transcriptional level, and by follicle-stimulating hormone (FSH) (Wolf et al., 
1993; Blok et al., 1989; Dai and Burnstein, 1996). 
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1.2.1 Functional domain structure of the AR 
Similar to the other SHRs, the AR consists of 4 different functional domains (Fig. 1-
2): an NTD, a DNA binding domain (DBD), a hinge region and a ligand binding 
domain (LBD). Besides this similarity in the organisation of functional domains, the 
amino acid homology between the DBDs of SHRs is relatively high (approximately 
80%) and for the LBD moderately high (approximately 50%). However, the 
homologies between the different NTDs and between the different hinge regions are 
relatively low (<15%) (Faber et al., 1989; Trapman et al., 1988; Evans, 1988). 
1.2.1.1 NH2-terminal domain 
This domain is also named the transactivation domain, since it contains the major 
transcriptional activation functions. It determines to a large extent the androgen-
specific regulation of gene expression, because of its unique amino acid 
composition, which differs extensively from that of the NTD of the other SHRs (Grad 
et al., 2001). It consists of 538 amino acid residues, which are encoded by the 3’-
part of exon 1 (Faber et al., 1989; Kuiper et al., 1989). Two Transcription Activation 
Units (TAUs) exist within this domain: residues 51-217 are designated as TAU-1 
and residues 376-510 are named TAU-5 (Jenster et al., 1991; Jenster et al., 1995). 
Remarkably, TAU-5 regulates transcription activation if the LBD is deleted, which 
suggests that TAU-5 in the full length AR is suppressed by the LBD (Jenster et al., 
1995).
Another functional characteristic of the NTD is its interaction with the LBD once 
hormone has been bound, the so-called NH2-/COOH-terminal domain interaction 
(Langley et al., 1995; Doesburg et al., 1997; Ikonen et al., 1997; Berrevoets et al., 
1998). The NH2-terminal region involved in the interaction with the LBD has been 
mapped to the first 36 amino acids, which contain the 23FQNLF27 motif. A second
motif in the NTD with the sequence 433WHTLF437 might bind to a different region of 
the LBD (He et al., 2000). Interaction of these NH2-terminal domain motifs with the 
LBD decreases the dissociation rate of bound androgen. Furthermore the NH2-
/COOH-terminal domain interaction plays a role in stabilisation of the AR dimer via 
intermolecular interactions (Zhou et al., 1995b). More details about the NH2-/COOH-
terminal domain interaction will be described in paragraph 1.2.1.4 in the section on 
the LBD. 
1.2.1.2 DNA binding domain 
The core DBD of the human AR consists of amino acids 554-636 and is encoded by 
exons 2 and 3 of the AR gene (Brinkmann et al., 1989; Kuiper et al., 1989). The 
DBD has two zinc clusters. Each cluster contains 4 cysteine residues involved in 
coordination binding of a zinc atom. Each cluster has its own specific function. The 
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first zinc cluster contains the P(roximal)-box sequence (577GSCKV581), which is
involved in the recognition of specific androgen response elements (AREs) in the 
DNA (Claessens et al., 2001). The second zinc cluster harbours the D(istal)-box 
(596ASRND600) and other residues, and plays a role in the DNA-dependent
dimerisation of the AR (Luisi et al., 1991; Freedman, 1992). Another functional
characteristic of the DBD is its non-classical nuclear export signal, a 15 amino acid 
residues motif located between the two zinc clusters at position 580-595 (Black et
al., 2001). 
As a transcription factor, the AR can bind to AREs in promoter or enhancer 
regions of androgen target genes. High affinity steroid hormone response elements
(HREs) consist of two half-sites organised as an inverted repeat with a variable
three nucleotides spacer, 5’- AGAACAnnnTGTTCT-3’. AR, PR, GR and MR bind as
homodimers to this element due to identical P-boxes (Beato, 1989). Therefore, 
hormone and tissue specific responses of different receptors are induced by
additional determinants in receptor specificity. Important for specificity are DNA 
sequences flanking the hormone response element, receptor interactions with other
proteins and receptor concentrations. It has been shown that the effect of co-factors
on AR functioning might be different on either a general HRE or on a specific ARE 
(Geserick et al., 2003). It was previously thought that the inverted repeat of the HRE 
induces a tail-to-tail dimerisation of the AR and that a direct repeat induces a head-
to-tail dimerisation (Schoenmakers et al., 1999). However, this has been 
disapproved by crystal structure studies of a direct ARE repeat complexed with an 
AR dimer, which binds in a tail-to-tail fashion (Shaffer et al., 2004). Although a 
number of specific AREs have been identified in AR target gene promoters and in 
enhancer sequences, there is not a common specific ARE consensus sequence.
Therefore, AR binding response elements can be divided into 4 groups: (A) high 
affinity specific and (B) high affinity non-specific elements and (C) low affinity
specific and (D) low affinity non-specific elements (Claessens et al., 2001; Table 1-
1).
1.2.1.3 Hinge region
The hinge region is located between the DBD and the LBD, and stretches roughly 
between amino acid residues 622-670, which are encoded by parts of exons 3 and 
4. It is considered to be a flexible spacer, and its size and composition is not 
conserved between the different SHRs. After deletion of the hinge region, the AR 
appears to be more stable and displays an increased transcriptional activity,
suggesting that the hinge region has a negative influence on AR stability (Tanner et
al., 2004). A similar inhibitory effect on the activation function 2 (AF2) sequence
region in the LBD has also been found for a particular part of the hinge region 
located between amino acid residues 628-646 (Wang et al., 2001). The hinge region 
has been implicated in several other functions such as DNA binding, Nuclear
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receptor co-repressor (N-CoR) binding, protein-protein interactions and nuclear 
localisation via its bipartite nuclear localisation signal (Haelens et al., 2003; 
Schoenmakers et al., 1999; Simental et al., 1991; Jenster et al., 1993; Zhou et al., 
1994; Beitel et al., 2002; Fu et al., 2002; Fu et al., 2000). 
Table 1-1 Classification of androgen response elements 
(A) High affinity, non-specific sequence reference 
GRE GGTACA aac TGTTCT (Beato, 1989) 
C3(1) ARE AGTACT tga TGTTCT (Claessens et al., 1989) 
PSA ARE1 AGAACA gca AGTGCT (Riegman et al., 1991) 
SLP-HRE-3 GAAACA gcc TGTTCT (Loreni et al., 1988) 
(B) High affinity, AR-specific
PB-ARE2 GGTTCT tgg AGTACT (Rennie et al., 1993)
SLP-HRE-2 TGGTCA gcc AGTTCT (Loreni et al., 1988) 
SC ARE1.2 GGCTCT ttc AGTTCT (Verrijdt et al., 1999) 
(C) Low affinity, non-specific
PB-ARE1 ATAGCA tct TGTTCT (Rennie et al., 1993)
MVDP pARE TGAAGT tcc TGTTCT (Darne et al., 1997) 
GPX5 ATCCTA tgt TGTTCT (Lareyre et al., 1997) 
CRP2 AGAAGA aaa TGTACA (Devos et al., 1997) 
(D) Low affinity, AR-specific
SC ARE AGCAGG ctg TGTCCC (Haelens et al., 1999) 
SARG+4.6 TGTGCT aac TGTTCT (Steketee et al., 2004; Haelens 
et al., 1999)
Based on gel shift assays as well as transfection studies (Claessens et al., 1989; Schoenmakers et 
al., 1999; Vanaken et al., 1996; Schoenmakers et al., 2000), AREs can be divided into four classes: 
high affinity, non-specific (A), high affinity, specific (B), low affinity, non-specific (C) and low affinity, 
specific (D). Typical examples with names, sequences and their references are given. Adapted from 
(Claessens et al., 2001). 
1.2.1.4 Ligand binding domain 
The LBD is encoded by part of exon 4, exons 5 – 7 and part of exon 8, and consists 
of amino acid residues 671-919 (Brinkmann et al., 1989; Kuiper et al., 1989). This 
region is the second most conserved part of SHRs (approximately 50%) and its 3D 
structure is highly conserved within the NR family (Wurtz et al., 1996). The 3-
dimensional structure of the AR LBD has been determined in the presence of DHT 
and R1881, and predicts 11 alpha-helices (helix 1 – helix 12; there is no helix 2) and 
four short beta-strands arranged in two anti-parallel beta-sheets (Matias et al., 2000; 
Sack et al., 2001). Helix 12 of the AR, amino acid residues 892-908, is longer than 
in other NRs, and is split into two shorter helical segments (Matias et al., 2000; 
Poujol et al., 2000; Sack et al., 2001). In the agonist-bound conformation, the folding 
of helix 12 allows a closure of the ligand binding pocket (LBP), also named binding 
function 1 (BF1) (Matias et al., 2000; Poujol et al., 2000; Sack et al., 2001; 
Estebanez-Perpina et al., 2007). Depending on the kind of hormone, this 
conformational change allows the AR to recruit selectively co-activators or co-
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repressors and to communicate with proteins of the transcription initiation complex 
(Berrevoets et al., 2004; Wang et al., 2005c). Before the 3D crystallographic
structure of the AR LBD was determined, its dynamic folding in the presence of
different ligands was predicted by limited proteolytic digestion experiments (Kuil et
al., 1995). Upon agonist binding a conformational change occurs, which is different
from that found in the presence of anti-androgens (Kuil and Mulder, 1995). 
The AR LBD also contains an AF2 region like the other NRs. However, this AF2
is much weaker compared to those in the other SHRs (He et al., 2004; Jenster et al.,
1995). Nevertheless, the AF2 region is very important for the maximal transcriptional 
activity of the AR and functions as an important interaction domain for the NH2-
terminal domain and for co-factors (Doesburg et al., 1997; Berrevoets et al., 1998;
Langley et al., 1998). The AF2 consists of 6-8 crucial amino acid residues, which
form a hydrophobic cleft that can interact with short D-helices present in co-
activators and the AR NTD. This interaction site is also named BF-2 (Estebanez-
Perpina et al., 2007). The 23FQNLF27 motif of the NTD, which is part of an 
amphipatic D-helix, interacts specifically with the BF-2 site (Berrevoets et al., 1998; 
He et al., 2000; Steketee et al., 2002; Dubbink et al., 2006). To mediate NH2-
/COOH-terminal domain interaction and co-activator binding, the charged residues
surrounding the hydrophobic cleft interact with oppositely charged residues flanking 
the 23FQNLF27 motif (He et al., 2000; Steketee et al., 2002; Dubbink et al., 2004). 
Co-regulatory proteins (see section 1.5) also bind to the BF-2 to enhance the 
transcriptional activity of the AR (Glass and Rosenfeld, 2000). Most of these co-
regulatory proteins have an LXXLL motif (Heery et al., 1997; Voegel et al., 1998).
Also co-factors with a FXXLF motif can bind and co-activate the AR (Hsu et al., 
2003). In the same way as the FXXLF motif, charged residues flanking the LXXLL 
motif interact with the charged residues surrounding the hydrophobic cleft in the 
LBD (He et al., 2000). 
The dynamic behavior of the AR LBD is not restricted to a repositioning of helix 
12 upon hormone binding. The crystal structures of either a FXXLF or a LXXLL motif
embedded in peptides and bound to the AR LBD predict a difference in the 
positioning of just a few amino acid residues of the hydrophobic interaction surface 
(He et al., 2004). Binding of the FXXLF motif is more preferred than binding of the 
LXXLF motif. In the same study it was demonstrated that substitution of the AR AF2 
surface amino acid residues by those of other NRs results in the transition of a 
FXXLF motif favourable binding into an LXXLL motif favourable binding (He et al., 
2004). The preferred binding for the FXXLF motif by the AR LBD is also predicted 
by a computer model, in which the phenylalanine residue at position 27 fits in the 
deep groove of the AR hydrophobic cleft and not in the shallow groove of the ERĮ
LBD (Dubbink et al., 2004). 
Interestingly, a previously unknown regulatory surface cleft, named BF-3, has 
been recently identified in the AR LBD (Estebanez-Perpina et al., 2007). BF-3 
comprises of Ile-672, Phe-673, Pro-723, Gly-724, Asn-727, Phe-826, Glu-829, Asn-
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833, Glu-837 and Arg-840 (Estebanez-Perpina et al., 2007). The AR transcriptional 
activity and co-activator binding can be decreased by binding to the BF-3 of thyroid 
hormones triiodothyronine (T3) and TRIAC and three nonsteroidal anti-inflammatory 
drugs (Estebanez-Perpina et al., 2007). In addition, several mutations of the amino 
acid residues of BF-3 have been found in subjects with either androgen insensitivity 
syndrome (AIS, loss of function mutation) or in prostate cancer (gain of function 
mutation) (Gottlieb et al., 2004b). Mutational analyses have shown the requirement 
of several of these amino acid residues for AR transactivity. However, these 
analyses have been performed only in the presence of DHT (Estebanez-Perpina et 
al., 2007). The influence of each of these residues in the presence of T3, TRIAC or 
other nonsteroidal anti-inflammatory drugs is therefore unknown. 
1.3 AR FUNCTION IN GENERAL 
All SHRs, including the AR, have comparable 3D structures of LBD and DBD and 
have also a comparable modular domain structure. In addition the general 
mechanism of steroid hormone action display many features, which are also valid 
for the mechanism of androgen action. Testosterone freely diffuses through the cell 
membrane into the cytoplasm of an androgen target cell, the so-called free hormone 
hypothesis, and binds subsequently to the AR either directly or after conversion to 
DHT. Before hormone binding, the AR is mainly cytoplasmic and is kept inactive by 
a heat shock protein complex of Hsp90, Hsp70 and FKBP52 (Jenster et al., 1993; 
Veldscholte et al., 1992b; Cheung-Flynn et al., 2005). In the absence of hormone, 
the cytoplasmic AR is constitutively phosphorylated on Ser-650 (Wong et al., 2004). 
Another study has shown a constitutive phosphorylation of Ser-94 (Gioeli et al., 
2002). Phosphorylation of the AR will be discussed extensively in section 1.4. Upon 
hormone binding the AR is further phosphorylated and the Hsp complexes are 
released (Veldscholte et al., 1992a). At the same time the AR translocates to the 
nucleus (Simental et al., 1991; Jenster et al., 1993; Jenster et al., 1991) and binds 
as homodimer to AREs in promoter and/or enhancer regions of androgen target 
genes to modulate gene transcription (Glass and Rosenfeld, 2000; Gobinet et al., 
2002).
There are some indications that the above described free diffusion model might 
not be complete. Recently it has been shown that testosterone bound to sex 
hormone binding globulin (SHBG) can be taken up by target cells via megalin, an 
endocytic receptor in reproductive tissues (Hammes et al., 2005). The inhibition of 
megalin-mediated uptake resulted in less cellular testosterone ex vivo and in a 
failure of testicular descent in megalin knockout male mice (Hammes et al., 2005). 
This suggests that testosterone can reach the AR by another mechanism than 
diffusion. Hsp90 seems to be essential for AR nuclear import. The blockade of 
Hsp90 by geldanamycin resulted in an arrest of the AR in the cytoplasm (Georget et 
al., 2002). 
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1.4 POST-TRANSLATIONAL MODIFICATION OF THE AR 
Hormone binding is not the only mechanism by which conformational changes 
and/or transcriptional activity of SHRs, including the AR, can be influenced. 
Modulation of the AR conformation and/or transcriptional activity can also occur via 
post-translational modifications, like acetylation, sumoylation, ubiquitylation and 
phosphorylation (Fig 1-3). In the following sections, these 4 different types of AR 
post-translational modifications are being described and discussed.  
 
 
 
 
Figure 1-3 
Post-translational modifications of the human androgen receptor 
The known amino acid residues which can be acetylated, sumoylated, or phosphorylated are 
indicated in the schematic view of the AR. 
 
 
1.4.1 Acetylation 
Acetylation is the reversible attachment of an acetyl group to lysine residues 
catalysed by an acetyltransferase. The histone acetylases p300, p300/cAMP-
response element-binding (p300/CREB) protein (Fu et al., 2000) and co-factor Tat-
interactive protein 60 (Tip60) (Gaughan et al., 2002) can directly acetylate the AR in 
vitro and in vivo at a highly conserved 630KLKK633 motif in the hinge region. 
Substitutions of the residues Lys-630, Lys-632 or Lys-633 by an alanine reduce the 
DHT-induced transactivation of androgen-responsive reporter genes (Fu et al., 
2000) and co-activation by SRC1 (steroid hormone receptor co-activator 1), Ubc9, 
TIP60 and p300 (Fu et al., 2002). However, the acetylation mutants are still able to 
transrepress other androgen-responsive reporter genes and display a tenfold 
enhancement of the interaction with N-CoR (Fu et al., 2002). In another study, it was 
shown that compared to the wild-type AR, the AR lysine mutants display a marked 
delay in ligand dependent nuclear translocation (Thomas et al., 2004). A study, 
published already in 1993 showed, that the acetylation motif 630KLKK633 is part of the 
bipartite nuclear localisation signal (Jenster et al., 1993). This suggests that 
phosphorylation
acetylation
sumoylation
NTD DBD LBD
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acetylation might play a role in AR nuclear localisation. Furthermore, the acetylation 
mutants undergo misfolding and form aggregates. They also co-localise within the 
cell with an ubiquitin-protein isopeptide E3 ligase carboxyl terminus of Hsc70 
interacting protein (CHIP), and inhibit proteasome activity (Thomas et al., 2004). 
Interestingly, AR lysine mutants mimicking neutral polar substitution acetylation 
(K630Q and K630T) display an enhanced p300 binding and their transactivation 
activity in the presence of DHT can not be influenced by the antagonist Flutamide, in 
contrast to that of the wild-type AR (Fu et al., 2003). This indicates that AR 
acetylation sites govern ligand sensitivity and specificity. Unfortunately, ligand 
binding characteristics of these mutants were not determined.
To summarise: acetylation of AR is determining its association with its co-
regulators (co-activators and co-repressors), its proper folding and nuclear 
translocation. Furthermore, there is an indication that acetylation modulates AR 
ligand sensitivity and specificity. 
1.4.2 Ubiquitylation 
Ubiquitylation is the reversible coupling of ubiquitin, a small polypeptide, to lysines 
via an E3 ubiquitin ligase. The ubiquitylation sites of the AR have not been 
determined yet. E3 ubiquitin ligase Mdm2 (mouse double minute 2), Akt kinase and 
the AR are reported to form complexes in which the AR becomes initially 
phosphorylated (Gaughan et al., 2005; Lin et al., 2002), and subsequently 
ubiquitylated and finally degradated via the 26S proteasome. These processes are 
impaired in Mdm2 negative MEFs (mouse embryo fibroblasts) (Lin et al., 2002). 
Degradation results in an overall lower AR transcriptional activation (Lin et al., 2002). 
Another protein with E3 ubiquitin ligase activity, androgen receptor N-terminal-
interacting protein (ARNIP) can interact with the AR in a ligand-independent manner 
(Beitel et al., 2002). However, no direct evidence for the ubiquitylation of the AR by 
ARNIP exists. ARNIP reduces the interaction between the NTD and the carboxy-
terminal domain of the AR, but has no effect on the transactivation of the full-length 
receptor (Beitel et al., 2002). The finding that mice deficient in the E3 ubiquitin ligase 
E6-associated protein (E6-AP) show strongly reduced androgen responses also 
indicates a possible role of ubiquitylation for regulating AR function (Smith et al., 
2002). These findings are in line with the suggested role of ubiquitylation in general, 
actually polyubiquitylation, which results in degradation of proteins (Thrower et al., 
2000). Interestingly, another AR interacting protein, tumour susceptibility gene (TSG) 
101, can induce monoubiquitylation of the AR and thereby enhances AR 
transactivation (Burgdorf et al., 2004). This transcriptional enhancement by 
monoubiquitylation has also been shown for other proteins (Schnell and Hicke, 2003) 
To summarise: ubiquitylation determines either AR degradation 
(polyubiquitylation) or AR transcriptional activation (monoubiquitylation). 
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1.4.3 Sumoylation 
Sumoylation is the reversible coupling of a small protein, small ubiquitin-like modifier
(SUMO, also called Sentrin), to lysine residues of proteins. This coupling is
mediated by a SUMO-E3 ligase. The sumoylation sites are in most cases
embedded in a consensus sequence (I/L/V)KXE, where X represents any amino
acid residue (Sternsdorf et al., 1999; Johnson and Blobel, 1999). In the AR several 
sumoylation sites have been identified. Substitution of Lys-386 by Arg in the AR 
reduces the sumoylation by SUMO-1 and results in an enhanced AR transactivation 
(Poukka et al., 2000). AR transactivation is even more enhanced when both Lys-386 
and Lys-520 are mutated, whereas a single mutation of Lys-520 does not have an 
influence (Poukka et al., 2000). This finding indicates that sumoylation of AR results 
in repression of its transcriptional activity. However, the trans-repressing activity of 
the AR in presence of co-repressors is unchanged after mutation of Lys-386 
(Poukka et al., 2000). Another study showed that mutation of Lys-386 or mutation of
both Lys-386 and Lys-520, resulted in inhibited SMRT interaction and repression 
(Dotzlaw et al., 2002). Also DNA binding by Lys-386 Arg mutant AR is unaffected as 
demonstrated in a promoter interference assay (Poukka et al., 2000) and in an in
vitro EMSA (electrophoretic mobility shift assay) (Callewaert et al., 2004). 
Lysine residue 386 in the AR is sumoylated by SUMO-E3 ligases, PIAS1 (protein 
inhibitor of activated STAT) and PIASxD/ARIP3 (Kotaja et al., 2002; Nishida and 
Yasuda, 2002). Remarkably, the effect of AR sumoylation by ectopically expressed 
PIASxD/ARIP3 and PIAS1 is cell-type dependent (Kotaja et al., 2002). It can result 
in either a reduced or an enhanced AR transactivation, depending on the response
element used in the assay (Geserick et al., 2003; Callewaert et al., 2004). In another
study it was shown that a PIAS like protein, without the RING finger-like ligase
domain, hZimp10, can interact with the AR and can enhance AR transactivation and 
sumoylation (Sharma et al., 2003).
A possible mechanism for the decreased transactivation observed after 
sumoylation of the AR, has been presented in a study. It was shown that in vitro 
sumoylation of AR can result in interaction with Daxx, which in turn reduces AR 
transactivation (Lin et al., 2004). Daxx can inhibit the transcriptional potential of 
several transcription factors and can therefore function as a kind of co-repressor. 
This effect is due to a reduced DNA binding of the AR as shown with EMSA and 
ChIP (chromatin immunoprecipitation) analyses (Lin et al., 2004). Furthermore, 
studies in human and rodent Sertoli cells consistently show an inverse correlation 
between the expression levels of AR and of SUMO-1 and their
compartmentalisation as determined with fluorescence microscopy (Vigodner et al.,
2005).
To summarise: sumoylation of the AR at a particular site can result in either a 
decreased or an increased transactivation potential of the AR protein, depending on 
the cell type and promoter context. The exact mechanism(s) remain to be elucidated.
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1.4.4 Phosphorylation 
Of all post-translational modifications of SHRs, phosphorylation is the most studied 
one. Phosphorylation by protein kinases in general is an important biological 
regulatory signalling mechanism in eukaryotic cells. In 1992, Fischer and Krebs 
received the Nobel Prize for medicine for their discovery of the impact of protein 
phosphorylation in a large number of cellular processes. About 518 kinases may be 
expressed in a cell, and one-third of all intracellular proteins may be phosphorylated, 
representing as many as 20,000 phosphoproteins, and approximately one of every 
400 diseases is associated with a defective protein kinase-mediated pathway 
(Hubbard and Cohen, 1993). Phosphorylation is often a trigger for switching from 
one cellular activity state to another and can therefore also regulate the function of 
transcription factors. Phosphorylation of transcription factors can regulate, for 
example, their DNA binding capacity, their interaction with other 
proteins/transcription factors, their degradation or their shuttling between cytoplasm 
and nucleus (Whitmarsh and Davis, 2000). 
1.4.4.1 Phosphorylation of the androgen receptor 
One of the most studied post-translational modifications of the AR protein is 
phosphorylation. However, it remains unclear what exactly the impact is of 
phosphorylation on the AR transactivation potential. Much more is known about 
which sites in the AR protein are phosphorylated. 
1.4.4.1.1 AR phosphorylation sites 
Van Laar et al. showed that the AR is a phosphoprotein and that extra 
phosphorylation of the AR is induced when cells are exposed to androgens, in 
addition to the so-called basal AR phosphorylation observed in the absence of 
androgens (van Laar et al., 1990; van Laar et al., 1991; Gioeli et al., 2002; Wong et 
al., 2004). Basal and hormone-induced phosphorylation occurs predominantly at 
serine residues which are mainly located in the NH2-terminal domain (Kuiper et al., 
1993; Gioeli et al., 2002; Kuiper and Brinkmann, 1995). Furthermore, the hormone-
induced increase in AR phosphorylation was not observed in the presence of anti-
androgens (Kemppainen et al., 1992). 
The first identified phosphosites of the AR, serine residues 81, 94, and 650, were 
found indirectly after mutational analyses in combination with SDS-PAGE (Jenster 
et al., 1994; Zhou et al., 1995a). Several years later the first non-mutational in vivo
phosphosite Ser-308 was detected by mass spectrometry (Zhu et al., 2001). Soon, 
more phosphosites, serine residues 16, 81, 94, 256, 308, 424, and 650, were all 
identified and confirmed as phosphosites by mutagenesis, peptide mapping and 
mass spectrometry (Gioeli et al., 2002; Wong et al., 2004). However, cell-free in
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vitro protein kinase assay studies on AR mutants also demonstrated serine residues
213, 515, and 791 as phosphosites (Lin et al., 2001; Wen et al., 2000; Yeh et al.,
1999). Recently, with the use of phosphoserine antibodies it was demonstrated that 
serine residues 81, 213, and 650 are also phosphosites in the AR (Black et al., 2004;
Gioeli et al., 2006; Taneja et al., 2005). 
1.4.4.1.2 Phosphorylation and AR isoforms 
The first experiment showing a correlation between AR phosphorylation and the 
appearance of AR isoforms, was established via SDS-PAGE gel electrophoresis
and by the use of alkaline phosphatase (Kuiper et al., 1991). Dephosphorylation by
alkaline phosphatase treatment in the absence of hormone resulted in the loss of 
the largest isoform. Substitution of phosphosite Ser-81 by a glycine residue resulted 
in the loss of the largest isoform irrespective of the presence of ligand (Jenster et al.,
1994). Similar results were obtained for the double-mutant S81/94A (Zhou et al., 
1995a). However, substitution of Ser-81 with an alanine residue resulted in the loss
of one isoform only in the presence of hormone (unpublished data). 
Thus, the influence of phosphorylation on the isoform appearance is somewhat
complex. With reversed-phase HPLC of 32P labelled AR it was demonstrated that 
after de novo AR synthesis, the 110 kDa isoform becomes immediately and 
predominantly phosphorylated on Ser-650 (Chapter 2). The larger isoform of 112 
kDa displayed an additional phosphorylation at Ser-94 (Chapter 2). The relationship 
between phosphorylation of Ser-94 and the appearance of the 112 kDa isoform is in 
agreement with immunoblot studies in which the phosphosite mutant S94A caused 
disappearance of the 112 kDa isoform in the absence of hormone and 
disappearance of the 114 kDa isoform in the presence of hormone (Jenster et al., 
1994; Fu et al., 2004). Furthermore, the appearance of the 114 kDa isoform induced 
by R1881 is directly linked to an overall increase in phosphorylation of several sites
as compared with the 110 and 112 kDa isoforms (Chapter 2). Van Laar et al. (1991) 
has shown previously that in the presence of hormone in addition to a stabilisation
of the AR protein also an extra 1.8 fold increase of AR phosphorylation can be 
induced.
In contrast with the S94A AR mutant, substitution of Ser-650 with an alanine 
residue does not influence the isoform pattern on SDS-PAGE (Fu et al., 2004; Wong 
et al., 2004). This is probably due to the fact that the Ser-650 site represents a basal 
phosphorylation site of the AR. Only changes in phosphorylation of other sites could 
likely contribute to the appearance of the isoforms. To emphasise the complex
relation between phosphorylation and the isoform appearance, another study 
showed that substitution of serine residues 81, 256, 308, and 515 by alanine has no 
influence on the isoform pattern. However, the mutant S424A has only one isoform, 
irrespective of the presence of hormone (Fu et al., 2004). In conclusion, several 
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phosphosites are clearly involved in the relationship between phosphorylation and 
isoform pattern of the AR. 
1.4.4.1.3 AR phosphorylation and function 
As mentioned in the previous paragraphs the role of AR phosphorylation is not 
exactly clear. In this paragraph more details will be presented on the impact of every 
phosphorylated site on AR function. These data are also summarised in Table 1-2. 
Table 1-2 AR serine phosphorylation sites and their function 
site identification
method
function of 
phosphorylation 
mutated 
isoform
pattern
ligand induced 
phospho-
rylation  
potential 
kinase
reference 
mass
spectrometry 
not found n.d.1 slight n CaM II 2
not PKA 
(Gioeli et 
al., 2002) 
S16
phospho-
antibody
n.d. n.d. slight n n.d. (Yang et al., 
2007) 
mutagenesis not found only 110 
kDa 
n.d. n.d. (Jenster et
al., 1994) 
mutagenesis not found unchanged n.d. n.d. (Fu et al., 
2004) 
mass
spectrometry 
not found n.d. n.d. not PKC (Gioeli et 
al., 2002) 
phospho-
antibody
not found n.d. n n.d. (Black et al., 
2004) 
S81
phospho-
antibody
not found n.d. n CDK1 3 (Chen et al., 
2006) 
mass
spectrometry  
not found n.d. basal,
constitutive 
Ser-Pro 
Kinases 4
not MAPK 
(Gioeli et 
al., 2002) 
mass
spectrometry 
n.d. n.d. 112 kDan
114 kDan
n.d. (Wong et 
al., 2004) 
mutagenesis not found 1 isoform 
less
n.d. n.d. (Jenster et
al., 1994) 
mutagenesis n.d. n.d. n.d. n.d. (Zhou et al., 
1995a) 
mutagenesis DHT: wt activity 
DHT+TSA 5: inactive 
p300+DHT: 50% active
-DHT: 
only 1 
isoform
n.d. n.d. (Fu et al., 
2004) 
S94
phospho-
antibody
not found n.d. basal,
constitutive 
n.d. (Yang et al., 
2007) 
in vitro kinase 
assay
n.d. n.d. n.d. Akt (Wen et al., 
2000) 
in vivo +cAkt6 decreased AR activity n.d. n.d. Akt (Lin et al., 
2001) 
phospho--
antibody
+cPI3Kinase 7Æ60%
activity 
n.d. n PI3K/Akt 
pathway
(Taneja et 
al., 2005) 
S213
mass
spectrometry 
n.d. n.d. no phospho-
rylation
not Akt (Gioeli et 
al., 2002) 
in vivo +cAkt docking site for Mdm2 
ubiquitin ligase 
n.d. n.d. Akt (Lin et al., 
2002) 
S213
+
S791 S231D+
S791D 8
decreased stability, no 
nuclear transfer 
n.d. n.d. n.d. (Palazzolo 
et al., 2007)
S256 mass
spectrometry  
not found n.d. n CK II 2 (Gioeli et 
al., 2002) 
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mutagenesis not found unchanged n.d. n.d. (Fu et al., 
2004)
mass
spectrometry
not found n.d. n Ser-Pro
Kinases 4
not MAPK 
(Gioeli et 
al., 2002) 
mass
spectrometry
not found n.d. n.d. n.d. (Zhu et al., 
2001)
mutagenesis not found unchanged n.d. n.d. (Fu et al., 
2004)
S308
cyclin D3 
+CDK11p58
overexpressed
CDK11p58Æ AR 
activityp
n.d. n.d. CDK11p58 (Zong et al., 
2007)
mass
spectrometry
not found n.d. n Ser-Pro
Kinases 4
not MAPK 
(Gioeli et 
al., 2002) 
S424
mutagenesis not found 1 isoform 
less
n.d. n.d. (Fu et al., 
2004)
in vitro kinase
assay
HER2/Neu+DHTÆ AR 
activity increased
n.d. n.d. MAPK (Yeh et al., 
1999)
mass
spectrometry
not found unchanged n.d. n.d. (Wong et
al., 2004) 
mass
spectrometry
n.d. n.d. no phospho-
rylation
not MAPK (Gioeli et 
al., 2002) 
S515
mutagenesis 50% decreased activity n.d. n n.d. (Ponguta et
al., 2008) 
S578 phospho-
antibody
with EGF inactive n.d. n.d. n.d. (Ponguta et 
al., 2008) 
mass
spectrometry
not found n.d. n CK II 2
PKC
(Gioeli et 
al., 2002) 
mass
spectrometry
not found unchanged basal n.d. (Wong et
al., 2004) 
phospho-
antibody
decreased nuclear AR 
export
n.d. +PMA: n p38/JNK (Gioeli et
al., 2006) 
mutagenesis AR activity 10 to 30% 
decreased
n.d. n.d. n.d. (Zhou et al., 
1995a)
S650
mutagenesis not found unchanged n.d. n.d. (Fu et al., 
2004)
in vitro kinase
assay
n.d. n.d. n.d. Akt (Wen et al., 
2000)
S791
in vivo +cAkt not found n.d. n.d. Akt (Lin et al., 
2001)
This table summarises literature data available about serine phosphorylation sites of the AR. The
identification method, functional consequences, isoform pattern after mutation, ligand induced
phosphorylation, potential kinase and their references are represented.
1n.d.= not determined
2predicted kinase based on a consensus sequence
3CDK= cyclin-dependent kinase
4Ser-Pro kinases are serine-proline-directed kinases (Ser/Thr-Pro), MAPK and cyclin-dependent 
kinases
5TSA = trichostatin A, a histone deacetylase inhibitor
6cAKT = constitutive active AKT kinase
7cPI3Kinase = constitutive active PI3Kinase 
8D=aspartic acid, a phosphorylation mimicking amino acid 
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Two-dimensional thin-layer electrophoresis and ascending chromatography was 
used to detect one of the phosphorylation sites. The phosphorylation status of 
phosphosite Ser-16 increases slightly when hormone is added (Gioeli et al., 2002). 
This slight increase was also observed with antibodies directed against the 
phosphorylated Ser-16 (Yang et al., 2005; Yang et al., 2007). However, upon 
mutation of this phosphosite, AR transactivation activity was similar to that of wt AR 
(Gioeli et al., 2002; Fu et al., 2004). 
Phosphorylation of Ser-81 was studied in more detail. Mutation of this site does 
not change the transactivation of the AR in the presence of hormone (Gioeli et al., 
2002; Fu et al., 2004; Chen et al., 2006). In the presence of the histone deacetylase 
inhibitor Trichostatin A (TSA) or of the co-activator p300 the transactivation activity 
of the Ser-81 Ala mutant displayed the same level of activation as the wt AR (Fu et 
al., 2004). The AR mutant F582Y found in androgen insensitivity syndrome (AIS), 
the export double mutant (F582A, F583A) or the 'F582 mutant showed androgen 
dependent arrest in sub-nuclear foci and accumulation of histone acetyl transferase 
CREB binding protein (CBP). Remarkably, these mutants have a 
hypophosphorylated Ser-81 (Black et al., 2004). This might indicate that recruitment 
of CBP by the AR occurs before Ser-81 becomes phosphorylated. Furthermore, the 
arrest in the foci can be a consequence of the mutations together with the 
hypophosphorylated status of Ser-81. Unfortunately, the arrest in foci of the AR 
'F582 mutant or the F582A, F583A double mutant together with the S81A mutation 
has not been studied. Furthermore, based upon the late induced increase of both 
the Ser-81 phosphorylation and the prostate specific antigen (PSA) gene
transcription, which occurs after approximately 4 hours of DHT stimulation, Chen et 
al. hypothesised that Ser-81 might contribute to the delayed transcription of the PSA
gene (Chen et al., 2006). However, this hypothesis was not supported by 
experimental evidence. 
In the presence of androgens, phosphorylation of Ser-94 increases (Wong et al., 
2004). Also phosphorylation of this site in isoforms 112 and 114 kDa increases (see 
Chapter 2). Other research groups reported that phosphorylation of Ser-94 occurs 
constitutively and did not change after addition of hormone (Gioeli et al., 2002; Yang 
et al., 2005; Yang et al., 2007). Mutation of Ser-94 to alanine does not influence AR 
transactivation activity (Fu et al., 2004; Gioeli et al., 2002; Jenster et al., 1994). 
However, in the presence of TSA the mutant AR became inactive, while co-
activation by co-factor p300 is decreased by 50% (Fu et al., 2004). 
There are some contradictory reports about Ser-213, which makes it 
questionable whether Ser-213 is a phosphorylation site and what the effect is on AR 
activity of phosphorylated Ser-213. First, a research group found that constitutive 
active Akt kinase (cAkt) increases the activity of the mutant AR T877A present in 
LNCaP (Lymph Node Carcinoma of the Prostate) cells and that Ser-213 and Ser-
791 were the candidate sites in an in vitro kinase assay (Wen et al., 2000). However, 
another study showed that co-transfection of AR and cAkt in DU-145 prostate 
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cancer cells resulted in a decrease of AR activity, which merely depends on whether
Ser-213 is mutated (Lin et al., 2001). This was confirmed in a study using a human 
embryonic kidney cell line (293) with a constitutive active PI3 kinase, which is an 
activator of Akt (Taneja et al., 2005). The decrease in AR activity was due to the fact
that phosphorylation of both Ser-213 and Ser-791 together with cAkt and the Mdm2 
ubiquitin ligase resulted in the enhanced degradation of the AR protein (Lin et al., 
2002). A less stable AR protein and a lower AR transactivation were also observed 
for the phosphorylation mimicking mutation of Ser-213 to aspartic acid (S213D), 
whereas the protein level and the AR transactivation were normal when the serine 
residue was mutated to an alanine (Palazzolo et al., 2007). Furthermore, the 
transfer of the AR S213D/S791D double mutant to the nucleus was arrested. On the 
contrary, the AR S213A/S791A double mutant was able to transfer to the nucleus 
similar as the wild-type AR (Palazzolo et al., 2007). The phosphorylation status of
Ser-213 has not been studied for androgen induced nuclear transfer. Remarkably,
with the use of a phosphosite-specific antibody against Ser-213 it was demonstrated 
that addition of R1881 is necessary for the phosphorylation of this site (Taneja et al., 
2005). Furthermore, with immunohistochemistry it was shown that phosphorylated 
AR Ser-213 is already present in human prostate epithelial cells of 14-week old 
human tissue, but not in those of 24 weeks-old human foetuses (Taneja et al., 2005). 
This corresponded positively with the initially more active and higher expressed Akt 
kinase in the 14 weeks old human foetuses. In contrast to another study, it was 
shown after mass spectrometry analysis that only the non-phosphorylated Ser-213 
existed (Gioeli et al., 2002). In addition, inhibition of the constitutive active PI3 
kinase did not change the phosphorylation status of this residue (Gioeli et al., 2002). 
It can be concluded that the role of Ser-213 phosphorylation is still unclear. It has to
be kept in mind that the majority of the studies on the phosphorylation status of Ser-
213 has either not been verified in vivo or are based on the use of constitutively
active kinases.
Although phosphorylation of Ser-256, Ser-308 and Ser-424 increases in 
presence of hormone, no change in AR activation has been found once these sites 
were mutated to alanine (Gioeli et al., 2002; Fu et al., 2004). Recently, it has been 
shown that overexpression of cyclin D3 and the 58 kDa isoform of cyclin-dependent
kinase 11 (CDK11p58) can repress AR transcriptional activity and this repression is
abolished when Ser-308 is mutated to an alanine (Zong et al., 2007). In addition, the 
mutation abolished the cyclin D3+CDK11p58 induced overall phosphorylation of AR 
(Zong et al., 2007). Unfortunately, the phosphorylation status of Ser-308 alone has
not been studied (Zong et al., 2007). Remarkably, mutation of Ser-424 resulted in 
phosphorylation of another not identified peptide (Gioeli et al., 2002). This
conditional phosphorylation could be caused by a more accessible surface for 
kinases after a conformational change due to mutation of Ser-424.
It is doubtful whether Ser-515 is being phosphorylated. The first indication that 
Ser-515 is a phosphosite came from an in vitro kinase study, which showed that the 
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NTD of the AR was phosphorylated in the presence of MAPK kinase (Yeh et al., 
1999). Ser-515 was suggested to be a phosphosite after observation of a decreased 
activity of the AR mutant S515A in the presence of DHT and HER2/Neu, a MAPK 
pathway activator (Yeh et al., 1999). However, in this study the phosphorylation 
status of the mutant AR was not shown. Mass spectrometric analyses showed that 
Ser-515 is not phosphorylated and that the use of MAPK inhibitor did not change the 
phosphorylation of any site (Gioeli et al., 2002). Interestingly, mutation of this site 
did not result in the non-phosphorylated form of the expected peptide, but of the 
peptide containing Ser-650 (Wong et al., 2004). Opposite to what happens with 
mutation of Ser-424, probably a conformational change may have caused the 
absence of a phosphate group at Ser-650. Furthermore, mutation of this site does 
not influence AR transactivation (Yeh et al., 1999; Wong et al., 2004). However, 
when mutant Ser-515 Ala is being tested in the context of an extremely expanded 
polyglutamine stretch (112 glutamine residues instead of the normal number of 
approximately 20), then the mutant AR becomes less toxic and less prone to 
degradation. Also the mutation blocked AR induced cell death (LaFevre-Bernt and 
Ellerby, 2003). It can be concluded therefore that phosphorylation at serine 515 
enhances the ability of caspase-3 to cleave the AR and generate cytotoxic 
polyglutamine fragments in the context of an expanded 112 polyglutamine stretch. 
In addition, contradictory results were found for the function of phosphorylated 
Ser-650. We found that phosphorylation of Ser-650 is constitutive and did not 
change in each isoform relative to total AR phosphorylation (Wong et al., 2004). The 
first indication for the function of phosphorylated Ser-650 came from a study in 
which the mutated Ser-650 showed a 10 to 30% decreased activity (Zhou et al., 
1995a). In addition, in another study it was found that this mutant displays less 
export from the nucleus to the cytoplasm, suggesting a role of Ser-650 in nuclear 
export of the AR (Gioeli et al., 2006). However, this mutation has not resulted in a 
different AR activity (Fu et al., 2004; Gioeli et al., 2002; Wong et al., 2004).
In conclusion, studies up till now do not show a clear relationship between 
phosphorylation of the AR and function, not even in double mutants like 
S81A/S650A or S81A/S94A (Zhou et al., 1995a; Gioeli et al., 2002). In addition, 
transactivation was comparable to the wt AR for an AR mutant in which serine 
residues 81, 94, 256, 308, 424 were mutated to alanine or to aspartic acid (Yang et 
al., 2007). Unfortunately, newly phosphorylated sites induced specifically by 
hormone could not be identified. These kinds of sites could have a higher impact on 
AR transactivation. 
1.4.4.1.4 AR and kinases 
Ser-16 is a candidate phosphorylation site for Calmodulin-dependent protein kinase 
II (CaM-II) and for protein kinase A (PKA) as predicted by NetPhosK 1.0 (Kemp and 
Pearson, 1990; Kennelly and Krebs, 1991; Blom et al., 2004). However, forskolin 
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(FSK) a protein kinase A activator did not increase the phosphorylation of Ser-16 
(Gioeli et al., 2002). 
The kinase involved in phosphorylation of Ser-81 is still unknown, but Ser-81 is
embedded in a consensus sequence for PKC (Kishimoto et al., 1985). PKC is both a 
positive and a negative regulator of the AR and of the AR-responsive PSA gene
(Andrews et al., 1992; de Ruiter et al., 1995). A study with a PKC activator, 4E-
phorbol 12-myristate 13-acetate (PMA), showed that no extra overall AR 
phosphorylation was found (de Ruiter et al., 1995). Furthermore, another study 
showed that phosphorylation of this site was not changed in the presence of
inhibitors, which can block certain PKC isoforms (Gioeli et al., 2002). However, not 
all PKC isoforms were blocked in this study. Recently, it was found that 
overexpression of CDK1 could increase the phosphorylation of Ser-81 (Chen et al., 
2006).
The identified phosphosites Ser-94, Ser-308 and Ser-424 are so-called Ser-Pro
sites, which can be phosphorylated by serine-proline-directed kinases (Ser/Thr-Pro), 
MAPK and cyclin-dependent kinases such as Cdc2 and CDKs. However, it has 
been shown that MAPK has no influence on AR phosphorylation (Gioeli et al., 2002).
Furthermore, the overall phosphorylation of the AR is increased by overexpression 
of the 58 kDa isoform of CDK11 (CDK11p58), which does not occur when Ser-308 is
mutated to an alanine (Zong et al., 2007). However, the phosphorylation status of 
Ser-308 alone has not been determined. 
Although, several studies described the involvement of constitutive active Akt in 
Ser-213 and Ser-791 phosphorylation (see section on AR function and 
phosphorylation, 1.4.4.1.3), a study showed that inhibition of the constitutive active
PI3k/Akt in LNCaP cells did not change the AR phosphorylation status (Gioeli et al., 
2002).
Ser-256 is predicted to be a consensus site for casein kinase II (Pinna, 1990). 
However, phosphorylation of this site and all other potential casein kinase II sites 
has not been investigated in vitro with the particular kinase. 
It is uncertain whether Ser-515 is phosphorylated by MAPK. The phosphorylation
status of Ser-515 in the presence of MAPK was not shown and inhibition of MAPK 
did not change the Ser-515 phosphorylation status (Yeh et al., 1999; Gioeli et al., 
2002).
Which candidate kinase phosphorylates Ser-650 remains also unclear. Ser-650 
is a specific consensus site for casein kinases 1 and 2. One study suggested that 
also PKC could be a candidate. PMA, a PKC activator, increased the 
phosphorylation of Ser-650 (Gioeli et al., 2006; Gioeli et al., 2002). This is in 
contradiction with another study (de Ruiter et al., 1995). There is an indication that 
PKC is not involved in the phosphorylation of Ser-650 directly, because the PMA 
induced phosphorylation was completely inhibited by the use of p38 and JNK kinase
inhibitors (Gioeli et al., 2006). The same study showed that an increased amount of 
JNK and p38 resulted in more binding of the AR protein by the Ser-650 
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phosphosite-specific antibody. However, whether this in vivo also occurs, remains to 
be proven. 
It has long been questioned whether phosphatases play a role in the 
dephosphorylation of the AR. Initially only in vitro studies showed that added 
alkaline phosphatase or phosphatase 2A resulted in the disappearance of two of the 
three phosphorylated AR isoforms (Wang et al., 1999; Jenster et al., 1994). 
Recently, it has been shown that simian virus 40 small t antigen (SV40 ST) in 
combination with the synthetic androgen R1881 can mediate the interaction 
between the liganded AR and phosphatase 2A (PP2A), followed by a decreased AR 
transcriptional activity and a decreased binding of the AR to AREs (Yang et al., 
2005; Yang et al., 2007). However, the AR transactivity has not been studied in a 
PP2A knockout situation or after a mutational disruption of the PP2A-AR interaction. 
In addition, SV40 ST mediated the dephosphorylation of the liganded AR complexed 
with PP2A of serine residues 81, 94, 256, 308 and 424 (Yang et al., 2005). However, 
mutation of these serines did not change the AR transcriptional activity, which 
suggests that the decreased AR activity is not caused by dephosphorylation of the 
investigated serine residues (Yang et al., 2007).
Interestingly, there are indications that kinases can phosphorylate the AR before 
androgen binding and that phosphatases play a role in keeping the AR less 
phosphorylated in the unliganded state (Yang et al., 2007). Therefore, it has been 
suggested that phosphorylation of the AR is regulated by a balance between 
phosphatases and kinases, in which the unliganded AR is favoured by 
phosphatases and the liganded AR by kinases. 
1.4.4.2 Phosphorylation of other steroid hormone receptors 
Phosphorylation has been studied more extensively for other SHRs than for the AR. 
A picture emerges from the many studies that the function of phosphorylation is 
different for each receptor. However, a clear conclusion for the function of each 
SHR cannot be easily drawn, because of the complexity of phosphorylation on 
multiple sites.  
1.4.4.2.1 Phosphorylation of the glucocorticoid receptor 
As most of the SHRs the GR is phosphorylated predominantly on residues in the 
NTD. The human GR is only phosphorylated on five serine sites (Ser-131, Ser-141, 
Ser-203, Ser-211, Ser-226) whereas one threonine residue is also phosphorylated 
at position 159 and 171 in the mouse and rat GR, respectively (Ismaili and 
Garabedian, 2004).
The human GR with all five serine sites mutated to alanine showed dramatic 
reduction in phosphorylation level, when expressed in yeast, however, without any 
change in the transactivation of the hGR (Almlof et al., 1995). Only mutation of a 
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single phosphosite at Ser-203 to an alanine resulted in 50% reduction in hGR 
activity (Almlof et al., 1995). With the use of an antibody specific for this phosphosite 
it was shown that Ser-203 of the human GR is phosphorylated in the absence of
hormone, whereas phosphorylation of the corresponding Ser-224 in rat GR is
hormone dependent (Krstic et al., 1997; Pocuca et al., 1998; Wang et al., 2002b).
Although, phosphorylation of Ser-211 in the hGR is indeed hormone dependent 
as shown with a phosphosite specific antibody, once mutated, the transactivation 
activity of the mutant hGR is unaffected (Wang et al., 2002b; Almlof et al., 1995). 
Consequently, the hormone-induced phosphorylation site is only involved in GR
transactivation, in the hormone-induced transactivation status. 
Interestingly, immunohistochemistry with two different phosphosite-specific
antibodies each interacting with phosphosite Ser-203 and Ser-211 respectively,
revealed that there are different GR phosphorylated isoforms and that these 
isoforms are located at different regions within the cell at the same time (Wang et al., 
2002b).
Phosphorylation status is also important for protein-protein interactions. For 
instance if the GR is hyperphosphorylated, the receptor displays an increased 
interaction with the co-activator DRIP150, which results in a further enhancement of 
GR transactivation (Wang and Garabedian, 2003). Furthermore, the transcription 
inhibitory protein TSG101 binds preferentially to hypophosphorylated and non-
phosphorylated forms of the GR (S203A/S211A) and prevents in this way
degradation of the unliganded GR (Ismaili et al., 2005). A significant decrease in 
degradation has also been shown for the mouse GR, when 7 to 8 phosphosites are 
mutated (Webster et al., 1997). 
Two protein kinase families are known to be involved in phosphorylation of the
GR. The GR can be phosphorylated in a cell cycle dependent way and thereby 
influencing GR transcriptional activation, because cyclin-dependent kinases (CDKs) 
are involved in this event (Bodwell et al., 1998; Ismaili and Garabedian, 2004). 
Family members of the superfamily of mitogen-activated protein kinases (MAPKs) 
can phosphorylate directly the GR as well. c-Jun N-terminal kinase (JNK), but not 
extracellular signal-regulated protein kinase (ERK), can phosphorylate directly rat
GR at Ser-246 (homologous site in hGR Ser-226), which results in inhibition of the 
transactivation activity of the hGR and in an increase of the nuclear export of the GR 
(Rogatsky et al., 1998; Itoh et al., 2002). 
Indirect evidence exists for a role of phosphatases in the dephosphorylation of 
the GR. Okadaic acid, a serine/threonine protein phosphatase inhibitor, blocked the 
release of hsp90 complexed with the GR and thereby nuclear translocation of the 
GR in the presence of hormone and GR nuclear accumulation in the absence of 
hormone (Galigniana et al., 1999; Dean et al., 2001). Indirect evidence exists that
decreased expression of phosphatases results in an increase in DNA binding and a 
tenfold increase in hormone induced transcription and in an increase in basal 
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activity in the absence of hormone (Zuo et al., 1999). However, the 
(de)phosphorylation status of the GR in that study has not been investigated. 
Phosphorylation of GR seems to be involved in the downregulation of the GR 
protein, although the role of each phosphosite still has to be elucidated. 
1.4.4.2.2 Phosphorylation of estrogen receptors 
Phosphorylation of human (h)ERE has not been studied in detail, in contrast to the 
hERD. This protein can be phosphorylated on serine residues in the NTD (Ser-104, 
Ser-106, Ser-118, Ser-167) and in the DBD (Ser-236). In addition, a tyrosine residue 
in the LBD can also be phosphorylated. Tyrosine phosphorylation in the estrogen 
receptor was first extensively described by the group of Ferdinando Auricchio 
(Migliaccio et al., 1989; Auricchio et al., 1987; Migliaccio et al., 1986; Migliaccio et 
al., 1984). The phosphorylation at tyrosine 537 in the LBD predominantly stabilises 
this region, but is not required for hormone binding (Arnold et al., 1997; Weis et al., 
1996). Phosphorylation of Ser-104 and Ser-106 can be induced by the cyclin A-
CDK2 complex, resulting in an enhanced transactivation (Rogatsky et al., 1999). 
Ser-167 can be phosphorylated in a hormone-dependent way by Casein kinase II 
and by constitutive active Akt kinase, which changes the antagonistic characteristics 
of Tamoxifen to a more agonistic one (Campbell et al., 2001; Arnold et al., 1994). 
However, the study of Le Goff et al. showed the absence of phosphorylation at this 
particular site when estradiol was added (Le Goff et al., 1994).  
Estradiol can also induce phosphorylation of the ER on Ser-118. However, 
antagonists 4-OHT and ICI 164,384 have the same effect, although to an lesser 
extend (Ali et al., 1993). This site can be phosphorylated by kinases, such as MAPK 
or CDK7 (Bunone et al., 1996; Joel et al., 1995; Kato et al., 1995; Chen et al., 2002). 
In addition, recruitment of splicing factor (SF)3a p120 can take place via this 
phosphorylated site (Masuhiro et al., 2005). Normally the estrogen receptor 
migrates as a doublet in the presence of estradiol. However, migration of the ER 
mutant S118A results in the absence of the largest isoform (Joel et al., 1995). Many 
studies have focused on Ser-118 phosphorylation, but have shown conflicting 
results about the effect of phosphorylated Ser-118 on the transactivation activity of 
the ER (Lannigan, 2003). 
Ser-236 in the DBD can be phosphorylated by protein kinase A, which regulates 
dimerisation and DNA binding of ER (Chen et al., 1999b). Phosphorylation of Ser-
305 blocks acetylation of Lys-303, which results in an enhanced transactivation (Cui 
et al., 2004). 
Only indirect evidence is present for the involvement of phosphatases in the 
possible dephosphorylation of the ER. Phosphatase Cdc25B can interact with the 
ER and enhance ER transactivation, but its phosphatase activity is not required for 
this enhancement (Chavez et al., 2001). Another phosphatase, protein phosphatase 
2A (PP2A) can interact with the ER via its catalytic subunit and its 
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dephosphorylation capacity could be shown in an in vitro kinase assay (Lu et al., 
2003). However, the role of this phosphatase in vivo has not been shown. 
There are conflicting results about the function of the ER phosphorylated sites. 
Therefore, no clear conclusion can be drawn about the effect of phosphorylation of
the ER and its transactivation. An extensive overview of ER phosphorylation has
been published by Lannigan (Lannigan, 2003). 
1.4.4.2.3 Phosphorylation of progesterone receptors 
The human PR-A of 97 kDa has seven phosphosites in the NTD (Ser-190, Ser-213,
Ser-294, Ser-345, Ser-400, Thr-430, Ser-554) and one phosphosite in the hinge 
region (Ser-676). The longer PR-B protein of 120 kDa has six additional 
phosphosites in the unique NTD region (Ser-20, Ser-25, Ser-81, Ser-102, Ser-130,
Ser 162). Most of these sites are being phosphorylated in vivo with the exception of
Ser-25, Thr-430 and Ser-554, which can be phosphorylated by Cdk2 in vitro (Knotts
et al., 2001; Zhang et al., 1997; Zhang et al., 1994; Zhang et al., 1995). 
Ser-81, 162, 190, 213 and 400 are defined as “basal” phosphorylation sites and 
are constitutively phosphorylated in the absence of hormone (Zhang et al., 1997;
Knotts et al., 2001). Ser-102, 294 and 345 are hormone-dependent phosphorylation 
sites and become maximally phosphorylated in vivo one to two hours after progestin 
stimulation (Zhang et al., 1995). The phosphorylation stoichiometry of residues Ser-
20, Ser-130 and Ser-676 has not been studied.
The phosphosites Ser-294 and Ser-400 have been studied in somewhat more 
detail. Phosphorylation of Ser-294 together with an active p42/p44 MAPK is the 
signal for the hormone-dependent degradation by the 26S proteasome (Lange et al.,
2000). The activation of p42/p44 MAPK is induced by MEKK1 (MAPK kinase kinase
1), which is also involved in the phosphorylation of Ser-294 and the enhanced 
transactivation of the PR (Shen et al., 2001). Mutation of this serine site to alanine 
decreases the MEKK1 and the ligand-induced transactivation of the PR dramatically
(Shen et al., 2001). In addition, nuclear export of this mutant does not take place 
(Qiu and Lange, 2003).
Phosphorylation of Ser-400 is involved in the Cdk2-induced, but not in the 
ligand-induced, transactivation of the PR (Pierson-Mullany and Lange, 2004). This
event depends on the Ser-400 necessity for nuclear translocation, because mutation 
of Ser-400 to Ala results in a dramatic decrease in Cdk2 –induced nuclear import of 
PR (Pierson-Mullany and Lange, 2004). However, in the presence of hormone, the 
Ser-400-Ala mutant has only a delayed nuclear accumulation, (Pierson-Mullany and 
Lange, 2004). Therefore, Ser-400 seems to be only necessary for hormone-
independent activation. 
Phosphorylation of Ser-162 and Ser-294 in the hPR is cell-cycle dependent as 
was shown with the use of site-specific phospho-antibodies. Phosphorylation is
absent in the G2/M phase along with a decrease in transcriptional activation of the 
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PR (Narayanan et al., 2005). However, a functional analysis with mutant Ser-162 
has not been performed. Another study revealed that mutation of either 
phosphorylation sites Ser-190 or a cluster of serines just upstream of the DBD or 
Ser-676 inhibit transcription by 20-50% depending on cell- and/or promoter context 
(Takimoto et al., 1996). In the same study was also shown that after mutation of all 
serines unique to the NTD of the PR-B to alanine, the transactivation activity of this 
mutant construct is equal to that of the wt PR-B. 
Studies on the PR from other species indicated more functions associated with 
the phosphorylation status of the PR. The rabbit PR in the presence of hormone or 
the antagonist RU 486 was found to be hyperphosphorylated (Chauchereau et al., 
1991). This hyperphosphorylated PR has a decreased electrophoretic mobility 
(Chauchereau et al., 1991). Furthermore, the constitutive active receptor (without 
the LBD) exhibited only a low basal level of phosphorylation (Chauchereau et al., 
1991). When Ser-530 of the chicken PR was mutated to alanine, it reduced the 
transcriptional activity of the PR at low hormone concentrations but did not affect 
maximal activity (Bai et al., 1994). Mutation of Ser-211 to alanine resulted in a 
decrease in the transcriptional activity of the receptor and affects the 
phosphorylation-dependent decrease in mobility on a SDS-PAGE gel (Bai and 
Weigel, 1996). 
1.4.4.2.4 Phosphorylation of the mineralocorticoid receptor 
Phosphorylation of the MR has not been studied in very much detail, despite the fact 
that the MR contains numerous potential phosphorylation sites. One potential 
tyrosine phosphorylation site, at position 73 in NTD of the rat MR from the Fisher 
344 strain is a cysteine at the same position in the MR of the Brown Norway rat, a 
strain which is insensitive to adrenalectomy. The Y73C substitution leads to a gain 
of function for the rat MR with a stronger transactivation activity in the presence of 
aldosterone, and interestingly also by progesterone (Marissal-Arvy and Mormede, 
2004; Marissal-Arvy et al., 2004). However, it remains to be proven that Y73 is 
being phosphorylated in the Fischer 344 rat MR and therefore reduces its 
transactivation potential. Aldosterone can induce a rapid (already within 15 minutes) 
MR phosphorylation on serine and threonine (but not tyrosine) residues which is 
mediated at least in part through the PKCD-signalling pathway (Le Moellic et al., 
2004).
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Figure 1-4
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Mechanisms of androgen and anti-androgen action
A) Agonist bound AR translocates to the nucleus where it binds to the promoter regions and
enhancers of androgen-responsive genes and recruits activating co-factors, such as chromatin
remodelling complexes, histone acetylases and mediator complexes. By recruiting RNA polymerase
(Pol) II, TATA binding protein (TBP), several TBP-associated factors (TAFIIs) and general
transcription factors (GTFs), transcription initiation of a target gene can start. B) Antagonist bound
AR has a conformation favourable for recruiting co-repressors and histone deacetylases. This 
complex inhibits transcription of genes.
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1.5 TRANSCRIPTION REGULATION 
The AR can bind to AREs in the promoter and/or enhancer regions after hormone 
binding and subsequent migration to the nucleus, as outlined in section 1.2.1.2, and 
can initiate transcription activation or repression of target genes. Bound to the 
response elements the AR is the DNA binding activator protein that serves as a 
nucleation site for the recruitment of co-factors, general transcription factors (GTF), 
other transcription factors and RNA polymerase II (Pol II) (Fig. 1-4). At the same 
time the activator together with co-factor complexes coordinates transcription by Pol 
II (Kraus and Wong, 2002; Lemon and Tjian, 2000; Roeder, 2005). 
Eukaryotic DNA is approximately two meters in length and is compacted to 
chromatin together with nucleoprotein complexes (Widom, 1998). At the first level of 
organisation, 146 bp of DNA is wrapped in 1.75 superhelical turns around a histone 
octamer with two copies of four histones (H2A, H2B, H3 and H4) (Kornberg and 
Lorch, 1999; Chakravarthy et al., 2005). These octamers, nucleosomes, are in a 
dynamic equilibrium between a fully wrapped state and a set of partially unwrapped 
states (Mellor, 2005). The wrapped state prevents the initiation of transcription by 
blocking the access for Pol II and general transcription factors. The concept is that 
SHRs and other NRs act as pioneer factors in the initiation of the chromatin 
remodelling process to unwrap the DNA. Besides the wrapped state of DNA, it has 
recently been discovered that there are pre-existing regions of open chromatin to 
which a SHR, GR, can bind. This has been suggested to play a role in the 
determination of tissue-selective receptor function (John et al., 2008).
The access of SHRs to nucleosomes is gained by recruitment of 2 groups of 
chromatin modifying enzymes. Group 1 contains histone modifying enzymes (HME), 
which relieve the DNA-histone interaction, and group 2 consists of ATP-dependent 
chromatin remodelling complexes (CRC) that displace or remove the nucleosomes. 
Beside chromatin modifying enzymes three other groups of co-factors can be 
recruited. Group A: Mediator complexes, which are essential for recruitment of 
GTFs and Pol II. Group B: Co-activators, which can enhance transcriptional 
activation. Group C: Co-repressors, which repress transcription. These co-factors 
will be discussed in more detail for the AR in the following sections. 
1.5.1 Chromatin remodelling complexes 
Chromatin remodelling ATPase complexes are the first group of chromatin 
modifying enzymes to prepare transcription initiation by remodelling nucleosomes. 
Based on the identity of the ATPase subunit, the ATP-chromatin remodelling 
complexes can be subdivided into three distinct families, namely, the SWI/SNF, 
ISWI and the Mi-2/NuRD complexes (Narlikar et al., 2002; Becker and Horz, 2002). 
These chromatin remodelling complexes use the energy stored in adenosine 
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triphosphate (ATP) to mobilise or structurally alter nucleosomes (Kingston and 
Narlikar, 1999). 
1.5.1.1 SWI/SNF 
The SWI/SNF family was originally discovered in yeast (Yoshinaga et al., 1992). In 
humans there are two ATPase catalytic subunits, brahma related gene 1 (BRG1; 
also named BAF or hSwi/Snf-A) and human brahma (hBRM; also named PBAF or
hSwi/Snf-B) (Kwon et al., 1994; Wang et al., 1996a; Wang et al., 1996b). Each of 
these ATPase subunits belong to a complex of approximately 2 MDa molecular
mass with 10–12 additional protein subunits termed as Brg-1-associated factors or 
BAFs (Kwon et al., 1994; Wang et al., 1996a; Wang et al., 1996b). Purification and 
characterisation studies of the separate complexes demonstrate differences in 
activity and subunit composition suggesting distinct regulatory roles (Bultman et al., 
2000; Lemon et al., 2001).
The mouse mammary tumour virus (MMTV) promoter is widely used as a model
system for studying the molecular mechanisms of SHR-dependent transcriptional 
regulation in a chromatin context (Hager, 2001). The MMTV-long terminal repeat 
(LTR) of retroviral DNA is organised in six nucleosomes if integrated in mammalian 
chromosomes (Richard-Foy and Hager, 1987). In vitro studies with the MMTV-LTR
assembled into chromatin in Xenopus oocytes and in cell-based transfection assays
suggest a requirement for BRG1 during AR-dependent transcription and chromatin 
remodelling of the MMTV promoter (Huang et al., 2003). In this study, ChIP analysis
showed that BRG1 is recruited to the MMTV promoter in the presence of the AR 
ligand R1881. In addition, AR ligand-dependent activation of the MMTV promoter 
was impaired in SW13 cells, which lack BRG1, supporting a role for BRG1 complex 
in AR dependent gene regulation. Transient transfection studies have suggested 
that the AR differentially requires hBRM to activate the probasin promoter in vivo
(Marshall et al., 2003). However, addition of PSA-enhancer to the core PSA 
promoter bypassed SWI/SNF requirement (Marshall et al., 2003). Recently, it has
been shown that BAF57 directly binds to hormone stimulated AR and is recruited on 
AR targets, which increases AR transactivation via hBRM (Link et al., 2005).
Another member of the SWI/SNF family, AR interacting protein (ARIP4) can also
moderately enhance AR transactivation on minimal promoters (Rouleau et al., 2002). 
Interestingly, it was demonstrated that the co-repressor Krab-associated protein 1 
(KAP-1) together with HDAC-1/2 and SWI/SNF were components of the nuclear co-
repressor complex (N-CoR), suggesting a possible dual function for SWI/SNF 
(Underhill et al., 2000). 
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1.5.1.2 ISWI 
Many studies provide substantial evidence for a role of the BRG1 complex in SHR-
dependent chromatin remodelling and transcriptional regulation. However, less 
evidence exists for the ISWI/hSNF2h ATP-dependent complexes. ACF (ATP-
dependent chromatin assembly and remodelling factor) a chromatin remodelling 
complex that contains the ISWI subunit, did not support NR-dependent activated 
transcription in in vitro transcription assays (Lemon et al., 2001). Another study 
showed that synergistic transactivation by PR and NF1 of an MMTV promoter was 
enhanced by recombinant ISWI, but in absence of SWI/SNF (Di Croce et al., 1999). 
ISWI, unlike BRG1 always exists as subunit in other complexes (NURF, CHRAC 
and ACF) and a role is suggested in transcription termination by stimulation of 
phosphorylation of the CTD in RNA Pol II (Ito et al., 1999b; Morillon et al., 2003). 
1.5.1.3 Mi-2/NURD 
The third class of ATP-dependent remodelling complexes is the Mi-2/NURD 
complex. Evidence suggests that complexes such as the Mi-2/NURD complex that 
contain the Mi-2 ATPase subunit are involved in transcriptional repression when 
recruited by DNA binding proteins to specific DNA sequences (Knoepfler and 
Eisenman, 1999; Solari and Ahringer, 2000). The Mi-2 was shown to be a subunit of 
the nucleosome remodelling and deacetylation (NURD, NuRD or NRD) complex. 
NURD complexes include members of histone deacetylases (HDAC1/2), histone 
H4-interacting proteins RbAp46/48, methyl-binding proteins MBD2/MBD3 and Mi-2 
as the ATPase subunit (Zhang et al., 1998; Wade et al., 1999). A common feature of 
the Mi-2 complex is the presence of the members of the metastatic-associated 
protein gene family (Zhang et al., 1998; Wade et al., 1999). A role for the Mi-
2/NuRD complex in SHR-dependent transcription regulation has not been studied 
extensively. Mi-2/NURD mediated repression of NR-dependent transcription was 
suggested in a study showing that the co-repressor KAP-1 together with HDAC-1/2 
and SWI/SNF were components of the nuclear co-repressor complex (N-CoR) 
(Underhill et al., 2000). KAP-1 was shown to associate with an isoform of Mi-2 
protein, an integral component of the NURD complex (Schultz et al., 2001). Two 
independent laboratories have found MTA1 and MTA3 components of the Mi-
2/NURD complex, to be involved in ER-dependent transcription repression 
(Mazumdar et al., 2001; Fujita et al., 2003). 
1.5.2 Histone modifying enzymes 
Although ATP-dependent chromatin remodelling is required for NR-dependent 
transcription regulation, it is not sufficient (Dilworth et al., 2000; Li et al., 1999). 
Chromatin remodelling complexes may allow the access for the second group of 
chromatin modifying enzymes, the histone modifying enzymes (Dilworth et al., 2000; 
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Li et al., 1999). Extensive post-translational modifications of histones, either by 
acetylation, methylation, phosphorylation, ubiquitylation/ubiquitination and/or ADP-
ribosylation determine whether particular nucleosomes remain wrapped and hence 
repressed or become unwrapped, resulting in gene activation (Loury and Sassone-
Corsi, 2003; de Murcia et al., 1988; Sun and Allis, 2002). It has been suggested that 
a certain pattern of histone modifications, the “histone code”, functions as a read out
for certain proteins, including transcription factors and co-activators (Strahl and Allis, 
2000). Recently, evidence has been provided that the 5’-specific and 3’-specific
regulation of nucleosome composition and the histone code are important for the 
location and kinetics of transcriptional initiation in Saccharomyces cerevisiae (Lieb
and Clarke, 2005). 
1.5.2.1 Acetylation
Numerous studies in yeast and higher eukaryotic organisms have demonstrated the 
link between acetylation of the N-terminal tails of histones and the activation of
transcription (Wade et al., 1997). Acetylation of lysines neutralises the positive 
charge of the histone tails and thereby decreases their interaction with the negative 
charged DNA (Hong et al., 1993). This is directly related to an increased 
transcription activity. Several subgroups of histone acetyl transferases (HATs) have 
been identified. 
p300/CBP was found to acetylate histones and to be tightly associated with 
RNA-Pol II (Ogryzko et al., 1996). p300/CPB is also able to acetylate the AR as 
already mentioned in section 1.4.1. It can enhance the transactivation of the AR and 
other SHRs, (Chakravarti et al., 1996; Aarnisalo et al., 1998; Heinlein and Chang,
2002).
A second subgroup is the p300/CBP-associated factor (P/CAF), which was 
initially identified as a p300/CBP interacting factor (Yang et al., 1996). It can 
acetylate the AR as well, which also enhances AR transactivation (Fu et al., 2000). 
The third group of HATs is the group of p160-co-activators, which consists of 
steroid hormone receptor co-activator (SRC)-1, (SRC)-2 and (SRC)-3 (or nuclear
receptor co-activator NCoA-1, -2 and -3) (Anzick et al., 1997; Chen et al., 1997; Tan 
et al., 2000; Yeh et al., 1998; Onate et al., 1995; Spencer et al., 1997; Yao et al., 
1996). SRC-2, also known as TIF2, has in contrast to SRC1 and SRC-3 no HAT
activity (Hong et al., 1997; Voegel et al., 1996; Chen et al., 1997; Spencer et al., 
1997). The HAT activity of p160-co-activators is much weaker than that of 
p300/CBP, which probably functions differently (Clements et al., 1999). Besides
they can interact with the AR, they can also associate with other HATs, p300/CBP 
and P/CAF and other factors, for example methyltransferases (Chen et al., 1999c). 
The SRCs appear to function as bridging factors.
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1.5.2.2 Deacetylation 
Deacetylation of histones is performed by histone deacetylases HDACs. Histone 
deacetylation is directly correlated with a decreased transcription activation (Pazin 
and Kadonaga, 1997; Hu and Lazar, 2000). There are 8 different HDACs (HDAC 1-
8). HDAC 1 and 2 are both subunits in two repressor complexes, the mSin3 and 
NuRD (nucleosome remodelling and deacetylation complex) complex. HDAC3 was 
found in an 1.5-2 MDa complex complexed with two co-repressors, nuclear co-
repressor (N-CoR) and silencing mediator of retinoid and thyroid receptors (SMRT) 
and it requires the interaction with N-CoR or SMRT for its deacetylase activity 
(Guenther et al., 2000; Li et al., 2000). These co-repressors can interact with the AR 
(Shang et al., 2000; Berrevoets et al., 2004). In fact it has been shown by ChIP 
technology that HDAC-1 and HDCA-2 are being recruited by the AR via SMRT or N-
CoR at the promoter region of the PSA gene (Shang et al., 2002). 
The AR has been found together with HDAC1 and Mdm2 as a trimeric complex, 
which results in a decreased AR transactivation (Gaughan et al., 2005). HDAC1-
DJBP (DJ-1-binding protein) complex can interact with the AR and represses AR 
transactivation (Niki et al., 2003). Pod-1 can repress AR transactivation by recruiting 
HDAC1, but not HDAC4 (Hong et al., 2005). The AR can recruit HDAC4 via ARR19 
(AR corepressor-19 kDa), but not HDAC1 nor HDAC5 and ARR19 represses AR 
transactivation only in the presence of HDAC4 (Jeong et al., 2004). 
1.5.2.3 Methylation 
Methylation of arginine and lysine residues of histones can either result in gene 
activation or gene repression (Lee et al., 2005). Gene activation or repression 
depends not only on the methylation status of histones, but also on the number of 
methyl groups (mono-, di- and trimethyl). Two arginine methyltransferases, co-
activator-associated arginine (R) methyltransferase 1 (CARM1) and protein arginine 
methyltransferase 1 (PRMT1) are known to enhance transactivation of AR and other 
NRs. This enhancement is only obvious in the presence of p160-co-activators and 
ligand (Koh et al., 2001; Chen et al., 1999a). It has been shown that CARM1 also 
binds to beta-catenin and can function in synergy with beta-catenin and p300 as co-
activators for AR (Koh et al., 2002). In addition to histone methylation, PRMT1 can 
also methylate other proteins, such as the RNA-interacting proteins heterogeneous 
ribonuclein particles (hnRNP) A and B, RNA, fibrillarin and nucleonin (Najbauer et 
al., 1993; Lee et al., 2005). 
Transactivation by the AR can result in a different methylation status of histone 3. 
Activation of PSA gene transcription by androgens can lead to reduced H3 Lys-4 
methylation in the promoter region, but in an increase of this modification in the 
coding region (Kim et al., 2003). Recently, a study showed that the lysine 
methyltransferase G9a is involved in AR transactivation. G9a enhanced AR 
Introduction
41
transactivation synergistically with NR co-activators TIF2, CARM1 and p300 (Lee et 
al., 2006).
1.5.2.4 Demethylation
Only recently, demethylases, the counterpart of methyltransferases, were identified 
(Kubicek and Jenuwein, 2004). Arginine demethylases are not involved in AR 
transactivation, but a lysine-specific histone demethylase, LSD1, is. Originally it was
found as KIAA0601/NPAO in several co-repressor complexes, the CtBP, NRD, Co-
REST, and subsets of the HDAC complexes (Hakimi et al., 2002; Hakimi et al., 2003; 
Humphrey et al., 2001; Shi et al., 2003; Tong et al., 1998; You et al., 2001). LSD1 
specificity and activity is regulated by associated protein co-factors (Lee et al., 2005; 
Metzger et al., 2005; Shi et al., 2005). The AR or its associated factor belongs to
proteins that are able to regulate LSD1 specificity. LSD1 can demethylate histone 
H3 at Lysine-9 in the presence of AR, but not histone H3 at Lysine-4. This loss of
repressive methylation revealed the co-activator function of LSD1 since it enhances
AR transactivation. Interestingly, this binding and co-factor function does not occur 
with the estrogen receptor or the retinoic acid receptor (Metzger et al., 2005). 
1.5.3 Mediator complexes
A mediator is an evolutionary-conserved complex that contains approximately 25-30 
subunits and is required for activator-dependent transcriptional activation (Conaway
et al., 2005). The first Mediator complex was identified as thyroid hormone receptor
associated proteins (TRAPs), which enhanced the transactivation by liganded-TR 
(Fondell et al., 1996). The TRAP complex turned out to be highly similar to other
mediator complexes. The vitamin D receptor interacting proteins (DRIP), activator-
recruited co-factor (ARC) and SRB/MED containing co-factor complex (SMCC) are 
identical to TRAP (Ito et al., 1999a; Gu et al., 1999; Rachez et al., 1998; Naar et al., 
1999). These complexes were later renamed as Mediator (MED)-complex according
to a unified nomenclature (Bourbon et al., 2004). 
Studies with transcription activators, like NRs, in systems with DNA templates 
and purified RNA polymerase II and corresponding general initiation factors, 
revealed that mediators were required for transcription activation but not for basal 
(activator-independent) transcription (Flanagan et al., 1991). Mediator proteins can 
interact with general transcription factors and RNA-Pol II. This interaction facilitates 
RNA-Pol II recruitment and promotes formation of the preinitiation complex (PIC). 
Furthermore, MED-complexes can also modulate the function of Pol II (Malik and 
Roeder, 2005). 
A recent study elegantly showed that both recruitment and postrecruitment steps
in transcription initiation required Mediator proteins. This was demonstrated in 
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Med23 negative cells, in which histone acetylation, methylation, and chromatin 
remodelling complex association at the Egr1 promoter were equivalent to that of 
wild-type cells, but Egr1 induction was largely reduced (Wang et al., 2005a). 
Knockouts of Mediator subunit confirmed the suggested general role for these 
complexes, since these knockouts result in embryonic lethal phenotypes (Ito et al., 
2000).
Several subunits of the TRAP complex, TRAP220, TRAP170 and TRAP100, can 
interact with the AR LBD in vitro and their overexpression results in an enhanced 
AR transactivation. Furthermore, Chromatin immunoprecipitation (ChIP) assays 
show that TRAP220 is recruited to the prostate-specific antigen (PSA) gene 
promoter in AR stimulated LNCaP cells (Wang et al., 2002a). 
1.5.4 RNA polymerase II and general transcription factors 
Prior to the initiation of transcription the preinitiation complex (PIC) is assembled at 
the core promoter. The giant PIC, consisting of RNA-Pol II, general transcription 
factors (GTFs), and Mediator complexes, is an assembly of minimal 48 proteins, 
with a total molecular mass of approximately 2.5 MDa. The general transcription 
factors, TFIIA, TFIIB, TFIID, TFIIE, TFIIF and TFIIH are assembled in a particular 
order (Roeder, 1996; Buratowski et al., 1989). TFIID consists of TATA binding 
protein (TBP) and several TBP-associated factors (TAFIIs) and binds to the TATA-
box to position the other proteins of the PIC at the core promoter. The other GTFs 
either stabilise intermolecular interactions and the interaction of TFIID with DNA or 
destabilise non-specific RNA-Pol II DNA interactions. TFIIH has helicase activity to 
unwind the DNA. The assembly and stability of the PIC is usually controlled by a 
second class of transcription factors, such as the AR, which can be found on the 
promoter region and/or on distant enhancer regions. It is not clear how the AR 
regulates the PIC assembly and its stability. But two studies nicely showed the 
tracking of the RNA-Pol II from the PSA enhancer over approximately 4 kilobases to 
the PSA promoter upon androgen induction (Louie et al., 2003; Wang et al., 2005c). 
1.5.5 Other transcription factors 
Recently, studies on the PSA promoter and enhancer have shown the necessity of 
recruitment of transcription factors other than the GTFs (Wang et al., 2007). GATA2 
and Oct1 are cooperating in androgen mediated PSA gene expression (Wang et al., 
2007). After binding of DHT to the AR, the receptor interacts with GATA2 in order to 
be recruited to the PSA enhancer, whereas Oct1 acts at a step subsequent to 
GATA2 action (Wang et al., 2007). 
Introduction
43
1.5.6 Co-activators 
The Group B of non-chromatin modifying enzymes (see paragraph 1.5), the so-
called co-activators, do not bind to DNA, but interact indirectly through association 
with DNA binding proteins, such as SHRs. A list of co-activators has been published 
at www.nursa.org. Lists of AR interacting co-activators are also published (Heinlein
and Chang, 2002; Jasavala et al., 2007; Heemers and Tindall, 2007). Many co-
activators interact with domains of the AR via their LXXLL motifs (Savkur and Burris,
2004). The highly similar FXXLF motif, which is present in the AR NH2-terminal
domain, is also present in the co-activators ARA70, ARA55, ARA54 and FHL2 
(Kang et al., 1999; Fujimoto et al., 1999; Muller et al., 2000; Yeh and Chang, 1996). 
The AR favours the interaction with the FXXLF motif more than with the LXXLF
motif, in contrast to other SHRs (He et al., 2004; Dubbink et al., 2006). 
The primary function of co-activators is to facilitate AR directed target gene 
expression and to enhance AR transactivation. For example, a component of the 
Hsp90 chaperone heterocomplex, BAG-1L, is presumed to enhance the AR 
transactivation by promoting the appropriate folding of the AR (Froesch et al., 1998). 
AR protein stability can also be enhanced by co-activators (Moilanen et al., 1998). 
Several co-activators, like ARIP (PIASDx), SRC1 and TIF2 are capable to enhance 
NH2-/COOH-terminal domains interaction (Moilanen et al., 1999; Spencer et al., 
1997; Berrevoets et al., 1998). Furthermore, DNA binding of the AR can also be 
enhanced by co-activators, as shown for the co-activator RAF (Kupfer et al., 1993)
Some of the mentioned co-activators and many other co-activators act through 
multiple mechanisms to influence AR transactivation and harbour more than one 
function. p300/CPB is such a co-activator. It can enhance AR transactivation by
acetylation of the AR and of the nucleosome. Furthermore, co-activators together
can enhance AR transactivation in a synergistic way, probably by facilitating each
other’s recruitment. An example of the synergistic action of co-activators on AR 
mediated transcription activation is the cooperative action of FHL2, CBP/p300 and 
E-catenin (Labalette et al., 2004). 
In general, co-activators are proteins. The only exception so far is SRA, which is 
a RNA transcript. SRA is able to co-activate AR transactivation. It is present in 
ribonucleoprotein complexes together with SRC1 (Lanz et al., 1999).
1.5.7 Co-repressors 
Co-activators are recruited to activate gene transcription. For the fine tuning of
cellular processes, repression of gene transcription by co-repressors is also
essential. Two of the most well known nuclear co-repressors N-CoR, and SMRT, 
can inhibit AR transactivation by recruiting HDACs, which in turn results in
deacetylation of histones to make the DNA less accessible for factors necessary for 
gene transcription (Privalsky, 2004). However, the AR can also recruit HDAC1 by
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itself (Gaughan et al., 2002). When either N-CoR or SMRT is overexpressed, 
interaction of the co-repressor with agonist bound AR can occur, which 
consequently results in transactivation inhibition (Cheng et al., 2002; Liao et al., 
2003). However, partial agonist and antagonist bound AR can recruit more 
efficiently N-CoR and SMRT. Interestingly, N-CoR can compete with TIF2 for AR 
binding sites, which has led to an equilibrium model, in which the protein level of co-
activator and co-repressor determines whether AR activity is enhanced or repressed 
(Berrevoets et al., 2004). Similarly, this competition between TIF2 and SMRT has 
also been shown. Furthermore the NH2-/COOH-terminal domain interaction appears 
to be inhibited by SMRT (Liao et al., 2003). Cyclin D1 is another co-repressor which 
is able to inhibit the association between the co-activator P/CAF and the AR 
(Reutens et al., 2001). hRad9, a member of the checkpoint Rad protein family, can 
also interfere with the NH2-/COOH-terminal domain interaction of the AR (Wang et 
al., 2004). Other mechanisms to repress AR transactivation activity is by 
interference of AR DNA binding as illustrated by studies with calreticulin (Dedhar et 
al., 1994). An overview on AR co-repressors has been published recently (Wang et 
al., 2005b). 
Thus an agonist bound AR recruits merely co-activators and less co-repressors, 
which is the opposite of an antagonist bound AR which merely recruits co-
repressors. All these results are based on experiments with synthetic antagonists. It 
remains therefore questionable whether a repressive mechanism is operating, since 
the existence of natural AR antagonists is not evident. 
1.5.8 The transcriptional clock 
Results from studies with ChIP assays illustrated the dynamics of the recruitment 
and dissociation of the estradiol (E2) liganded ERD together with several co-factors 
involved in transcription activation at a target promoter. These studies revealed that 
estradiol (E2) liganded ERD in synchronised cells can associate with the cathepsin 
D-promoter or the pS2 gene promoter in a cyclic way with cycles of approximately 
45 minutes. In the first cycle, approximately 15 minutes after addition of E2, in 
addition to ERD, p300, SCR-3 (AIB1), MED1, CPB, PRMT1 and RNA Pol II were 
detected on the promoter (Shang et al., 2000; Metivier et al., 2003; Reid et al., 
2003). The sequential and combinatorial assembly of a transcriptionally productive 
complex on a promoter has been defined as a “transcriptional clock”. 
For ERD three different cycles can be distinguished (Metivier et al., 2003). In the 
initial unproductive cycle without RNA Pol II, SWI/SNF chromatin remodellers were 
recruited, followed by PRMT1 and HATs (Tip60 and p300). Thereafter, several 
components of the basal transcription machinery are recruited. In the next step ERD
was targeted to the proteasome and degraded. After the initial cycle the 
transcriptionally productive cycle was started with the recruitment of p68 RNA 
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helicase, which is assumed to serve as an adapter protein to attract AF2 co-
activators (Endoh et al., 1999). Next, the histone modifications were started with a 
large complex containing HMTs (PRMT1 and/or CARM), HATs and p160-co-
activators that serve as scaffold proteins. Subsequently, TAFII250, TAFII130 and 
mediator-complexes were attracted to the promoter to start transcription elongation. 
This is followed by the targeting of ERD to proteasomes, and recruitment of HDACs
and SWI-SNF complexes, which are probably needed for reorganising the 
nucleosomes in the subsequent cycles. At the end of the second productive cycle,
approximately 180 min after the start of the unproductive cycle, NuRD components
were recruited, presumably to remove TFIIA/TBP. A reinitiation cycle is then 
occurring in which remodelling of the nucleosomal structure is needed prior to the 
start of new cycles.
1.5.9 The concept of the transcriptional clock in the mechanism of androgen 
action
A similar cyclic pattern as described for ERD was also found for the AR and several 
co-activators, although it has not been studied extensively. However, the 
transcriptional clock ticks slower during the AR cycle. The first two cycles of the AR 
and RNA Pol II binding on the PSA and KLK2 promoters take approximately 85 min 
each. Remarkably, after the second cycle, maximum binding of AR, RNA Pol II
binding and some modified histones was reached and did not change for at least
300 min, whereas only two cycles were found on the enhancers of both genes
(Kang et al., 2004; Kang et al., 2002). However, time points for measuring protein 
recruitment were taken every 15 min or 25 min. instead of 1 min. as in the ERD
study. More timepoints would reveal a far more detailed protein recruitment. Another 
study showed that the amount of AR, SRC1, GRIP1, AIB1, p300, TRAP230,
CARM1 and TBP recruited on the PSA promoter increases for at least 16 hours 
(Wang et al., 2005c). Interestingly, AR, p160, CBP, p300 and RNA Pol II are 
preferentially recruited to the PSA enhancer on androgen stimulation (Louie et al., 
2003). Furthermore, in the presence of the pure anti-androgen bicalutamide, AR 
associated with the promoter regions and with components belonging to co-
repressor complexes, but RNA Pol II and HATs were not detected on the promoters
(Kang et al., 2004; Kang et al., 2002; Masiello et al., 2002; Shang et al., 2002). The 
sequential and cyclic recruitment of proteins shows that a highly regulated process
at the molecular level is involved in transcription regulation mediated by the AR.
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1.6 ANDROGEN RECEPTOR DISORDERS 
1.6.1 Androgen insensitivity syndrome 
Disorders of androgen action can be caused either by defective androgen synthesis 
or metabolism, or by defective AR functioning. A defective functioning AR can result 
in a partial or complete androgen resistance in androgen target tissues. This 
disorder is called androgen insensitivity syndrome (AIS). AIS is characterised by a 
mild or severe undervirilisation in 46,XY individuals due to a mutation in the AR
gene (McPhaul et al., 1993; Quigley et al., 1995; Boehmer et al., 2001; Gottlieb et 
al., 2004a; Brinkmann et al., 1996). The clinical phenotypic spectrum ranges from a 
female phenotype to an undervirilised male phenotype or an infertile but otherwise 
normal male phenotype, and strongly depends on the type of mutation. The 
complete form of AIS (CAIS) is characterised by a female phenotype with breast 
development, but absence of axillary and pubic hair, no uterus, no ovary, no 
fallopian tubes, a blind ending vagina and the presence of testes in the abdomen. 
The 46,XY individuals with partial AIS (PAIS) have phenotypes ranging from a 
predominantly female external appearance, with mild cliteromegaly and some fusion 
of the labia, to phenotypes with ambiguous genitalia or to a predominantly male 
phenotype with micropenis, perineal hypospadias, and cryptorchidism. Individuals 
with the mildest form of AIS have mild undervirilisation and are infertile (Hiort et al., 
2000).
The different mutations in the AR gene causing AIS are often single base 
substitutions. However, deletions (1-6 base pairs), partial or complete gene 
deletions (>10 base pairs), insertions or duplications are also found. Mutations are 
compiled in the AR database (Gottlieb et al., 2004b; www.mcgill.ca/androgendb). 
Most of the mutations are found in the LBD (approximately 62%). Many mutations in 
this domain are affecting ligand binding resulting in a non-active or partially active 
AR. Approximately 15% of all mutations are found in the DBD, causing defective 
DNA binding of the AR, and consequently a defective activation of androgen-
responsive genes. Only 17% of all mutations are found in the NTD (Gottlieb et al., 
2004b). Most mutations in this region are associated with CAIS, mainly due to 
premature stop codons, although PAIS phenotypes have also been described. 
1.6.2 Spinal and bulbar muscular atrophy (Kennedy’s disease) 
Kennedy’s disease, also known as spinal and bulbar muscular atrophy (SBMA), is a 
slowly progressing degeneration of lower motor neurons, resulting in muscle 
weakness in adult males (Kennedy et al., 1968; Greenland and Zajac, 2004; Arbizu 
et al., 1983). These patients may also develop gynaecomastia and sometimes 
reduced fertility, indicating a defect in AR functioning. La Spada and colleagues 
were the first to demonstrate a direct correlation of SBMA with an extension of the 
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(CAG)nCAA- repeat in exon 1, which encodes the polymorphic polyglutamine stretch 
in the AR NTD (La Spada et al., 1991). In the normal human population the repeat is
between 11 and 38, also depending on the ethnic background (Caskey et al., 1992; 
Sleddens et al., 1992; Edwards et al., 1992). In SBMA, the number of glutamine 
residues varies between 40 and 63.
1.6.3 Prostate cancer
Prostate cancer is the second leading cause of death by cancer in men in Western 
countries (Gronberg, 2003). Most prostate cancers express relatively high levels of 
AR protein (van der Kwast et al., 1991). Initially prostate cancer is androgen 
dependent, because removal of androgens or blocking the AR by anti-androgens
results in growth arrest of the tumour. However, tumour growth arrest is only
temporarily, because most tumours undergo a transition to an androgen 
unresponsive state.
Despite many suggestions for a possible mechanism for the development of the 
androgen unresponsive state of prostate tumours, the exact mechanism underlying 
the transition to androgen independency is still unclear (Feldman and Feldman,
2001; Grossmann et al., 2001). Since the AR is expressed in androgen independent
prostate tumours, it is assumed that the AR is still involved in some way in tumour 
growth. One mechanism may be a higher AR protein expression, caused by
amplification of the AR gene (Edwards et al., 2003a; Edwards et al., 2003b;
Visakorpi et al., 1995). Under extremely low androgen levels (by hormone 
deprivation) the AR can still be activated. Also somatic mutations in the AR gene 
can result in a more active receptor protein (www.mcgill.ca/androgendb) or may 
broaden the ligand specificity towards anti-androgens or other steroid hormones, 
such as found for the AR mutant T877A (Veldscholte et al., 1990; Zhao et al., 2000). 
This mutation is found frequently in androgen independent prostate tumours. 
Another mechanism that has been proposed is the increased expression of AR 
specific co-factors, resulting in an enhanced AR activity and consequently in 
enhanced tumour growth. Finally, a mechanism has been suggested involving 
ligand-independent activation of the AR. This might be achieved by cross-talk with
other activated signal transduction pathways.
1.7 SCOPE OF THIS THESIS 
To better understand the various actions of androgens in different cellular systems, 
and the dysregulation of such actions, it is important to obtain more information on 
processes and factors which modulate AR transcriptional activity. Modulating 
processes and factors have been described in a number of studies, but the picture 
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is far from complete. The aim of the experiments described in this thesis is to gain 
more insight in the effect of several AR processes and modulating factors. 
Phosphorylation is involved in many processes via modulation of enzymes or 
proteins in signal transduction pathways. This posttranslational modification also 
has been shown to influence the function of several SHRs. The AR is known to be 
phosphorylated, but the effect of phosphorylation on AR function is largely unknown. 
Chapter 2 describes the studies in which an attempt has been made to answer the 
following question: 
Question 1: What is the influence of AR phosphorylation on AR isoforms and AR 
transactivation?
Androgen insensitivity is predominantly caused by mutations in the AR gene. 
However, the correlation between a specific AR mutation and the AIS phenotype is 
not always consistent. After a novel mutation was found in an individual with PAIS, 
we addressed the following question in Chapter 3:  
Question 2: What is the effect of the novel mutation F826L on AR transactivation?
Most, if not all, of the AR binding co-factors have been isolated by yeast-two-
hybrid assays, GST pull-down, or co-immunoprecipitation methodology. DNA 
binding does not play a role in these methods, whereas there are indications that 
DNA can influence the AR conformation and co-factor recruitment. In Chapter 4, we 
describe the set up and the use of an assay with DNA-bound AR as target in which 
both DNA and AR are expected to play a role in co-factor recruitment. This research 
was done to answer the following question: 
Question 3: Can existing and novel AR co-factors be isolated when complexed with 
the AR in an oligonucleotide-based in vitro assay? 
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Phosphorylation of the human AR (androgen receptor) is directly
correlated with the appearance of at least three AR isoforms on
an SDS/polyacrylamide gel. However, it is still not clear to what
extent phosphorylation is involved in the occurrence of isoforms,
which sites are phosphorylated and what are the functions of these
phosphosites. The human AR was expressed in COS-1 cells and
AR phosphorylation was studied further by mutational analyses
and by using reversed-phase HPLC and MS. The reversed-phase
HPLC elution pattern of the three isoforms revealed that Ser-650
was phosphorylated constitutively. After de novo synthesis, only
Ser-650 was phosphorylated in the smallest isoform of 110 kDa
and both Ser-650 and Ser-94 were phosphorylated in the second
isoform of 112 kDa. The hormone-induced 114 kDa isoform
shows an overall increase in phosphorylation of all the isolated
peptides. The activities of the Ser–Ala substitution mutant S650A
(Ser-650→Ala) was found to be identical with wild-type AR
activation in four different cell lines and three different func-
tional analyses, e.g. transactivation, N- and C-terminal-domain
interaction and co-activation by transcriptional intermediary fac-
tor 2. This was also found for mutants S94A and S515A with re-
spect to transactivation. However, the S515A mutation, which
should eliminate phosphorylation of the potential mitogen-
activated protein kinase site, Ser-515, resulted in an unphos-
phorylated form of the peptide containing Ser-650. This suggests
that Ser-515 can modulate phosphorylation at another site. The
present study shows that the AR isoform pattern fromAR de novo
synthesis is directly linked to differential phosphorylation of a
distinct set of sites. After mutagenesis of these sites, no major
change in functional activity of the AR was observed.
Key words: androgen receptor, isoform, MS, phosphorylation,
reversed-phase HPLC, transactivation.
INTRODUCTION
The AR (androgen receptor) is a ligand-dependent transcription
factor belonging to the family of steroid hormone receptors.
Similar to other members of the steroid hormone receptor family
including the oestrogen receptor, progesterone receptor, gluco-
corticoid receptor and mineralocorticoid receptor, the AR be-
comes activated after ligand binding. This results in stabilization,
a conformational change and tight nuclear binding of the receptor
and, eventually, in a positive and/or negative transcription regu-
lation of target genes.
Ligand binding is not the only regulatory event in the functions
of steroid hormone receptors. Post-translational modification of
steroid hormone receptors by proteins participating in other sig-
nal-transduction pathways plays a role in the regulation as well.
Phosphorylation of oestrogen receptor α influences transactiv-
ation and association with the co-activators p160 and p300/
CBP [CREB (cAMP-response-element-binding protein)-binding
protein] [1–3] or with the co-repressors N-CoR (nuclear receptor
co-repressor) and SMRT (silencing mediator for retinoic acid
receptor and thyroid hormone receptor) [4]. Transactivation of
the glucocorticoid receptor is also regulated by phosphorylation
[5–7]. A hormone-dependent phosphosite in the progesterone
receptors A and B plays a role in receptor degradation [8], trans-
activation [9] and nuclear export [10,11]. Thus phosphorylation
of specific sites in steroid hormone receptors has been shown to
play a role in various processes.
Post-translationalmodifications such as acetylation and sumoy-
lation have been shown to influence the transactivation potential
of the AR [12,13]. However, it is not clear whether phosphory-
lation has an effect on the properties and activity of the AR.
It has been shown that the AR is a phosphoprotein [14,15]
and extra phosphorylation of the AR is induced when cells are
exposed to androgens, in addition to the so-called basal AR phos-
phorylation observed in the absence of androgens [15,16].
Phosphorylation occurs predominantly at serine residues [16,17],
which are mainly located in the N-terminal domain [18]. Further-
more, phosphorylation is correlated with the three AR isoforms
that appear on an SDS/polyacrylamide gel [19]. Within minutes
after the start of de novo synthesis, the AR appears as a 110 kDa
isoform, whereas generation of the second (112 kDa) isoform
follows within 15 min as shown by radioactive methionine-
labelling studies [20,21]. Only after hormone binding does the
third (114 kDa) isoform appear [19]. The AR isoform pattern is
correlated with AR phosphorylation as was shown in previous
studies by using phosphatases. The dephosphorylation of AR by
phosphatases resulted in the loss of one isoform either in the pre-
sence or absence of hormone [19]. This effect was also observed
when AR phosphosites were mutated [19]. Furthermore, several
phosphorylation sites have been identified. The first identi-
fied phosphosites, Ser-81, Ser-94 and Ser-650, were found by
mutagenesis analyses in combination with SDS/PAGE [19,22].
Ser-308 was the first phosphosite identified by mutagenesis and
MS [23]. Ser-16, Ser-81, Ser-94, Ser-256, Ser-308, Ser-424
Abbreviations used: AR, androgen receptor; CHO cell line, Chinese-hamster ovary cell line; dcc, dextran-coated charcoal; DMEM, Dulbecco’s modified
Eagle’s medium; FCS, fetal calf serum; MAPK, mitogen-activated protein kinase; MMTV, murine-mammary-tumour virus; RP, reversed phase; TIF2,
transcriptional intermediary factor 2; WT, wild-type.
1 These authors have contributed equally to this work.
2 To whom correspondence should be addressed (email a.brinkmann@erasmusmc.nl).
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and Ser-650 were all identified and confirmed as phosphosites
by mutagenesis, peptide mapping and MS [16]. However, cell-
free in vitro phosphorylation reaction studies on AR mutants also
demonstrated Ser-213, Ser-515 and Ser-791 to be phosphosites
[24–26].
It is still not clear to what extent phosphorylation is
involved in the appearance of isoforms and which sites in the
different isoforms are phosphorylated. In the present study, phos-
phorylation of the isoforms was further explored by studying
the differential phosphorylation of the three AR isoforms. An
attempt was made to identify all the phosphosites. Furthermore,
the consequences of transcriptional activation of the identified and
potential phosphosites were evaluated using functional assays,
which tested the transactivation, N- and C-terminal-domain in-
teraction and co-activation by TIF2 (transcriptional intermediary
factor 2), and the functional assays were performed in COS-1
and CHO (Chinese-hamster ovary) cell lines and two prostate
cancer cell lines (PC-3 and DU-145). In contrast with a pre-
vious study, which showed that Ser-94 was constitutively phos-
phorylated [16], our study showed that the Ser-650 is con-
stitutively phosphorylated.
MATERIALS AND METHODS
Materials
Phosphate-free DMEM (Dulbecco’s modified Eagle’s medium)
and goat anti-mouse agarose beads were purchased from Sigma–
Aldrich (St. Louis, MO, U.S.A.). Media (GlutaMAX I-supple-
mented DMEM/F12 and RPMI 1640) and filtertop culture flasks
were purchased from Invitrogen (Paisley, U.K.). Multiwell tissue
culture plates were obtained from Nunc (Roskilde, Denmark).
FCS (fetal calf serum)was obtained fromGreiner (Frickenhausen,
Germany) and the mixture of penicillin and streptomycin was
fromBioWhittaker (Walkersville, MD, U.S.A.). The oligonucleo-
tides used in plasmid construction and sequencing were syn-
thesized by Eurogentec (Liege, Belgium). FuGENE 6, Complete
inhibitor EDTA-free, shrimp alkaline phosphatase and Rapid
DNA Ligation kits were obtained from Roche (Basel,
Switzerland) and Quik Change Site-DirectedMutagenesis kit was
from Stratagene (La Jolla, CA, U.S.A.). Steady-Glo Luciferase
assay system and sequencing-grade modified trypsin (specific
activity, 16 000 units/mg)were obtained fromPromega (Madison,
WI, U.S.A.). [32P]Pi was from Amersham Biosciences (Uppsala,
Sweden). F39.4.1 is a mouse monoclonal antibody raised against
amino acids 301–320 of the human AR [27] and SP197 is
a rabbit polyclonal antibody [18]. The 10× Tris/glycine/SDS
electrophoresis buffer and N,N,N ′,N ′-tetramethylethylenediamine
were obtained from Bio-Rad Laboratories (Hercules, CA,
U.S.A.). HPLC reagents were of sequencing grade and obtained
from Merck (Darmstadt, Germany). Deltapack C18 column was
purchased from Waters and C-18 Z-tips were from Millipore
(Milford,MA,U.S.A.). NENLife Science Products (Boston,MA,
U.S.A.) supplied R1881 (methyltrienolone). MMTV-Luc reporter
plasmid (where MMTV stands for murine-mammary-tumour
virus) was kindly provided by Dr R. Dijkema (Organon, Oss, The
Netherlands) and has been described previously [28]. SpeedVac
concentrator was obtained from Thermo Savant (Division of
Thermo Electron Corporation, Waltham, MA, U.S.A.).
Plasmid construction
Plasmid construction was performed according to standard
methods [29] and, where indicated, the plasmids were rendered
blunt-ended with Klenow. Constructs including a PCR-ampli-
fication step for preparation were sequenced to verify the correct
reading frame and the absence of random mutations. All the AR
amino acid numbers used in the present study are based on the
National Center for Biotechnology Information accession number
AAA51729, which refers to the AR consisting of 919 amino acids
[30]. The mutants AR S650A (Ser-650→Ala) and AR S515A
were constructed by site-directed mutagenesis using PCR DNA
amplification techniques. The following sense oligos were used
for introducing the substitution with a Quik Change: AR S650A,
5′-CCAGCACCACCGCCCCCACTGAG-3′; and AR S515A, 5′-
CCTATCCCGCTCCCACTTGT-3′. The mutations are indicated
in italics and underlined. AR104 was described previously as
pSVAR-104, which is the AR construct containing sequences
encoding the C-terminal amino acids 537–919 [31]. The N-ter-
minal construct, pSVAR(TAD1-494), consists of the AR amino
acids 1–503 [32]. AR104/S650Awas prepared by the digestion of
BHEXARS650A with SacI and ligating the fragment into AR104
by using the Rapid DNA Ligation kit. TIF2 is described as a
co-activator in [33,34].
COS-1 cell culture, transfection, metabolic labelling
with [32P]Pi and immunoprecipitation
COS-1 cells were cultured in DMEM/F12 supplemented with
GlutaMAX I and 5% (v/v) FCS treated with dextran-coated
charcoal (dcc-FCS). For steady-state labelling, 1.5× 106 COS-1
cells were grown overnight in an 80 cm2 flask with 8 ml of
DMEM/F12, followed by transfection with the following mix:
4 μg of the indicated plasmid with 12 μl of FuGENE 6 trans-
fection reagent in 200 μl of serum- and antibiotics-free DMEM/
F12. Transfections were performed according to the manu-
facturer’s instructions for FuGENE 6. After 30 h, cells were
washed twice with 0.9% (w/v) NaCl and incubated in phosphate-
free DMEM, supplemented with 50 mM Hepes buffer and 5%
dcc-FCS, which had been dialysed for 24 h against 0.9% NaCl.
Subsequently, cells were incubated with R1881 as indicated
and [32P]Pi (0.333 mCi/ml) for 16 h. Cells were harvested and
lysed at 4 ◦C in immunoprecipitation buffer A [40 mM Tris/
HCl (pH 7.4), 5 mM EDTA (pH 8.0), 10% (v/v) glycerol,
10 mM sodium phosphate, 10 mM sodium molybdate, 50 mM
sodium fluoride, 0.5 mM sodium orthovanadate, 0.6 mM PMSF,
0.5 mM Bacitracin, Complete inhibitor EDTA-free and 10 mM
dithiothreitol], supplemented with 1% (v/v) Triton X-100, 0.5%
(w/v) deoxycholic acid and 0.08% (w/v) SDS. Subsequently,
the lysate was centrifuged at 100 000 g for 30 min at 4 ◦C. The
supernatant was then incubated at 4 ◦Cwith the antibody F39.4.1,
which was linked to goat anti-mouse agarose. After 2 h, the
agarose beads were washed as follows: three times with buffer A
supplemented with 1% Triton X-100, 0.5% deoxycholic acid
and 0.08% SDS, three times with buffer A supplemented with
0.2%Triton X-100 and 0.4 MNaCl and three times with buffer A
without any additions. The immunoprecipitatedARwas separated
by SDS/PAGE (7% gel). After fixing the gel in 10% (v/v) acetic
acid and 50% (v/v) methanol, the gel was subjected to Coomassie
Blue staining and destaining. Subsequently, the AR band was
excised from the gel and digestedwith sequencing-grademodified
trypsin.
In-gel digestion and RP (reversed-phase) HPLC analysis
The excised AR spot was in-gel-digested as described by
Shevchenko et al. [35]with 20 units of sequencing-grademodified
trypsin for 16 h at 37 ◦C. The amount of trypsin necessary to
secure full digestion of the higher amount of AR protein in the pre-
sence of hormone was verified by varying the amount. The
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peptides were extracted as described by Shevchenko et al. [35]
and dried in a SpeedVac for 1.5 h. The peptides were dissolved
in 0.1% (v/v) trifluoroacetic acid. Then, 25 μl of this solution
was applied to a 2 mm× 150 mmWaters Deltapack C18 column.
The flow was set to 0.18 ml/min and fractions were collected
every 1.5 min until a gradient of 18% (v/v) acetonitrile in 0.1%
trifluoroacetic acid was reached.
Peptide gel
A 40% (w/v) acrylamide alkaline peptide gel was cast and run as
described by West et al. [36].
Characterization of the HPLC fractions with MS
AR tryptic peptides were separated by RP-HPLC. The fractions
with retention times corresponding to 32P-labelled tryptic phos-
phopeptides were collected and, after drying in a SpeedVac,
they were dissolved in 20 μl of 50% acetonitrile. With electro-
spray ionization MS and MS/MS, data were collected from the
individual fractions using a Q-TOF (Micromass, Wythenshaw,
Manchester, U.K.). The peptides were directly infused in the
Q-TOF with a nanospray needle (Micromass) containing a 3 μl
sample plus 0.3 μl of 10% (v/v) formic acid. Low-energy col-
lision-induced dissociation of selected precursor ions was used
to obtain fragmentation spectra. These were deconvoluted
(Masslynx software; Micromass) and used to identify the cor-
responding tryptic peptides, including modifications, of the AR.
CHO, PC-3, DU-145 and COS-1 cell culture, transfection
and luciferase assay
CHO and COS-1 cells were maintained in DMEM/F12 culture
medium, supplemented with 5% dcc-FCS. PC-3 and DU-145
were cultured in RPMI 1640 medium, supplemented with 5%
FCS. For transcription activation experiments, the cells were
plated in 24-well plates at a density of 2× 104 cells/well (1.9 cm2)
in 500 μl of either DMEM/F12 or RPMI 1640 and grown over-
night. Cells were transfected using 100 μl of either serum- and
antibiotics-free DMEM/F12 or RPMI 1640 containing FuGENE
6 (FuGENE/DNA ratio of 3:1) with AR expression plasmids and,
where indicated, with TIF2 reporter plasmids (50 ng/well)
and pTZ19 carrier plasmid to a total DNA concentration of
250 ng/well. After 5 h, R1881 was added, followed by an over-
night incubation; at the end of this incubation, the cells were
harvested for a luciferase assay. Then, 50 μl of lysis buffer
[25 mM Tris/phosphate (pH 7.8), 15% glycerol, 1% Triton
X-100, 8 mM MgCl and 1 mM dithiothreitol] was added to the
cells. After incubation for 10 min, 25 μl of the supernatants
were transferred to white non-transparent 96-well assay plates,
and 25 μl of 16 mg Steady-Glo Luciferase assay substrate per
ml of Steady-Glo luciferase assay buffer was added. Luciferase
activity was measured with a TopCount luminometer (Packard
Bioscience, PerkinElmer Life Sciences, Zaventem, Belgium).
Western blotting
COS-1 cells were plated at a density of 1× 106 cells/80 cm2 flask
and transfected with 4 μg of AR expression plasmid and 12 μl
of FuGENE. After an overnight incubation with hormones, the
cells were washed once with PBS, and immunoprecipitation
buffer (see the COS-1 cell culture subsection), supplemented
with protease inhibitors, was added. Lysates were centrifuged for
10 min at 400 000 g and AR was immunoprecipitated with the
monoclonal antibody F39.4.1. Next, samples were subjected to
Figure 1 AR isoforms on a Coomassie Blue-stained SDS/polyacrylamide
gel
WT AR was expressed in COS-1 cells and labelled with [32P]Pi for 16 h in the absence or presence
of 10 nM R1881 for 16 h. The same amount of total lysate of the two conditions was used
for AR immunoprecipitation with the monoclonal antibody F39.4.1. The immunoprecipitated
AR was separated by SDS/PAGE (7 % gel) and Coomassie Blue-stained (A) or blotted and
immunostained with the polyclonal antibody SP197 (B). The corresponding autoradiogram is
also shown in (B).
SDS/PAGE and blotted on to a nitrocellulose membrane. AR
was immunoblotted with the AR polyclonal antibody SP197
and visualized by chemiluminescence detection or by using an
alkaline phosphatase-conjugated secondary antibody.
RESULTS
AR isoform expression
To verify the AR isoform pattern on an SDS/polyacrylamide gel,
WT (wild-type) human AR was expressed by transient trans-
fection into COS-1 cells and metabolically labelled with [32P]Pi
either in the absence or presence of the synthetic androgen R1881.
The same amount of total lysate of the two conditions was used
for AR immunoprecipitation. After immunopurification, the gel
was stained with Coomassie Blue. In the absence of R1881, the
two isoforms (110 and 112 kDa) were clearly visible and the pre-
sence of R1881 resulted in the appearance of the third isoform of
114 kDa (Figure 1A).
Lysates obtained by the same procedure as the previous experi-
ment were also immunoprecipitated and blotted. The immunoblot
showed the same isoform pattern (Figure 1B) as the Coomassie
Blue-stained gel. An autoradiogram of the corresponding im-
munoblot showed an upshift of a phosphorylated band and an
increase in phosphorylation (Figure 1B). This increase is partly
due to stabilization of the AR. These results confirm that the AR is
phosphorylated in the absence of hormone and that phosphoryl-
ation of the AR is increased in the presence of hormone [16].
Furthermore, this suggests that the upshift of a phosphorylated
band corresponds to the 114 kDa isoform.
Changes in AR phosphorylation induced by R1881
To investigate whether androgenic activation increases the phos-
phorylation of existing phosphosites and/or induces phosphoryl-
ation of new sites, the AR was expressed by transient transfection
into COS-1 cells and metabolically labelled with [32P]Pi either in
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Figure 2 R1881-induced changes in AR phosphorylation pattern
AR was expressed in COS-1 cells and labelled with [32P]Pi for 16 h in the absence (A) or
presence (B) of 10 nM R1881. The same amount of total lysate of the two conditions was
used for AR immunoprecipitation (with anti-AR monoclonal antibody F39.4.1). The precipitated
AR was digested with trypsin and the peptides obtained were separated on an RP HPLC C18
column. HPLC fractions were collected and the amount of [32P]Pi incorporated was determined.
The different radioactive fractions are indicated with A–F. Note that the ordinates have a different
scale.
the absence or presence of R1881. After immunopurification and
subsequent digestion with trypsin, the resulting peptides were
separated on an RP HPLC column. The RP HPLC elution pattern
ofAR in absence ofR1881 showed that several fractions contained
32P-labelled peptides (Figure 2A, fractions A, B, D and E). After
stimulating the cells with 10 nM R1881, an increase in phos-
phorylation of the peptides in fractionsA,B,D andEwas observed
(Figure 2B). In addition, the relative phosphorylation level of two
peptides in fractions C and F was slightly increased (Figure 2B).
It is important to note that the overall phosphorylation pattern was
highly reproducible in ten independent experiments. These results
are in agreement with a previous report that hormone binding
results in increased phosphorylation of existing phosphorylated
sites [16].
Differential phosphorylation of AR isoforms
To study differential phosphorylation of the three isoforms of 110,
112 and 114 kDa in more detail, COS-1 cells were transfected
with AR and stimulated for 16 h with R1881 and labelled with
[32P]Pi. Each 32P-labelled AR isoform was isolated separately
from an SDS/polyacrylamide gel. The phosphorylation pattern
of tryptic fragments of the individual isoforms revealed that the
110 kDa isoform is predominantly phosphorylated on the peptide
in fraction D (Figure 3A). The phosphorylation level of fraction
Figure 3 Differential phosphorylation of AR isoforms
AR was expressed in COS-1 cells and labelled with [32P]Pi for 16 h in the presence of
10 nM R1881. AR was immunoprecipitated (with anti-AR monoclonal antibody F39.4.1) and the
isoforms of 110 kDa (A), 112 kDa (B) and 114 kDa (C) were separately cut out from the same
lane on an SDS/7 % polyacrylamide gel followed by trypsin digestion. The peptides obtained
were separated on an RP HPLC column. HPLC fractions were collected and the amount of [32P]Pi
incorporated was determined. The different radioactive fractions are indicated with A–F.
D in the 112 kDa isoform was similar to that in the 110 kDa iso-
form (Figures 3A and 3B) and slightly increased further in the
114 kDa isoform (Figure 3C). Since fraction D contains the pep-
tide with the phosphorylated Ser-650 (see below), these results
indicate that Ser-650 is constitutively phosphorylated.
The phosphorylation level of the different RP HPLC fractions
for each isoformwas found to be different and to get an impression
of quantitative changes, the fold increase has been calculated.
First, the phosphorylation level of each peptide is based on the
sum of the radioactivities in three consecutive fractions. Since
phosphorylation of fraction D was shown to be more or less
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Table 1 Phosphorylation ratios of AR peptides
The phosphorylation ratio of different fractions is calculated relative to the intensity of phosphorylation of fraction D (1.0, see also text).
Phosphorylation
HPLC fractions Fraction X/D (110 kDa isoform) Fraction X/D (112 kDa isoform) Fold increase (relative to 110 kDa) Fraction X/D (114 kDa isoform) Fold increase (relative to 110 kDa)
A 0.3 0.8 2.9 1.4 5.1
B 0.2 0.4 1.9 0.9 4.3
C 0.1 0.1 0.7 0.2 1.3
D 1.0 1.0 1.0 1.0 1.0
E 0.3 0.3 1.0 0.4 1.2
F 0.1 0.1 1.1 0.2 2.9
Figure 4 Separation of individual HPLC fractions on a 40% acrylamide
alkaline peptide gel
Peptides from HPLC fractions were separated on a 40 % acrylamide alkaline peptide gel. Note
that the separation is according to size and charge. Phosphopeptides were visualized by using
a PhosphorImager (Molecular Dynamics). The different radioactive fractions are indicated with
A, B, D and E.
constant in the different isoforms, the level of phosphorylation
in the other fractions was calculated relative to the level of phos-
phorylation in fractionD. Furthermore, the change in ratios for the
112 and 114 kDa isoforms were calculated relative to the ratios
for the 110 kDa isoform, resulting in fold increase (Table 1). The
fold increase of the fractions A, B, C, E and F obtained from
the 110 kDa isoform were low. For the 112 kDa isoform, the fold
increase of fractions A and B was 2–3-fold higher (Table 1). The
fold increase of fractions C, E and F was the same in the 112 kDa
isoform compared with the 110 kDa isoform.
Moreover, analysis of the 114 kDa isoform showed that, in the
presence of R1881, the fold increase of fractions C and E was
rather small, but the fold increase of phosphorylation in frac-
tions A, B and F were higher (Table 1). These results confirm that
a correlation exists between phosphorylation status and the SDS/
PAGEmigration pattern for the threeAR isoforms [19]. In conclu-
sion, increase in phosphorylation is correlated with a decreased
migration rate.
Phosphopeptide analysis
To characterize the HPLC fractions in more detail, the most
intensely phosphorylated fractions (A, B, D and E) were sub-
jected to further analysis on a 40% acrylamide alkaline peptide
gel. Peptide analysis revealed that fractions A, D and E each
contained a single phosphorylated peptide and that each peptide
was different from the others (Figure 4). However, fraction B con-
tained two phosphorylated peptides. The peptide in fraction B,
which migrated into the gel as far as the peptide in fraction A, is
most probably identical with the phosphorylated peptide from
fractionA and is present in fractionB due to incomplete resolution
during HPLC separation. These data show that at least four
different peptides derived from the AR are phosphorylated.
Peptide analysis by MS
To identify the phosphorylated amino acid residues, MS analysis
was used to characterize first the phosphorylated peptides in
the HPLC fractions. Out of the six HPLC fractions collected
(fractions A–F), five contained tryptic peptides from the AR
(Table 2). The identified peptides in fractions B, D and E were
Table 2 MS data of phosphorylated peptides in RP HPLC fractions
Fraction Measured mass Tryptic peptide fragment* AR peptide Putative phosphosite Prediction†
A 962.4 T70–T71 Cys-852 with acrylamide adduct 847–854 Ser-851 0.962
B 2056.8 T7–T8 plus phosphate probably on Ser-94 84–100 Ser-94 0.572
C n.d.‡
D 2232.0 T50 plus phosphate probably on Ser-647 639–658 Ser-647 0.760
or Ser-650 Ser-650 0.997
E 1226.6 T28 plus phosphate probably on Ser-515; 511–520 Ser-515 0.967
Cys-518 with carbamidomethyl
F 1554.7 T15 221–235 §
* Peptide identification is based on comparison of the detected mass and the corresponding MS/MS information of the measured peptides with all possible tryptic fragments (T1–T79).
† NetPhos 2.0 [40] was used to search for possible phosphorylation sites. A prediction of 0.5 and higher was considered as representing a potential phosphorylation site.
‡ n.d., not determined.
§ No potential phospho-serine residue was present in the peptide.
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phosphorylated. The theoretical mass of these peptides was in-
creased by the mass of one phosphate group (79.9799 Da) and,
moreover, MS/MS data confirmed the presence of this modifi-
cation, probably on a serine residue. The MS/MS data from
fraction D could not discriminate between two possible serine
phosphosites (Ser-647 and Ser-650). Both of the identified tryptic
AR peptides in fractions A and F contained a serine residue, but
were not phosphorylated. The results are summarized in Table 2
together with information on possible putative phosphosites.
A small number of the fractions displayed a variable low level
of phosphorylation, most probably due to contaminations, and
were excluded from further analyses.
Phosphosite identification by site-directed mutagenesis
The peptide in fraction D (amino acid residues 639–658) con-
tains two potential phosphorylation sites, Ser-647 and Ser-650
(Table 2). Substitution of Ser-650 with an alanine residue resulted
in the disappearance of peptide phosphorylation in fraction D
(Figure 5A). In contrast, substitution of Ser-647 toAla-647 did not
result in any change in phosphorylation (results not shown). This
substantiates the observation that fraction D contains the peptide
consisting of amino acids 639–658 and shows that Ser-650, but
not Ser-647, is a phosphorylation site. Another peptide identified
by MS and consisting of amino acid residues 84–100 (fraction B)
contains the potential phosphosite Ser-94 (Table 2). Substitution
of Ser-94 to Ala-94 resulted in a 40% loss of radioactive phos-
phate incorporation in both fractions A and B (Figure 5B and
Table 3). A third phosphorylated peptide identified in these
experiments is the peptide from fraction E consisting of amino
acid residues 511–520 and containing the potential phosphosite
Ser-515. Remarkably, substitution of Ser-515 to Ala-515 did
not result in disappearance of radioactivity from fraction E. In
contrast, fractionD,which contained the peptidewith phosphosite
Ser-650, was no longer radioactive after the Ser-515 to Ala-515
substitution (Figure 5C). This result indicates that changes in
Ser-515 might exert an influence on the phosphorylation status
of Ser-650. In fraction A, the peptide consisting of amino acids
847–854 has the predicted phosphosite Ser-851. Substitution of
Ser-851 with an alanine residue did not result in a change in the
phosphorylation pattern (results not shown). This indicates that
the identified peptide consisting of amino acids 847–854 present
in fraction A does not contain the predicted Ser-851 phosphosite.
No phosphosites were predicted for the identified peptide present
in fraction F and no peptides could be detected in fraction C.
Phosphorylation and AR transcriptional activity
Since the phosphorylation level of the AR was changed in the
presence of R1881, AR phosphorylation might regulate the func-
tional activity of the AR. The transactivation activity of AR
mutants S515A, S650A and S94A was tested using an MMTV-
Luciferase reporter assay in CHO cells. Substitution of Ser-650
to Ala-650 did not result in a change in transactivation of the
MMTV-Luc reporter gene when compared with the WT AR
(Figure 6A). The same neutral effect was found for the S515A
and S94A mutants (results not shown). To exclude the possibility
that CHO cells exert AR phosphorylation in a peculiar cell-type-
specific manner, the same experiment was performed in COS-1
as well as PC-3 and DU-145 cells (both prostate cancer cell lines).
No differences in AR transactivation activity for the three AR
mutants could be detected in any of these three cell lines (results
not shown). These results indicate that loss of AR phosphorylation
on Ser-650, Ser-515 and Ser-94 does not have an effect on AR
transactivation activity.
Figure 5 AR phosphorylation on Ser-650 and Ser-94 and the phosphoryl-
ation influenced by Ser-515
The AR mutant S650A (A), S94A (B) or S515A (C) was expressed in COS-1 cells and labelled
with [32P]Pi for 16 h in the presence of 10 nM R1881. The AR mutant was immunoprecipi-
tated (with anti-AR monoclonal antibody F39.4.1) and digested with trypsin. The peptides
obtained were separated on an RP HPLC C18 column. HPLC fractions were collected and the
amount of [32P]Pi incorporated was determined.
Table 3 Phosphorylation of S94A mutant
The phosphorylation of peptides in fractions A and B from the WT AR (Figure 2B) and the S94A
mutant (Figure 5B) were normalized to their corresponding fractions D. Percentage change in
phosphorylation between the mutant and WT for fractions A and B was calculated from the ratios.
Phosphorylation
Ratio WT AR Mutant S94A Change in phosphorylation (%)
A/D 0.65 0.38 − 42
B/D 0.42 0.23 − 44
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Figure 6 Functional studies on WT AR and the AR mutant S650A
CHO cells were transfected with 50 ng of reporter construct MMTV-Luc, different amounts of DNA
plasmids from either the AR or AR mutant S650A (A), C-terminal construct AR104 or C-terminal
mutant construct AR104/S650A together with 10 ng of N-terminal construct pSVAR(TAD1-494)
(B) or 100 ng of TIF2 cDNA (C). The cells were harvested 16 h after treatment with ethanol or
1 nM R1881. Fold induction is shown at the top of each bar and represents the ratio of activity
determined after incubation in the presence or absence of R1881.
The AR protein can undergo conformational changes resulting
in intra-molecular interaction between the N- and C-terminal
domains [32,37] and this N- and C-terminal interaction can be in-
fluenced by several mutations in the AR, resulting in altered trans-
criptional activation activity of the AR [38,39]. To examine
whether phosphorylation exerts an influence on this interaction,
the C-terminal-domain construct containing the S650A mutant
and the N-terminal-domain construct were co-transfected in CHO
cells. As shown in Figure 6(B), the S650A mutant displayed a
similar functional N- and C-terminal interaction as the WT AR
C-terminal construct.
To investigate whether phosphorylation has an influence on
TIF2 co-activation, CHOcellswere co-transfectedwith constructs
of AR C-terminal domain with or without the S650A substitution
and TIF2. The mutant showed a similar functional interaction
with TIF2 as the WT AR C-terminal domain (Figure 6C).
Figure 7 Immunoblot of S650A and S515A AR mutant isoforms
AR S650A and S515A mutants were expressed in COS-1 cells in the absence or presence of
10 nM R1881 for 16 h. The AR mutants were immunoprecipitated with the monoclonal antibody
F39.4.1, separated by SDS/PAGE (7 % gel), blotted and immunostained with the polyclonal
antibody SP197.
AR isoforms on SDS/PAGE
It has been shown that substitution of the phosphosite Ser-94
by an alanine residue results in a loss of isoforms both in the
absence and presence of hormone [19]. To determine whether
there is a change in isoform pattern of the AR mutants S650A
and S515A, these mutants were expressed in COS-1 cells and
immunoprecipitated. The precipitatedARmutants were separated
by SDS/PAGE. The isoform patterns of both mutants were similar
to the WT AR (Figure 7). Both mutants expressed two isoforms
in the absence of hormone and three isoforms in the presence of
R1881. This indicates that Ser-515 and Ser-650 are not essential
for the migration of 112 and 114 kDa isoforms in the absence or
presence of R1881. Furthermore, these results demonstrate that
loss of phosphorylation on certain sites does not always result in
a change in isoform pattern.
DISCUSSION
The present study shows that the AR isoform pattern after AR
de novo synthesis is directly linked to differential phosphoryl-
ation. It appeared that, after synthesis, the AR 110 kDa isoform
is predominantly phosphorylated at Ser-650, and there is a higher
phosphorylation level for other existing sites in the 112 and
114 kDa isoforms. These results reveal that Ser-650 is consti-
tutively phosphorylated. Moreover, loss of phosphorylation on
certain sites does not always result in a change in isoform pattern.
Functional analysis of the identified phosphosites Ser-94, Ser-650
and Ser-515 revealed that substitution of these sites with alanine
does not influence AR function.
Recently, several AR phosphosites were identified after transi-
ent expression in COS-1 cells, by sequencing AR peptides using
tandem MS and Edmann degradation [16]. Our approach was
different, i.e. RPHPLCwas used instead of two-dimensional thin-
layer electrophoresis and ascending chromatography. With the
purified fractions of the tryptic peptides containing possible phos-
phosites, tandem MS can be a good tool for identification.
However, it is not always possible to identify the exact position of
the phosphate group. Fragmentation data may lack the specific
fragment ions containing the phosphate group owing to the
individual fragmentation behaviour of the peptide or by loss of
their positive charges during the collision-induced dissociation.
Although all fractions contained radioactivity, only three phos-
phopeptides could be identified. A possible explanation is that
the concentration of the peptides containing the phosphate group
is too low or the peptides containing the phosphate group are
not easily ionized with electrospray. MS is a valuable tool, but
additional information, such as site-directed mutagenesis in this
case, is necessary.
The autoradiogram and the HPLC elution pattern revealed that
the phosphorylation was increased approx. ten times. A previous
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study showed that hormone binding results in an increased phos-
phorylation of existing phosphorylated sites by approx. 1.8 times
[15]. This indicates that the apparent extra phosphorylation of
approx. five times results from stabilization by hormone binding.
The phosphorylation pattern of the isoforms revealed that
Ser-650 is already phosphorylated in the 110 kDa isoform
and Ser-94 in the 112 kDa isoform. However, these phosphoryl-
ation patterns were studied in the presence of R1881, which raises
the question whether Ser-650 is phosphorylated in the 110 kDa
isoform and Ser-94 in the 112 kDa isoform in the absence of
R1881 as well. However, the RP HPLC elution pattern of the AR
in the absence of R1881 also showed the presence of phosphoryl-
ation in fractions A, B and D (Ser-94 and Ser-650; Figure 2A). It
is therefore probable that the phosphorylation pattern of the 110
and 112 kDa isoforms in absence of R1881 is the same as that in
the presence of R1881. Moreover, this suggests that phosphoryl-
ation of fraction D in the 110 kDa isoform and phosphorylation
of fractions A and B in the 112 kDa isoform are not hormone-
induced.
Surprisingly, site-directed mutagenesis of the Ser-515 to an
alanine residue revealed dephosphorylation of a totally different
site, Ser-650. This type of distal influence on phosphorylation
caused by the substitution of another site has been observed by
others [16]. Gioeli et al. [16] suggested that substitution of Ser-424
with an alanine residue resulted either in the mobility shift of
a phosphorylated peptide or in phosphorylation of new sites.
In the present study, the dephosphorylation of Ser-650 induced
by the S515A substitution might be due to a conformational
change, which resulted in a surface more accessible for phospha-
tases or less accessible to kinases. Interestingly, both sites are
flanking the DNA-binding domain and are located in flexible
regions of the AR protein.
The reason why substitution of Ser-515 with an alanine residue
does not result in the disappearance of phosphorylation in frac-
tion E might be that other serine residues in this peptide are phos-
phorylated as well. Although these serine sites are not predicted
as potential phosphosites by NetPhos [40], it predicts that
Tyr-513 is a phosphorylation consensus site [40]; however, two-
dimensional phosphopeptide mapping studies have shown that
only serine residues in the AR are phosphorylated [16,17]. Sub-
stitution of Ser-94 with an alanine residue resulted in a partial
decrease in phosphorylation level (40%) in fractions A and B.
This suggests that one phosphopeptide of the two in fraction B as
seen on the peptide gel was identical with a peptide with the same
mass and charge in fraction A. In addition, this also suggests that
there might be another peptide present in both fractions. Alternat-
ively, the presence of a partially digested peptide containing
Ser-94 is excluded. The partially digested peptide would consist
of amino acids 41–99 and contains the identified phosphosite
Ser-81 [16].However, the peptidewill be very large and, therefore,
difficult to elute from an SDS/polyacrylamide gel. Furthermore,
the presence of two phosphopeptides only in fraction B and not
in fraction A is in favour of a complete digestion.
Substitution of Ser-851 with an alanine residue did not result
in the disappearance of radioactive phosphate in fraction A.
Partial digestion of AR, resulting in a peptide containing Ser-851
and another potential phosphorylation site, is unlikely, since this
would result in a very large peptide that cannot be eluted from
a gel. Substitution of Ser-851 did not result in a change of phos-
phorylation in fraction A or other fractions (results not shown),
which indicates that Ser-851 is not a phosphosite at all. The
presence of another phosphopeptide cannot be excluded.
A change in AR phosphorylation appears to have no prominent
function in AR transactivation. Similar findings were reported
by Gioeli et al. [16] by using the PSA-Luc reporter construct in
CV1 cells. In contrast, Zhou et al. [22] showed a decreased trans-
activation of the mutant S650A of 10–30% on the MMTV-Luc
reporter also in CV1 cells.
It appears that phosphorylation does not play a major role in
hormone-induced AR N- and C-terminal interaction or TIF2 co-
activation, although it cannot be excluded that the cellular context
as well as the reporter construct could influence this activity and
that other so far unidentified phosphosites are involved [41].
After AR de novo synthesis, the 110 kDa isoform became
immediately and predominantly phosphorylated on Ser-650. The
112 kDa isoform displayed an additional phosphorylation of
Ser-94 and another peptide in fractions A and B only. The
relationship between phosphorylation of Ser-94 and the appear-
ance of the 112 kDa isoform corresponds to an immunoblot study
in which S94A caused disappearance of the 112 kDa isoform in
the absence of hormone and disappearance of the 114 kDa isoform
in the presence of hormone [19].
In contrast with S94A AR mutant, substitution of Ser-650 with
an alanine residue does not influence the isoform pattern on SDS/
PAGE, which is understandable because Ser-650 phosphorylation
occurs already in the 110 kDa isoform and is unchanged in the
112 kDa isoform and slightly changed in the 114 kDa isoform.
The Ser-650 site represents basal phosphorylation of the AR
and only changes in phosphorylation of other sites could perhaps
contribute to the appearance of the isoforms. Substitution of the
phosphosite Ser-81 to a glycine residue resulted in the loss of
the largest isoform irrespective of the presence of ligand [19].
Similar results were obtained for the double-mutant S81/94A
[22]. However, substitution of Ser-81 with an alanine residue
resulted in the loss of one isoform only in the presence of hormone
(results not shown). The RP HPLC elution pattern of the three
isoforms illustrated the correlation between the phosphorylation
status of sites other than Ser-650 and the migration pattern of the
three AR isoforms during SDS/PAGE. Phosphorylation does not
necessarily contribute to the appearance of isoform as shown by
the mutant S650A.
The appearance of the 114 kDa isoform induced by R1881 is
directly linked to an overall increase in phosphorylation of several
sites as comparedwith the 110 and 112 kDa isoforms. This overall
increase in phosphorylation was shown previously by van Laar
et al. [15] and Gioeli et al. [16]. However, newly phosphorylated
sites could not be identified. It is quite probable that these sites
are important for the hormone-regulated transactivation of the
AR, because their phosphorylation is linked to DNA-binding and
transcription activation. Furthermore, these phosphorylation sites
could be target sites for AR activation via crosstalk with other sig-
nal transduction pathways as well. Thus identifying the kinase(s)
involved in the phosphorylation of these sites and the possible
signalling pathway will be useful to elucidate the mechanisms of
ligand-independent activation of the AR.
There are several kinases predicted to be involved in the
phosphorylation of AR. The identified phosphosites Ser-94 and
Ser-650 are so-called Ser-Pro sites, which can be phosphorylated
by serine-proline-directed kinases (Ser/Thr-Pro), MAPK (mito-
gen-activated protein kinase) and cyclin-dependent kinases such
as Cdc2 and Cdks. In addition, Ser-650 is a specific consensus site
for casein kinases 1 and 2. There are conflicting data concerning
which kinases phosphorylate the AR. It has been shown that pro-
tein kinase C [16,28], MAPK and AKT kinase [16] have no in-
fluence on the phosphorylation of the AR. However, other in vitro
kinase studies showed that AKT [24,25] is capable of phos-
phorylating the AR. Furthermore, MAPK was also a candidate
protein kinase of the AR [26]. However, in that particular study,
the phosphorylation status of the MAPK site S515A AR mutant
was not investigated [26].
c© 2004 Biochemical Society
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Although basal phosphorylation of the AR does not seem to
have a function, it is quite probable that a hormone-regulated
phosphorylation of theAR is associatedwith transcriptional activ-
ation. Identification of the hormone-induced AR phosphorylation
sites and subsequent elucidation of their possible function by
mutational analysis in vivo could contribute significantly to our
understanding of themechanismof androgen action. Furthermore,
it could reveal new targets for intervention in androgen action in
prostate cancer.
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a b s t r a c t
A novel mutation F826L located within the ligand binding domain (LBD) of the human androgen receptor
(AR)was investigated. Thismutationwas found in a boywith severe penoscrotal hypospadias (classified as
46,XYDSD). The ARmutant F826L appeared to be indistinguishable from thewild-type AR,with respect to
ligand binding affinity, transcriptional activation of MMTV-luciferase and ARE2-TATA-luciferase reporter
genes, protein level in genital skin fibroblasts (GSFs), and sub-cellular distribution in transfected cells.
However, an at least two-fold higherNH2-/COOH-terminal domain interactionwas found in luciferase and
GST pull-down assays. A two-fold increase was also observed for TIF2 (transcription intermediary factor
2) co-activation of the AR F826L COOH-terminal domain. This increase could not be explained by a higher
stability of the mutant protein, which was within wild-type range. Repression of transactivation by the
nuclear receptor co-repressor (N-CoR)wasnot affectedby theARF826Lmutation. Theobservedproperties
of AR F826L would be in agreement with an increased activity rather than with a partial defective AR
transcriptional activation. It is concluded that the penoscrotal hypospadias in the present case is caused
by an as yet unknown mechanism, which still may involve the mutant AR.
© 2008 Elsevier Ireland Ltd. All rights reserved.
1. Introduction
The androgen receptor (AR) belongs to the superfamily of
nuclear receptors (Mangelsdorf et al., 1995; Beato et al., 1995) and is
categorized in the subfamily of ligand-inducible steroid hormone
receptors. Like the other steroid hormone receptors, the AR con-
Abbreviations: aa, amino acid; AD, activation domain; AF2, activation function 2;
DHT, 5-dihydrotestosterone; DSD, disorders of sex development; GFP, green fluo-
rescent protein; GSF, genital skin fibroblast; LBD, ligand binding domain; LBP, ligand
bindingpocket;N-CoR,nuclear receptor co-repressor;NC-TDI,NH2-/COOH-terminal
domain interaction; NTD, NH2-terminal transactivation domain; T, testosterone;
TIF2, transcriptional intermediary factor 2; wt, wild-type.
∗ Corresponding author at: Department of Reproduction and Development, Eras-
mus MC, Room Ee 902, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Tel.: +31 10 7043574; fax: +31 10 7044736.
E-mail address: h.wong@erasmusmc.nl (H.Y. Wong).
sists of an NH2-terminal transactivation domain (NTD; amino acids
1–557), a DNA binding domain (DBD; aa 558–623), followed by a
flexible hinge region (aa 624–670) and a ligand binding domain
(LBD; aa 671–919) (Lubahn et al., 1988).
The NTD and the LBD account for the transcriptional activity of
the AR (Brinkmann et al., 1999). The NTD is involved in transacti-
vation via the ligand dependent activation function 1 (AF1) region,
which consists of aa 51–217 (Jenster et al., 1991). The LBD harbours
theAF2,which is involved in ligand-dependent transactivation, and
it also takes part in functional interaction with co-factors (Moras
and Gronemeyer, 1998; Jenster et al., 1995). Upon ligand binding, a
large group of co-factors can interact via the AF2, which is identi-
fied in helix 12 between residues 893 and 900 (Wurtz et al., 1996).
For example, TIF2 co-activation occurs when TIF2 binds to this
AF2 activation domain (AD) core via its LXXLL leucine motif and
thereby enhances AR transactivation (Slagsvold et al., 2000; Heery
et al., 1997; Berrevoets et al., 1998; Bevan et al., 1999). Besides
0303-7207/$ – see front matter © 2008 Elsevier Ireland Ltd. All rights reserved.
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co-activators, also co-repressors such as nuclear receptor co-
repressor (N-CoR) can bind to the AR, to both the NTD and the
COOH-terminal domain (Cheng et al., 2002).
Furthermore, once the ligand is bound, an intra- and/or inter-
molecular interaction takes place between the NH2-terminal and
COOH-terminal domain of the AR, the so-called NH2-/COOH-
terminal domain interaction (Doesburg et al., 1997; Langley et
al., 1995). This interaction, herein abbreviated as NC-TDI, occurs
through the FXXLFmotif in the NTD (He et al., 2000; Steketee et al.,
2002), and also the AF2 AD core plays a role (Berrevoets et al., 1998;
Langley et al., 1998; Doesburg et al., 1997; He et al., 1999). Recently,
experimental evidence was provided for the preference of the AR
binding to FXXLF motifs, by structural predictions based on pep-
tide interactions and on the crystal structure of the LBD containing
a bound FXXLF motif containing peptide (He et al., 2004; Dubbink
et al., 2004).
The influence on AR target gene expression will change dra-
matically, if the AR is not functioning properly due to mutations.
Mutations resulting in decreased ligand affinity, co-activator
interaction or DNA binding, ultimately lead to a decreased AR
transcriptional activation potential (http://androgendb.mcgill.ca).
Such mutations have been described for 46,XY individuals with
the androgen insensitivity syndrome (AIS), ranging frompartial AIS
(PAIS) to complete AIS (CAIS). AIS is classed as a 46,XY disorder of
sex development (DSD) (Quigley et al., 1995; Hughes et al., 2006).
In the present study, a novel AR mutation, F826L, was found
in a 46,XY DSD boy with severe penoscrotal hypospadias, possibly
associated with PAIS. Hypospadias can result from dysregulation
of androgen synthesis or its actions, but is also found without a
known cause (Hughes et al., 2006). Several aspects of AR functions
were studied to determine the effect of the F826L mutation, which
is located in the LBD. The studies were focused on protein expres-
sion level and hormone binding characteristics of the mutant AR in
genital skin fibroblasts (GSFs) from this boy. In addition, themutant
AR was transiently expressed in CHO and Hep3B cells, to com-
pare its functional properties to that of wild-type AR, with respect
to sub-cellular distribution, hormone responsivity, transactivation
potential, NC-TDI, TIF2 co-activation, and repression by N-CoR.
2. Materials and methods
2.1. Clinical data
The 46,XY boywith the ARmutation F826Lwas referred to the clinic for a severe
penoscrotal hypospadias at the age of 6 months. A mutation in codon 826 of the AR
was detected (TTC→TTA) resulting in a substitution of a phenylalanine by a leucine
residue. The mutation was also identified in the grandmother and the mother of
the boy. Sequence analysis of in total 252 alleles (from 82 normal men and from
85 normal women) revealed no alterations at codon 826, indicating that the C→A
mutation is not a common AR polymorphism. The poly Gln, Gly and Pro stretches
were22, 17and8 residues in length, respectively, andwithin thenormal range. There
were no reports on other affected family members. Furthermore, based on a human
chorionic gonadotrophin (hCG) stimulation test at the age of 6 months, well-known
causes of 46,XY DSD such as Leydig cell hypoplasia, 17-hydroxysteroid dehydro-
genase (HSD) type 3 deficiency, and 5-reductase type 2 deficiency were excluded
(Boehmer et al., 2001). The penoscrotal hypospadias was successfully corrected in
2 stages at the age of 1.5–2 years.
2.2. Site-directed mutagenesis and plasmids
All the AR amino acid numbers used in the present study are based on the
National Center for Biotechnology Information accession number AAA51729, which
refers to theARof919aminoacid residues (Lubahnetal., 1988). TheTTC→TTAmuta-
tion at codon 826 was introduced into the AR cDNA in the pSG5AR construct using
QuikChange Site-Directed Mutagenesis (Stratagene, La Jolla, CA, USA). The mutated
AR fragment was excised by EcoR1 digestion and exchanged with the correspond-
ingwild-type fragment in pSG5AR. Ligationwas performedwith RapidDNALigation
Kit (Roche Diagnostics, Basel, Switzerland). This resulted in pAR-F826L. Preparation
of the GST-AR.LBD construct was described previously (Steketee et al., 2002). The
TTC→TTA mutation was introduced into this construct using the same approach.
The NH2-terminal domain AR construct pSVAR(TAD 1–494) and the COOH-
terminal domain AR construct pSVAR-104 (herein indicated as AR-C; aa 537–919)
that were used for the NH2-/COOH-terminal domain interaction and for the TIF2
activation studies were described previously (Doesburg et al., 1997; Jenster et al.,
1995). The pSVAR-104 construct encodes the DBD-hinge-LBD regions of the AR. The
mutation was introduced into the pSVAR-104 construct via the EcoR1 restriction
fragment of pAR-F826L. This resulted in a construct encoding AR-C-F826L.
Generation of pGFP-AR constructs, coding for NH2-terminally tagged GFP-AR
fusion proteins of which the expression is driven by a CMV promoter, has been
describedpreviously (Farla et al., 2004). GFP-AR-F826Lwas constructed by replacing
an EcoRI–PvuI cDNA fragment encoding the LBD of pGFP-AR by the same fragment
of pAR-F826L. All constructs were sequenced to check for errors.
The N-CoR expression vector was constructed as described previously
(Berrevoets et al., 2004).
2.3. Scatchard plot analysis
A genital skin biopsy was obtained from the boy for the genital skin fibroblasts
(GSFs) culture. The GSFs were cultured in minimal essential medium containing
1% (v/v) nonessential amino acids (Invitrogen, Carlsbad, CA, USA), 10% (v/v) fetal
calf serum (FCS; Hyclone, Logan, UT, USA), 100 IU/ml penicillin, and 100g/ml
streptomycin (BioWhittaker, Verviers, Belgium). For ligand binding characteristics,
a whole-cell binding assay was performed as previously described (Bruggenwirth
et al., 1996). Briefly, GSFs were cultured to confluency, washed once with PBS, and
subsequently incubated overnight in medium without serum. Next, the cells were
incubated for 1h at 37 ◦C with increasing concentrations of the radiolabeled syn-
thetic androgen 3H-R1881 (NEN Life Science Products, Boston, MA, USA) in the
absence or presence of a 200-fold excess of nonradioactive R1881. Cells were then
placed on ice, washed 4 times with ice-cold PBS, and subsequently lysed in 0.5M
NaOH. 3H activity in the lysate was measured using a liquid scintillation counter.
Scatchard analysis was carried out to determine the equilibrium dissociation con-
stant (Kd) using the Kell software package (Radlig, Biosoft, Ferguson, MO, USA).
Protein measurement was performed with the RCDC protein assay according to the
instructions from the manufacturer (Bio-Rad, Hercules, CA, USA).
2.4. Luciferase assay
For transcription activation studies, CHO cells were cultured in DMEM/F12
medium (Invitrogen), supplemented with 5% (v/v) fetal calf serum (FCS; Hyclone)
that was dextran-coated charcoal-stripped, 100 IU/ml penicillin, and 100g/ml
streptomycin (BioWhittaker, Verviers, Belgium). For all transcription activation
studies, CHO cells were plated in 24-well plates (Nalge Nunc International,
Naperville, IL, USA) at a density of 2×104 cells per well. After 24h, cells were trans-
fected using FuGENE6 reagent (Roche Diagnostics), according to the instructions
of the manufacturer, at a DNA:FuGENE ratio of 1:2. The DNA mixture was com-
posed of 50ng/well of mouse mammary tumour virus (MMTV)-luciferase (LUC)
reporter plasmid, 3ng/well of SV40-Renilla-LUC, increasing concentrations of either
wild-type pSG5AR or pAR-F826L (0.1–3ng/well), and carrier plasmid pTZ19 to
adjust to a total amount of 250ng DNA per well. Five hours after transfection,
1nM R1881 or vehicle (0.1%, v/v, ethanol) was added to the cells, or in the case
of dose–response curves a range of 0.1pM to 1M R1881 was added. Testosterone
or 5-dihydrotestosterone were also added in a concentration range of 0.1pM to
1M as indicated in the figures (Steraloids Inc., Wilton, NH, USA). After overnight
incubation, cells were lysed in 50l lysis LUC buffer [25mM Tris-phosphate (pH
7.8), 15%, v/v, glycerol, 1%, v/v, Triton X-100, and 1mM dithiothreitol], and 25l
lysate was used to measure LUC activity. At 10min after addition of 25l Dual-Glo
the MMTV-LUC activity was measured. The luciferase reaction was stopped with
25l “Stop and Glo” and 10min thereafter the Renilla-LUC activity was measured
(Promega, Madison, WI, USA). The data shown are the mean of at least 2 (T) or
3 (R1881 and DHT) independent experiments (mean± S.E.M.). For this assay also
ARE2-TATA-LUCwas used. This luciferase reporter construct contains 2 AREs in front
of the E1b TATA sequence as a promoter (Jenster et al., 1997). To perform both LUC
assays and immunoblots from the same lysates, 12.5 times the usual amount of CHO
cells and DNA constructs were used. Thus 250,000 CHO cells were used for every
condition of which 20,000 were used for the LUC assay and the remaining cells for
the immunoblot.
2.5. Western blot analysis
For AR Western blot analysis, GSFs containing either the wild-type AR or the
F826L AR were cultured in the presence of unstripped FCS for 7 days, as described
above. When grown to confluency, medium was replaced by medium containing
10% (v/v) dextran-coated charcoal-stripped FCS in the presence of increasing con-
centrations of R1881 or vehicle (0.1%, v/v, ethanol) for 24h, and GSFs were washed
with PBS, collected in ice-cold PBS, and centrifuged for 5min at 800× g. The cell
pellet was resuspended in 100l ice-cold RIPA buffer [40mM Tris–HCl (pH 7.4),
5mM EDTA, 10%, v/v, glycerol, 10nM sodium phosphate, 10mM sodium molybdate,
50mM NaF, 0.5mM sodium orthovanadate, 10mM dithiothreitol, 1%, v/v, Triton X-
100, 0.08%, w/v, SDS, and 0.5%, w/v, desoxycholate] containing Complete protease
 F826L mutation in the human AR       81
inhibitors (Roche Diagnostics) and centrifuged for 10min at 400,000× g. GSF cell
lysates were loaded onto a 7% SDS-polyacrylamide gel and transferred to nitrocel-
lulose membrane (Schleicher & Schuell, Keene, NH, USA). Western immunoblotting
was performed using monoclonal antibody F39.4.1 and proteins were visualized by
Western Lightning chemiluminescence detection (PerkinElmer, Boston, MA, USA).
Western immunoblotting of CHO cells was performed by using lysates from the
correspondingLUCassay, by immunoprecipitationwith themonoclonalARantibody
F39.4.1 followed by SDS-PAGE, and subsequent detection with polyclonal antibody
SP197 targeting the NH2-terminal domain of the human AR (Kuiper et al., 1993).
2.6. NH2-/COOH-terminal domain interaction (NC-TDI) assay and TIF2 activation
assay
The functional NC-TDI assay and TIF2 activation assaywere performed in essen-
tially the sameway as the transactivation assay described above, except for the used
constructs. For the NC-TDI assay, 100ng/well of the NH2-terminal domain AR con-
struct AR-N (pSVAR(TAD 1–494)) (Doesburg et al., 1997) was used in combination
with increasing concentrations of the COOH-terminal domain AR construct AR-C
(pSVAR-104) (Jenster et al., 1995) or AR-C-F826L (0.3–30ng/well).
For TIF2 co-activation assay, 100ng/well of TIF2 expression vector was added in
combination with increasing concentrations of constructs encoding AR-C or AR-C-
F826L (0.3–30ng/well).
2.7. N-CoR repression and N-CoR-TIF2 competition assay
The functional N-CoR repression and N-CoR-TIF2 competition assays were per-
formed by essentially the same procedure as the transactivation assay described
above. For the N-CoR repression assay, different amounts of N-CoR expression
constructs were transfected together with 3ng of either wild-type pSG5AR or pAR-
F826L expression constructs. For the N-CoR-TIF2 competition assay, 30ng/well of
TIF2 and/or N-CoRwas used. pSG5 vector was added to obtain equal molar fractions
of plasmid in each well for both assays.
2.8. GST pull-down assay
In vitro interaction assays (pull-down assays) were performed as described pre-
viously (Steketee et al., 2002). In short, CHO cells were transfected with pSVAR(TAD
1–494) and either GST-AR.LBD-wt or GST-AR.LBD-F826L. After overnight incuba-
tion in medium supplemented with 100nM R1881 or vehicle, cells were lysed and
rotated for 5h at 4 ◦C with glutathione–agarose beads. Next, beads were washed,
subsequently boiled in Laemmli sample buffer, and subjected to SDS-PAGE. After
Western blotting, visualization of pSVAR(TAD 1–494) was performed with the AR
antibody SP197, and of GST-AR.LBDwith the AR antibody SP066 (Jenster et al., 1995).
The expression of eachproteinwas semi-quantified byQuantityOne® (Bio-Rad). The
relative NC-TDIwas determined as the ratio between the blotted protein amounts of
the NH2-terminal domain and the corresponding COOH-terminal domain. The ratio
of the wild-type AR-LBD expression vector was set at 1 and the ratios for 3 AR F826L
isolates were determined relative to that of the wild-type AR-LBD.
2.9. Confocal microscopy of GFP proteins
Hep3B cells were cultured in MEM (Cambrex, East Rutherford, NJ, USA) sup-
plemented with 2mM l-glutamine, 100U/ml penicillin, 100g/ml streptomycin and
5% (v/v) FCS (PAN Biotech GmbH, Aidenbach, Germany). Two days before confo-
cal microscopy, cells were seeded on glass coverslips in six-well plates. One day
prior to confocal microscopy, medium was substituted by medium supplemented
with 5% dextran-coated charcoal-treated FCS. Four hours aftermedium change cells
were transfected with 1g/well GFP-AR expression constructs in FuGENE6 (Roche)
transfection medium. Four hours after transfection, the medium was replaced by
medium containing 5% dextran-coated charcoal-stripped FCS with or without 1nM
R1881. Live-cell imaging was performed using a Zeiss LSM510 Meta confocal micro-
scope (Carl Zeiss, Jena, Germany) using the 488nm laser line of a 30mW Ar laser
with tube current set at 6.1A. Cells were kept at 37 ◦C. Images were obtained using
a 40×/1.3 NA oil immersion lens using 505–530nm emission filters.
2.10. Protein structure
The three-dimensional (3D) crystal structure of the AR ligand binding pocket
complexed with R1881 was obtained from the Protein Data Bank (PDB; accession
number 1XOW) deposited in the data bank byHe et al. (2004). The diagram showing
the LBD and selected residues that were subject to mutation was created using the
ViewerLite 5.0 program from Accelrys. The distance between amino acid residues
and the amino acid interaction surface were predicted by the ligand–protein con-
tacts (LPC) software (Sobolev et al., 1999).
Fig. 1. Expression and ligand binding properties of AR F826L in genital skin fibrob-
lasts (GSFs). (A) AR protein expression levels were analysed in GSFs after incubation
for 24h in the presence of R1881 (1, 10, and 100nM) or vehicle alone (0.1%
ethanol). An amount of 12g lysate was subjected to SDS-PAGE and immunoblot-
ting with AR monoclonal antibody F39.4.1. (B) Ligand binding properties of AR
F826L were determined by Scatchard analysis, after incubation of GSFs with
1–0.5–0.25–0.1–0.05–0.025nM3H-R1881 for 1h. Thedissociation constant (Kd)was
determined with the KELL program (Biosoft® KELL).
3. Results
3.1. Ligand binding and expression of AR F826L in genital skin
fibroblasts
To determine whether the expression of the F826L AR mutant
in GSFs was affected by the mutation, an immunoblot was per-
formed after incubation of GSFs with different concentrations of
R1881orvehicle for24h. Theproteinexpression level ofARF826L in
GSFs appeared to be similar at every R1881 concentration (Fig. 1A).
Scatchard plot analysis revealed aKd value of 0.073nM forAR F826L
versus a Kd value of 0.058nM for AR wild-type (normal range:
0.03–0.13nM) (Fig. 1B). The number of binding sites in the GSFs
of AR F826L was 57.2 fmol/mg and for AR wild-type 61.2 fmol/mg
(normal range: 39–169 fmol/mg) (Bruggenwirth et al., 1997). In
conclusion, the F826L mutation in the AR did not influence the
expression level and ligand binding properties of the AR.
3.2. Transcriptional activation and expression of AR mutant
F826L
The ligand-induced transactivation activity of the AR mutant
F826L appeared to be similar to that of the wild-type AR with
the MMTV-LUC reporter construct (Fig. 2A and B). Similar data
were found with the minimal promoter construct ARE2-TATA-
LUC (data not shown). To exclude ligand specificity of the mutant
the ARE2-TATA-LUC reporter was also tested in the presence of
5-dihydrotestosterone (DHT). Also under these conditions the
transactivation of the AR mutant F826L was found to be identical
to that of the wild-type AR (data not shown).
To study whether the mutation affected AR stability, an
immunoblot was performed with cell lysates used in the luciferase
assay presented in Fig. 2A. The expression level of ARmutant F826L
protein in CHO cells was only slightly higher, compared to the AR
wild-type expression level (Fig. 2C). It can be concluded that the
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Fig. 2. Transcriptional activation of AR mutant F826L. (A) CHO cells were trans-
fected with increasing amounts (0.1, 0.2, 0.3, 0.4, 1 and 3ng/well) of DNA plasmids
expressing either wild-type (wt) AR or AR mutant F826L, both in combination with
50ng of the reporter construct MMTV-LUC and 3ng/well of Renilla luciferase. The
cells were harvested 16h after treatment with 1nM R1881 or vehicle and luciferase
activity was measured. Represented are the means± S.E.M. for 3 separate experi-
ments. The MMTV-LUC activity was normalized with the Renilla LUC activity and
the activity of 1ng wt AR/well was set at 100%. Fold induction is shown at the top
of each bar and represents the mean ratio of activity determined after incubation
in the presence or absence of R1881. Statistical significance was calculated using
the Student’s t-test (p<0.01). (B) Dose–response curves of the wt AR and AR F826L
constructs (1ng/well) with increasing concentrations of R1881. LUC activity of the
wt AR at 1nM R1881 was set at 100%. (C) Part of the cell lysates used in the LUC
assay were used for immunoblotting. Cell lysates of CHO cells transfected with dif-
ferent amounts of DNA and incubated with 1nM R1881 were immunoprecipitated
with monoclonal AR antibody F39.4.1. The precipitate was thereafter subjected to
SDS-PAGE and immunoblotting with polyclonal AR antibody SP197.
mutation F826L did not influence the transactivation function and
stability of the AR protein.
3.3. Sub-cellular distribution of AR mutant F826L
The sub-cellular localisation of the AR mutant F826L, was
determined in the presence and absence of hormone by confo-
cal microscopy after transfection of GFP-AR and GFP-AR-F826L
expressing constructs into Hep3B cells. Both GFP-AR and GFP-AR-
F826Lwere predominantly located in the cytoplasm in the absence
of hormone (Fig. 3A and B). In the presence of 1nM R1881 both
GFP-AR and GFP-AR-F826L were translocated in a similar way to
Table 1
Quantification of GST pull-down assay
N/C ratioa Relative to wtb
Wild-type AR 0.1 1
AR F826L clone 1 0.6 4.7
AR F826L clone 2 0.3 2.2
AR F826L clone 3 0.3 2.7
a The relative NC-TDI from Fig. 6 was determined as the ratio between the blotted
protein amounts of the NH2-terminal domain (N) and the corresponding COOH-
terminal domain (C) in the pull-down fraction.
b The ratio of the wild-type (wt) AR was arbitrarily set at 1 and the ratios of the 3
AR F826L isolates (clones 1, 2 and 3) were determined relative to the wt AR.
the nucleus and displayed a typical punctuate nuclear distribution
pattern (Fig. 3C and D). This typical speckled pattern indicates an
active transcription of endogenous genes (Farla et al., 2005; van
Royen et al., 2007). It can be concluded that the F826L mutation
did not influence the sub-cellular distribution of the AR mutant
F826L.
3.4. Functional NH2-/COOH-terminal domain interaction
(NC-TDI) of AR mutant F826L
NH2-/COOH-terminal domain interaction (NC-TDI) is an impor-
tant parameter of AR function. The F826Lmutantwas tested for this
interaction. CHO cells were co-transfected with AR-NH2-terminal
domain, MMTV-LUC, and an increasing amount of either wild-
type AR-COOH-terminal domain AR-C or AR-C-F826L expression
vectors. In the presence of 1nM R1881, AR-C-F826L displayed an
almost two-fold increase in NC-TDI as compared with wild-type
AR (Fig. 4A; p<0.01). Immunoblots of cell lysates used in the LUC-
assay of Fig. 4A showed that the expression of AR-C-F826L was not
different from that of the wild-type AR-C (Fig. 4B).
The effect of different R1881 concentrations on the NC-TDI
was compared with that of testosterone (T) and of 5-
dihydrotestosterone (DHT) with the same assay and with an
ARE2-TATA-LUC reporter. At 0.1nM or higher concentrations of
R1881, T as well as DHT, the transactivation by AR-C-F826L was
increased, as compared with the transactivation by wild-type AR
(Fig. 5A–C). 0.1 nM T induced a smaller increase as compared with
DHT and R1881 for both the wild-type and mutant AR, indicat-
ing and confirming the relative lower affinity of the mutant and
wild-type receptors for T. It can be concluded that all three hor-
mones (R1881, T and DHT) display an at least two-fold increase
in the NC-TDI assay for the mutant AR-C-F826L as compared with
the wild-type AR-C. A similar increase for the mutant AR was also
observed with MMTV-LUC as reporter in the presence of DHT or
R1881 (data not shown).
3.5. GST pull-down assay of AR F826L
To confirmthe increasedNC-TDI ofARmutant F826L, aGST-pull-
down assaywas performedwith lysates fromCHO cells transfected
with the ARNH2-terminal domain expression vector and one of the
GST-AR.LBD constructs. The experiment was performed in tripli-
cate with 3 different GST-AR.LBD-F826L cDNA isolates. After GST
pull-down, SDS-PAGE and immunoblotting, the relative NC-TDI in
the presence of 1nM R1881 was determined as the ratio between
the blotted protein amounts of the NH2-terminal domain and the
corresponding COOH-terminal domain. The ratio for the wild-type
AR-LBD expression vector was arbitrarily set at 1 and the ratios for
the 3 AR F826L isolates (clones 1, 2 and 3) were determined rela-
tive to that of thewild-type AR-LBD. The assay revealed that at least
twice the amount of the NH2-terminal domainwas pulled down by
the 3 GST-AR.LBD-F826L isolates as compared with the wild-type
AR-LBD (Fig. 6 and Table 1).
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Fig. 3. Sub-cellular distribution of AR mutant F826L. Confocal laser-scanning microscope images of Hep3B cells transfected with 1g of GFP-AR or GFP-AR-F826L in the
absence of ligand (A and B) or in the presence of 1nM R1881 (C and D). The bars represent 10m.
3.6. TIF2 co-activation of AR mutant F826L
Interaction of the co-activator TIF2 with the COOH-terminal
domainof theARcanprovideadditional informationonAR function
(Berrevoets et al., 1998). To examine activation of the AR mutant
F826L by TIF2, an expression vector encoding this co-activator was
co-transfected with AR-C-F826L. The co-activation of AR-C-F826L
was significantly higher (p<0.01), up to two-fold compared to the
result obtained for the wild-type AR-C (Fig. 7A).
The same assay was performed with increasing concentrations
of R1881, testosterone and 5-dihydrotestosterone. From 0.1nM
onwards the TIF2 co-activation of AR-C-F826L by R1881 and DHT
was higher as compared with that of the wild-type AR-C (Fig. 7B
and D). TIF2 co-activation in the presence of T was higher from
1nM onwards for the mutant AR (Fig. 7C). This indicates and con-
firms again the relative lower affinity of T for both the mutant and
wild-type AR. It can be concluded that in the presence of either
R1881, T or DHT co-activation by TIF2 of the AR-C-F826L was at
least two-fold higher than of thewild-type AR-C. A similar increase
for the mutant AR was also observed with MMTV-LUC as reporter
in the presence of R1881 (data not shown).
3.7. Repression of AR mutant F826L by N-CoR, in absence and/or
presence of TIF2
Since the ligand binding affinity and the transactivation activ-
ity of AR F826L were comparable to that of the wild-type AR,
and the NC-TDI and the co-activation by TIF2 of mutant F826L
were increased, the question arose whether the severe penoscrotal
hypospadias of the boy could be explained by preferential binding
of co-repressors by the F826Lmutant. To answer this question, CHO
cells were transfected with either the wild-type AR or AR mutant
F826L with increasing concentrations of N-CoR expression vector
(0–30ng/well), in thepresenceof 1nMR1881.However, in thepres-
ence of N-CoR, the decrease in transactivation of wild-type AR and
AR F826L was not different (Fig. 8A).
The present experiments on the effects of TIF2 co-activation
and N-CoR repression involved relatively high expression levels
of these proteins. Differences between the AR mutant F826L and
AR wild-type, regarding differential affinities for TIF2 or N-CoR,
may go unnoticed in such an analysis. Therefore, we investigated
competition between N-CoR and TIF2, in CHO cells transfected
with AR constructs, and with different combinations of expression
constructs for N-CoR or TIF2. The transactivation observed in the
presence of N-CoR alone decreased with approximately 35%, for
both wild-type AR and AR F826L (Fig. 8B). If both N-CoR and TIF2
expressionvectorswere added, activity couldbe relieved to80–85%
for bothARwild-type andAR F826L (Fig. 8B). In the presence of TIF2
alone, the activity increased for both AR wild-type and AR F826L to
approximately 160% (Fig. 8B).
4. Discussion
The investigated F826L mutation in the AR was found in a
3-year-old boy with severe penoscrotal hypospadias. The grand-
mother and mother of the boy both were carriers of this genetic
alteration. Sequence analysis of 252 alleles (from 82 men and 85
women) and information from the AR gene mutations database
(http://androgendb.mcgill.ca/) revealed that alterations at codon
826 do not occur in the general population. Therefore it is highly
unlikely that the mutation at codon 826 of the AR gene in this
individual reflects a common polymorphism in the AR gene.
Remarkably, the activity of AR mutant F826L was identical to
the wild-type AR with respect to ligand binding, number of ligand
binding sites in GSFs, transactivation and repression. The repres-
sion by N-CoR of both the wt AR and AR mutant F826L could be
relieved by TIF2, although not to 100%. This indicates that repres-
sion by N-CoR is stronger than co-activation by TIF2 under these
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Fig. 4. NH2-/COOH-terminal domain interaction of AR mutant F826L. (A) CHO cells
were transfected with 50ng of reporter construct MMTV-LUC, 3ng/well of Renilla
luciferase, and different amounts (0, 1, 3, 10, and 30ng) of DNA plasmid for either
wt COOH-terminal domain construct AR-C or the mutant construct AR-C-F826L,
both togetherwith 100ng of ARNH2-terminal domain construct pSVAR(TAD1–494)
(AR-N). The cells were harvested 16h after incubation with 1nM R1881 or vehi-
cle, and luciferase activity was measured. Results represent data of 3 experiments
(means± S.E.M.). Fold induction is shown at the top of each bar and represents the
mean ratio of activity determined after incubation in the presence or absence of
R1881. The MMTV-LUC activity was normalized with the Renilla LUC activity and
the activity of wt AR-C at 10ng DNA/well was set at 100%. Statistical significance
was calculated between wt and mutant AR using the Student’s t-test (p<0.01) and
is indicated with asterisks (*). (B) Part of the cell lysates used in the LUC assay was
used for immunoblotting. Lysates of CHO cells transfected with AR COOH-terminal
domain constructs (30ng/well) and incubated with 10nM R1881 were immuno-
precipitated with monoclonal AR antibody F52.24.4 in the presence of 0.3M NaCl.
Subsequently, the immunoprecipitate was subjected to a 10% SDS-PAGE gel elec-
trophoresis and immunoblotted with polyclonal AR antibody SP066 against the
COOH-terminal domain.
conditions, which confirms a previous study for only the wild-type
AR (Berrevoets et al., 2004).
It was thought that AR F826L was more abundantly present
in the nucleus as compared to wild-type AR, resulting in a sim-
ilar outcome of transcription activity measurements, even if AR
F826L would be less active itself. However, this can likely be ruled
out, since the sub-cellular distribution was found to be similar for
AR F826L and wild-type AR. Furthermore, after addition of R1881,
GFP-AR and GFP-AR-F826L displayed a typical punctuate nuclear
distributionpattern, aspreviously shownbyFarlaet al. (2004,2005)
for the wild-type receptor. This typical speckled pattern overlaps
with sites of active transcription (van Royen et al., 2007).
Interestingly, this study showed that the NC-TDI of the AR
mutant F826L was increased compared to the wild-type AR and
this increase was shown with 2 different assays, 2 different pro-
moters and 3 different ligands. This increase in activity could not
be explained by a higher protein stability of the AR mutant. Fur-
thermore, the TIF2 co-activation of AR mutant F826L was also
enhanced compared to the wild-type AR. These experiments also
confirmed the lesser potency of T versus DHT, because higher T
concentrations were needed to achieve the same transcriptional
activity as with DHT (Askew et al., 2007). In addition, the NC-TDI
might be very sensitive to subtle changes in the AR ligand binding
domain. Also for other mutations, information on NC-TDI and TIF2
co-activation can be of much value to detect a possible difference
between wild-type and mutant AR. In contrast to our study, sev-
eral studies showed that AR mutations found in subjects with AIS
Fig. 5. Dose–response of theNH2-/COOH-terminal domain interaction of ARmutant
F826L. (A) NC-TDI of mutant F826L and wt AR COOH-terminal domain (10ng/well)
with AR NH2-terminal domain (100ng/well) in the presence of increasing concen-
trations of R1881. The ARE2-TATA-LUC activity was normalized with the Renilla LUC
activity and the activity of wt AR-C at 10nM was set at 100%. Results are based
on at least 3 experiments (mean± S.E.M.). (B) NC-TDI of mutant F826L and wt AR
COOH-terminal domain (10ng/well) with AR NH2-terminal domain (100ng/well)
in the presence of increasing concentrations of testosterone. The ARE2-TATA-LUC
activity was normalized with the Renilla LUC activity and the activity of wt AR-C
at 10nM was set at 100%. Results represent data of 2 experiments (mean± S.E.M.).
(C) NC-TDI of mutant F826L andwt AR COOH-terminal domain (10ng/well) with AR
NH2-terminal domain (100ng/well) in the presence of increasing concentrations
of 5-dihydrotestosterone. The ARE2-TATA-LUC activity was normalized with the
Renilla LUC activity and the activity of wt AR-C at 10nM was set at 100%. Results are
based on at least 3 experiments (mean± S.E.M.).
and prostate cancer, can result in an altered NH2-/COOH-terminal
domain interactionandco-factor interaction. Fivemutations result-
ing in AIS, L712F, F725L, I737T, Q733H and I898T, respectively, are
located in thehydrophobic region of AF2,which all result in a defec-
tive NC-TDI and in a defective interaction with TIF2 (Quigley et al.,
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Fig. 6. GST pull-down assay of AR F826L. Proteins were produced in CHO cells by
transfection of AR-N (1g) and co-transfected with either the wt GST-AR.LBD con-
struct or one of the 3 isolates of the GST-AR.LBD-F826L constructs (3g). After
overnight incubation in the absence or presence of 100nM R1881 the cells were
lysed. Subsequently, the pull-down assay and SDS-PAGE was performed, followed
by immunodetectionwith AR antibody SP197 against the NH2-terminal domain and
AR antibody SP066 against the COOH-terminal domain.
2004; He et al., 2006). In addition, the AR mutants F725L and I737T
have a defective interaction with SRC1 (Quigley et al., 2004). AR
mutations L907F and R885H, which both can result in an defective
NC-TDI, are also found in close proximity of the AF2 (Jaaskelainen
et al., 2006). Another mutation Q902K, also located close to AF2,
displays a defective NC-TDI and an increased R1881 equilibrium
dissociation constant (Umar et al., 2005). An affected NC-TDI and
TIF2 interaction is also found for two other mutations close to AF2,
G743V (PAIS) and V889M (CAIS) (He et al., 2006; Thompson et al.,
2001). In close proximity of G743, three mutations are reported
in AIS subjects, R871G, S814N and V866M, which were found to
have a defective NC-TDI (Ghali et al., 2003). The M745I mutated
residue from a CAIS subject is part of the ligand binding pocket,
and causes a defective NC-TDI and a defective interaction with
ARA70 (Bonagura et al., 2007). Remarkably, this mutation does not
affect the interaction of AR with TIF2 and SRC1, whereas the R1881
equilibrium dissociation constant is increased 5 times compared
to wild-type AR (Bonagura et al., 2007). Mutations D695N, Y763C,
E772A, R774H, R774C and Q798E from AIS subjects are all located
on the surface of the LBD at a relatively large distance from AF2,
but surprisingly all mutants display a defective NC-TDI (Ghali et
al., 2003; Jaaskelainen et al., 2006). Three of these residues (D695,
Y763 and R774) together with residues R752 and F754 have been
suggested to form a new region for protein–protein interactions,
although this is not supported by experimental data (Jaaskelainen
et al., 2006). Anothermutation, R855H, found in anAIS individual is
located also at a large distance from the AF2 region, within helices
10/11 which contain residues of the ligand binding pocket (Matias
et al., 2000). This mutant displays a decreased NC-TDI, but also
an increased androgen equilibrium dissociation constant (Elhaji et
al., 2004). For prostate cancer, several mutations (V715M, R726L,
H874Y) have been reported displaying either an increased NC-TDI
or an increased p160 co-activator activation or both (Thompson
et al., 2001; Duff and McEwan, 2005; He et al., 2006; Brooke et
al., 2008). The mutation V715M resulted in a small increase of
NC-TDI, but in a normal p160 co-activator activation, while for
the mutant R726L the reverse was found (Thompson et al., 2001).
However, in another study the mutant V715M has been reported
to display an increased NC-TDI as well as an increased p160 co-
activator interaction (He et al., 2006). The mutant H874Y has been
studied extensively and this mutant displayed an increased p160
co-activator interaction (Brooke et al., 2008; Duff and McEwan,
2005; He et al., 2006). Contradictory results were reported with
respect to the NC-TDI. Either wild-type activity (Duff and McEwan,
Fig. 7. TIF2 co-activation of AR mutant F826L. (A) CHO cells were transfected with
50ng of reporter construct MMTV-LUC, 3ng/well of Renilla luciferase, and different
amounts of DNA plasmids from either wt COOH-terminal construct AR-C or mutant
AR-C-F826L, both together with 100ng of a construct encoding TIF2. The cells were
harvested 16h after incubation with either vehicle or 1nM R1881, and luciferase
activity was measured. Results represent data of 3 experiments (means± S.E.M.).
Fold induction is shown at the top of each bar and represents themean ratio of activ-
ity determined after incubation in the presence or absence of R1881. TheMMTV-LUC
activity was normalized with the Renilla LUC activity and the activity of wt AR-C at
10ng DNA/well was set at 100%. Statistical significance was calculated between wt
and mutant AR using the Student’s t-test (p<0.01) and is indicated with asterisks
(*). (B) Dose–response curve of the 2 AR COOH-terminal constructs (10ng/well) in
the presence of TIF2 expression vectors (100ng/well) and increasing concentrations
of R1881. The ARE2-TATA-LUC activity was normalized with the Renilla LUC activ-
ity and the activity of wt AR-C at 10nM R1881 was set at 100%. Results represent
data of at least 3 experiments (means± S.E.M.). (C) Dose–response curve of the 2
AR COOH-terminal constructs (10ng/well) in the presence of TIF2 expression vector
(100ng/well) and increasing concentrations of T. The ARE2-TATA-LUC activity was
normalized with the Renilla LUC activity and the activity of wt AR-C at 10nM T was
set at 100%. Results represent data of at least 3 experiments (means± S.E.M.). (D)
Dose–response curve of the 2ARCOOH-terminal constructs (10ng/well) in the pres-
ence of TIF2 expression vector (100ng/well) and increasing concentrations of DHT.
The ARE2-TATA-LUC activity was normalized with the Renilla LUC activity and the
activity of wt AR-C at 10nM DHT was set at 100%. Results represent data of at least
3 experiments (means± S.E.M.).
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Fig. 8. N-CoR repression of AR mutant F826L. (A) CHO cells were transfected with
50ng of reporter construct MMTV-LUC, 3ng/well of Renilla luciferase, and differ-
ent amounts of N-CoR DNA plasmids together with 3ng of either wild-type AR or
pAR-F826L constructs. In the control situation, equalmolar fractions of empty vector
(pSG5) were transfected. The cells were harvested 16h after treatment with vehicle
alone or 1nMR1881, and luciferasewasmeasured. Results represent data of 3 exper-
iments (means± S.E.M.). The MMTV-LUC activity was normalized with the Renilla
LUC activity. The minus N-CoR situation for each AR construct was set to 100% from
which the relative repression by N-CoR was calculated. (B) Competition between
TIF2 (30ng/well) and N-CoR (30ng/well). Except for the different combinations of
transfected constructs, the assay was performed as described above (A). In the con-
trol situation, equalmolar fractions of empty vector (pSG5)were transfected and the
outcome was set at 100%. Results represent data of 3 experiments (means± S.E.M.).
The MMTV-LUC activity was normalized with the Renilla LUC activity.
2005) or a significant increase was found with the H874Y mutant
(He et al., 2006).
Summarising it can be concluded that mutations in or near the
AF2 region predominantly negatively influence the protein inter-
action with AF2. However, for certain mutations in prostate cancer
a positive influence on protein interactions with AF2 is reported.
Furthermore, mutations in the LBD at a far more distance from AF2
and not influencing ligand binding affinity, seem to influence the
protein interaction with AF2, as well.
What might be causing the increased NC-TDI and the increased
activation by TIF2 observed for the mutant AR F826L? Although
the 3D model for the AR-LBD predicts that residue F826 is nei-
ther part of the ligand binding pocket nor the co-activator binding
groove, this mutation might still influence the co-activator binding
groove indirectly. The ligand–protein contacts (LPC) software pre-
dicts that F826 can have hydrophobic interactions with residues
N727 and L728 (Sobolev et al., 1999). The distance to N727 is 3.5Å
and the distance to L728 is 3.8Å. However, the contact surface area
between F826 and N727 is about 4 times larger than between F826
and L728, which would indicate that F826–N727 might give the
strongest interaction. Residues N727 and L728 are both located
in the loop region between helices 3 and 4 (Fig. 9) (Wurtz et al.,
1996). Changes in the interaction between F826 and either N727
or L728 due to the F826L mutation could have consequences for
positions of residues in the LBD structure including those of the
co-activator groove. Since residues in helix 3 (K717 and K720) and
in the loop region between helices 3 and 4 (R726) belong to the co-
activator binding groove. A subtle rearrangement in the F826–N727
or F826–L728 interaction might have a considerable impact on the
co-factor interaction.
Most importantly, it has been suggested that residue N727 plays
a role in AR transcriptional activation, based on the presence of an
AR mutant N727K found in an individual with PAIS (Yong et al.,
1994). Other data indicated that N727 could influence NC-TDI and
TIF2 co-activation (Lim et al., 2000). Similar to the present findings
for the AR F826Lmutant, Lim et al. (2000) found that, theN727KAR
mutant has unaltered transcriptional activation and ligand binding
activities, but increased NC-TDI and TIF2 co-activation activities,
compared to wild-type AR. However, this was observed using the
synthetic androgen mesterolone, (1--methyl DHT). Remarkably,
when testosterone or DHT was used, the transcriptional activation,
NC-TDI and TIF2 co-activation of the AR N727K mutant were found
to be decreased, compared to the wild-type AR (Lim et al., 2000). It
appears that the effect of the N727K mutant depends on the type
of ligand used. But in the present study, this was not the case. The
synthetic androgen R1881 generated similar results as testosterone
and 5-dihydrotestosterone.
Recently, Estebanez-Perpina et al. (2007) showed that residue
F826 is part of an allosteric regulatory site termed binding func-
tion (BF)-3 in the AR LBD. Mutagenesis of residues that form BF-3
modulated AR function (Estebanez-Perpina et al., 2007). The AR
F826Amutant showednormal,wild-type level ofAR transcriptional
activity (Estebanez-Perpina et al., 2007). However, anothermutant,
F826R displayed a small decrease (15%) in transcriptional activity,
probably caused by the change in hydrophobicity (Estebanez-
Perpina et al., 2007). The F826L mutation changes the hydrophobic
phenylalanine to an even more hydrophobic leucine (hydropathy
Fig. 9. Position of AR F826 in the AR LBD with respect to the co-activator binding
groove. Structural model of the AR LBD with liganded R1881 in the ligand binding
pocket. Residue F826 might have hydrophobic interactions with residues N727 and
L728; the distances are 3.5 and 3.7Å, respectively. N727 and L728 are both in the
loop region between helices 3 and 4. R726 in the loop region and K717 and K720 in
helix 3 belong to the co-activator binding groove. The AR FXXLF peptide is shown to
indicate the co-activator binding groove. K720 and E897 represent the charge clamp
residues essential for binding of FXXLF and LXXLL motifs.
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index changes from 2.8 to 3.8) (Kyte and Doolittle, 1982). The
mutant residue F826A has become less hydrophobic (hydropathy
index of 1.8) and the mutant residue F826R became even lesser
hydrophobic (hydropathy index of −0.8). The hydrophilic arginine
has probably caused the 15% decrease in transcriptional activa-
tion activity. Such a change in hydrophobicity does not seem to
be notable in a functional assay with the full-length mutant AR.
For the AR mutant N727K, the change to a very hydrophilic residue
decreased the transcriptional activity (Lim et al., 2000).
The increase in hydrophobicity of the F826–N727 interaction
appeared tobe associatedwith anenhanced transcriptional activity
whereas a decreased hydrophobicity is associated with a reduced
transcriptional activity. Consequently, the observed increased NC-
TDI and TIF2 co-activation in the present experiments might be
caused by the increased hydrophobicity of the leucine residue of
AR mutant F826L.
Another question that remains, concerns the factor(s) causing
the severe penoscrotal hypospadias phenotype in the boy with the
ARmutation F826L. Several reports describedARmutations inhelix
9 in the region surrounding F826 that resulted in AIS. For example,
Q824L was identified in a boy with a partial androgen insensitiv-
ity syndrome. This mutation resulted in a decreased AR activity,
depending on the type of ligandused. In the presence ofDHT, 62%of
wild-type activitywasobserved,whereaswith the synthetic andro-
gen mibolerone, no difference in activity was found (Giwercman et
al., 2000). Another mutation close to the position of F826, F827V,
found in an individual classified as having CAIS, was reported to
result in just 20% less ligand binding affinity in genital skin fibrob-
lasts (Chavez et al., 2001a). The AR mutant L830V was also found
in a CAIS individual (Chavez et al., 2001b). These facts suggest that
mutations in the region of F826 result in AIS (ranging from par-
tial to complete). It has been shown that different cell types have a
cell-specific expressionof co-factors (Folkers et al., 1998; Shang and
Brown, 2002). The severe penoscrotal hypospadias observed in the
boy carrying the F826L AR mutation might be the result of a com-
bination of a different repertoire of tissue specific co-factors and a
subtle alteration of the co-activator binding groove. Consequently
this can result in less recruitment of important key co-activators,
other than TIF2, in genital skin fibroblasts. Alternatively, an altered
LBD conformation may enhance a preferential recruitment of co-
repressor(s), present in specific androgen target cells.
In conclusion, the mutant F826L displayed an unexpected
increased NH2-/COOH-terminal domain interaction and TIF2 co-
activation. These findings cannot directly explain the observed
severe penoscrotal hypospadias, but offer indirect indications for
an altered AR functioning.
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An oligonucleotide-based assay (OBA) was used to identify novel co-factors that can be recruited by the
deoxyribonucleic acid (DNA)-bound androgen receptor (AR). Nuclear extracts obtained from LNCaP cells,
after incubation with R1881, were incubated with biotinylated oligonucleotides bound to streptavidin coated
beads. The oligonucleotides contain 3 copies in tandem of the androgen responsive element ARE1 from the
prostate specific antigen (PSA) gene promoter. As control incubation, a scrambled version of the tandem ARE1
was used. Immunoblots of the eluents revealed that the AR was bound to the ARE1 oligonucleotide and to a
much lesser extent to the scrambled oligonucleotide. Proteins eluted from the oligonucleotides, were
separated on a 5–15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gradient gel,
followed by identification using mass spectrometry. Identified proteins were scored for having one or more
of the following known properties: nuclear localization, involved in transcription regulation, involvement in
steroid hormone receptor (SHR) function, or specifical involvement in AR function. A total number of 85
nuclear proteins were found in two separate OBAs. Based on peptide counting, we found enrichment of 7
proteins eluted from the ARE1 oligonucleotide, compared to the scrambled oligonucleotide. Taken together
with the obtained scores, these proteins are considered putative AR co-factors. One of these proteins, DDX17,
is known to be a co-factor for estrogen receptor α (ERα), but has never been associated with AR function. The
results indicate that the ARE oligonucleotide-based assay may allow enrichment of new candidate DNA-
bound AR interacting proteins.
Crown Copyright © 2008 Published by Elsevier B.V. All rights reserved.
1. Introduction
Androgens (testosterone and dihydrotestosterone) are powerful
hormones, exerting actions which are essential for male development
and functioning [1]. The androgenic steroid hormones exert their
functions by activating the androgen receptor (AR) after binding to the
ligand binding domain (LBD). Once activated, the AR uses its DNA
binding domain (DBD) to bind to specific DNA sequences, the so-called
hormone or androgen responsive elements (HRE or ARE), which
results in induction or repression of transcription of target genes.
However, androgen mediated transcription regulation does not take
place without the recruitment of several proteins from a repertoire of
co-factors by the AR [2–4]. These co-factors can be divided into 2
groups of chromatin modifying enzymes. One group is the family of
histone modifying enzymes (HME) which influence the DNA–histone
interaction by (de)acetylation and/or (de)methylation of core
histones [5]. The other group of chromatin modifying enzymes is
the ATP-dependent chromatin remodeling complexes (CRC) which
can displace or remove the histone complexes from the DNA. This
group consists of the SWI/SNF, ISWI/hSNF2h, and Mi-2/NURD
complexes [6–12]. Besides chromatin modifying enzymes three other
groups of co-factors can be recruited by the AR. The first group is the
Mediator (MED)-complex (TRAP, DRIP, ARC and SMCC) which is
essential for transcription activation by facilitating RNA-Pol II recruit-
ment [13–15]. The second group consists of co-activators, which can
enhance transcriptional activation, but do not belong to any of the
above-mentioned categories [16,17]. Finally, a last group represses
transcription, the co-repressors. Well known co-repressors in the
nuclear receptor field are N-CoR and SMRT [18,19]. An overview of
co-repressors which are able to inhibit the transactivation of AR and
other nuclear receptors has been published [20].
Co-factors have been isolated by different isolation methods, such
as yeast two-hybrid, mammalian two-hybrid, glutathione S-transfer-
ase (GST) pull-down and co-immunoprecipitation (co-IP) assays. The
protein interactions in yeast two-hybrid and mammalian two-hybrid
assays take place in vivo, in yeast or mammalian cells, respectively.
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The protein (fragment) of interest is expressed as a fusion protein
containing a GAL4–DNA binding domain. If an interaction takes place
with a possible partner containinga transactivationdomain, a functional
transcription factor is formed, which functions as the interaction
indicator [21,22]. Interacting proteins in co-immunoprecipitation assays
are obtained by using antibodies against the protein of interest.
Glutathione–agarose beads are used to capture GST-tagged proteins.
Theprotein of interest and the interactingproteins are either capturedas
an in vivo formed complex, or the complexes are formed in vitro when
cellular extracts are added to immobilised tagged proteins or antibodies.
In the early nineties, several studies showed the effects of DNA on
the conformation of DNA binding transcription regulators [for an
overview: [23]]. It was suggested that DNA alone, or together with
another DNA binding protein on or near the binding site, has allosteric
effects on DNA binding proteins. One study involving ERα and ERβ
clearly showed the allosteric effects of different response elements on
the conformation of these steroid hormone receptors [24]. Remark-
ably, these response elements together with the conformational
change of the ERα and ERβ resulted in a differential recruitment of co-
factors [24]. Recently, it has been shown that different response
elements from one or from different AR responsive promoters can
recruit a different repertoire of proteins [25,26]. Furthermore,
different AR binding response elements modified the hormone
response of the AR in the presence of different co-factors [27]. These
effects on the AR are probably caused by the response element
dependent conformational changes, which in turn influence the co-
factor recruitment and finally the transcription of genes.
The above-mentioned assays for co-factor identification (such as
yeast and mammalian two-hybrid, GST pull-down and co-IP) lack the
involvement of AR DNA binding during or after the procedure to
capture the interacting proteins. These assays may miss interacting
proteins normally attached to DNA-bound AR. Therefore, in the
present study DNA-bound AR interacting proteins are isolated by
using biotinylated oligonucleotides containing ARE1, one of the
strongest AR binding AREs of the prostate specific antigen (PSA)
gene promoter. In this oligonucleotide based assay (OBA), AR-co-factor
complexes from nuclear extracts were reconstituted in vitro and
isolated for further identification by mass spectrometry.
2. Materials and methods
2.1. Cell culture and nuclear extract preparation
AR expressing LNCaP cells were cultured in RPMI-1640 medium
(Invitrogen, Carlsbad, CA, USA), supplemented with 7.5% (v/v)
dextran-coated charcoal-treated fetal calf serum (FCS; Hyclone,
Logan, UT, USA), 100 IU/ml penicillin, and 100 μg/ml streptomycin
(BioWhittaker, Vervier, Belgium). This medium was replaced by
phenol-free RPMI-1640 containing similar supplements, 3 days before
harvesting. The synthetic androgen R1881 was added to a final
concentration of 10 nM, 16 h before harvesting. For harvesting, the
LNCaP cells were first washed twice with PBS and subsequently
scraped with ice-cold Buffer A [40 mM Tris–HCl (pH 7.4), 1 mM EDTA,
10% (v/v) glycerol, 10 mM sodium molybdate, 10 mM dithiothreitol
(DTT), Complete protease inhibitors (Roche Diagnostics, Basel,
Switzerland) and 0.2 μM R1881] and collected. The cell suspension
was frozen for 1 min in liquid nitrogen, thawed at 10 °C and mixed.
This procedure was repeated twice followed by centrifugation at
800×g at 4 °C for 10min. The obtained nuclear pellet was resuspended
and incubated for 5 min in ice-cold Buffer B [Buffer A supplemented
with 0.2% (v/v) Triton X-100], followed by centrifugation at 800×g at
4 °C for 10 min and resuspension in Buffer A. This was followed by
centrifugation at 800×g at 4 °C for 10 min. Extraction was carried
out by immediate resuspension of the nuclear pellet in 1 pellet
volume of Buffer C [Buffer A with 40 mM Tris–HCl (pH 8.5)
supplemented with 1 M sodium chloride] and 2 volumes of Buffer D
[Buffer C supplemented with 0.5 M sodium chloride]. After incubation
on ice for 1 h, the cell suspension was pelleted at 40,000×g for 10 min.
2.2. Oligonucleotide-based assay (OBA)
DNA-protein complexes were purified and analysed for AR content
using an adapted streptavidin–biotin complex DNA binding assay [28].
Two oligonucleotides were used; one contains three copies of the
ARE1 of the PSA promoter [29] and another one with three copies of a
scrambled version of the ARE1 (in capitals, bold and italic). It was
verified that the scrambled version of ARE1 and the flanking
sequences were not similar to an existing steroid hormone responsive
element, androgen responsive element, or a predicted responsive
element to which the AR can bind [30].
PSA ARE1 oligonucleotide
5VcttaaAGAACAGCAAGTGCTattgatttttagAGAACAGCAAGTGCTaattca-
AGAACAGCAAGTGCTtaatt-3′
Scrambled ARE1 oligonucleotide
5VcttaaCACGAGAAGGACTTAattgatttttagCACGAGAAGGACTTAaattca-
CACGAGAAGGACTTAtaatt-3′
The biotinylated oligonucleotides containing three copies of PSA
ARE1 or the scrambled version and their complementary sequence
were mixed in annealing buffer [40 mM Tris–HCl (pH 7.5), 20 mM
MgCl2, 50 mM NaCl], heated to 100 °C, and cooled slowly in boiled
water to room temperature. They were then incubated with washed
Streptavidin agarose beads (Sigma-Aldrich, St. Louis, MO, USA)
overnight, under constant shaking at 4 °C, in oligo binding buffer
[20 mM HEPES (pH 7.6), 10% (v/v) glycerol, 0.5 mM EDTA, 2.5 mM Mg
Acetate, 0.1% (v/v) Nonidet P-40, 130 mM NaCl, 2.5 mMDTT, Complete
protease inhibitors (Roche Diagnostics, Basel, Switzerland) and 0.2 μM
R1881]. It was verified that the AR did not bind to the Streptavidin
agarose beads. The flow-through fraction containing excess oligonu-
cleotides was removed, and the oligonucleotide-loaded agarose beads
were washed with oligo binding buffer. After that, the nuclear extract
was diluted to 130 mM NaCl with oligo binding buffer without NaCl
and supplemented with 0.2 μM R1881. This solution was mixed with
oligonucleotide-loaded agarose supplemented with 14.84 ng/μl of
double-stranded poly(dI–dC, dI–dC) and 14.84 ng/μl double-stranded
poly(dA–dT, dA–dT). Incubation was for 2 h at 4 °C under constant
shaking. After removal of the flow-through fraction, the protein-
bound oligo-loaded beads were transferred to Micro Bio-Spin
chromatography columns (Bio-Rad Laboratories Inc., Hercules, CA,
USA). This was followed by washing with oligo binding buffer
supplemented with 0.2 μM R1881. Elution of bound proteins was
performed with Laemmli sample buffer for 15 min at 4 °C.
2.3. SDS-PAGE, gel staining and Western immunoblotting
The protein content of the complexes was assessed by gel
electrophoresis (5–15% gradient SDS-polyacrylamide gel) and SYPRO
Ruby staining (Molecular Probes Inc., Eugene, OR, USA). For determi-
nation of AR content, the proteins were transferred from a 7% SDS-
PAGE gel to nitrocellulose membrane (Schleicher & Schuell, Keene,
NH, USA). Western immunoblotting was performed using monoclonal
antibody F39.4.1 raised against the human AR NH2-terminal domain
[31] and proteins were visualised by Western Lightning chemilumi-
nescence detection (Perkin-Elmer, Boston, MA, USA).
2.4. Mass spectrometric analysis
SDS-PAGE gel lanes were cut into slices of 1 mm using an
automated gel slicer, and 3 consecutive slices were pooled and
subjected to in-gel reduction with dithiothreitol, alkylation with
iodoacetamide and digestionwith sequencing grade trypsin (Promega
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Madison, WI, USA), essentially as described by Wilm et al. [32].
NanoLC-MS/MS for the first OBA was performed on a CapLC system
(Waters, Manchester, UK) coupled to a Q-ToF Ultima mass spectro-
meter (Waters, Manchester, UK), operating in the positive mode and
equipped with a Z-spray source. The 1100 series capillary LC system
(Agilent Technologies, Palo Alto, CA, USA) coupled to an LTQ mass
spectrometer (Thermo) operating in the positive mode and equipped
with a nanospray source was used for the second OBA. Peptide
mixtures were trapped on a Jupiter™ C18 reversed phase column
(Phenomenex; column dimensions 1.5 cm×100 μm, packed in-house)
at a flow rate of 7 μl/min. Peptide separation was performed on
Jupiter™ C18 reversed phase column (Phenomenex; column
dimensions 15 cm×50 μm, packed in-house) using a linear gradient
from 0 to 80% (v/v) acetonitrile in 0.1 M formic acid during 70 min
and at a constant flow rate of 200 nl/min using a splitter. The
column eluent was directly sprayed into the ESI source of the mass
spectrometer. Mass spectra were acquired in the continuum mode;
fragmentation of the peptides was performed in the data-dependent
mode.
2.5. Data analysis and protein identification
Peak lists were automatically created from raw data files using the
ProteinLynx Global Server software (version 2.0; Waters, Manchester,
UK) for Q-ToF spectra and the Mascot Distiller software (version 2.0;
MatrixScience, London, UK) for LTQ spectra. The Mascot search
algorithm (version 2.0, MatrixScience, London, UK) was used for
searching against the NCBInr database (release data: 3rd March 2006;
taxonomy: Homo sapiens). The peptide tolerance was typically set to
150 ppm and MS/MS tolerance to 0.2 Da in case of Q-ToF spectra, and
to 2 Da and 0.8 Da, respectively, in case of LTQ spectra. Only doubly
and triply charged peptides were searched for. A maximum number of
1 missed cleavage by trypsin was allowed and carbamidomethylated
cysteine and oxidised methionine were set as fixed and variable
modifications, respectively. The Mascot score cut-off value for a
positive protein hit was set to 45. Individual peptide MS/MS spectra
with Mascot scores below 40 were checked manually and either
interpreted as valid identifications or discarded.
3. Results
3.1. Isolation of DNA-bound AR interacting proteins
Searching for novel AR co-factors, an oligonucleotide based assay
(OBA) was used for the isolation and purification of candidate
proteins. The oligonucleotides were biotinylated and contained the
strong ARE1 of the PSA gene in triplicate in tandem [29]. An
oligonucleotide containing the scrambled version of the ARE1 was
used as a control. Streptavidin-agarose beads were first incubated
with one of the oligonucleotides, followed by incubation with the
nuclear extract from LNCaP cells. After elution, the proteins were
separated in a 5–15% acrylamide gradient on a SDS-polyacrylamide gel
and stained with SYPRO Ruby (Fig. 1A). The total protein amount
visible on the gels was comparable between the scrambled and the
ARE1 lane. Furthermore, the protein banding pattern for the two
conditions appeared to be identical, but differed from the input. The
eluents were also analysed by Western immunoblotting using an
antibody targeting the AR. It was found that the AR is present, both for
the ARE1 and the scrambled oligonucleotides, although a larger
amount of AR was bound to the ARE1 oligonucleotide (Fig. 1B). In
conclusion, with this approach we obtained a protein preparation
enriched with the androgen receptor, together with a large number of
other proteins. Although the stained protein band pattern did not
show a clear difference between the ARE1 oligonucleotide and the
scrambled oligo, the immunoblot analysis indicated that the AR was
preferentially bound to the ARE1 oligonucleotide. This difference in AR
binding may be associated with preferential binding of AR associated
proteins to the ARE1 oligonucleotide, as well.
3.2. Protein identification
To identify DNA-bound AR interacting proteins, whole lanes from
the SDS-polyacrylamide gel containing proteins from an OBA, were
cut into small slices and subjected to trypsin in-gel digestion and
followed bymass spectrometric analysis. The mass spectrometric data
were edited in several steps (Table 1). First, structural and extra-
nuclear proteins were excluded. The second step included sorting of
proteins into 3 groups, for binding to either one of the two
oligonucleotides (ARE1 or scrambled) or to both. The third step was
based on peptide counting which was performed only for proteins
that were isolated from both OBAs. Potential AR co-factors were
selected based on peptide counts of 1.5-fold or more for proteins from
the ARE1 as compared with the scrambled ARE1 oligonucleotide. The
fourth step was the scoring of proteins for a known characteristic. A
protein property score of 1 was assigned, when the proteinwas known
to be either: a) localized to the nucleus, b) involved in transcription
Fig. 1. Isolation of AR complexes. Equal amounts of nuclear extracts obtained from
R1881-treated LNCaP cells were incubated with either PSA ARE1 or with scrambled
biotinylated oligonucleotides bound to streptavidin beads. The 2% input lane contains
2% of the nuclear extract which is used for the oligonucleotide-based assay. The ARE
lane and the scrambled lane contain the eluted fractions from the ARE1
oligonucleotide and the scrambled oligonucleotide, respectively. (A) The protein
complexes were separated on a 5–15% SDS-polyacrylamide gradient gel and
subsequently stained with SYPRO Ruby. (B) Immunoblotting of AR was performed
with anti-AR antibody F39.4.1.
Table 1
Editing steps of mass spectrometry data
Step Type of action Variables
1 Deletion of structural and
extra-nuclear proteins
e.g. keratins, fibrinogen, and fibrinopeptide
2 Sorting by oligonucleotide
specific associated binding
ARE1 binding; scrambled ARE1 binding;
ARE1 and scrambled binding;
3 Peptide counting Peptide numbers of proteins from:
a) ARE1 oligonucleotide
b) scrambled ARE1 oligonucleotide
4 Protein scoring a) nuclear
b) involved in transcription regulation
c) involved in steroid hormone receptor function
d) involved in AR function
The column “type of action” indicates the four steps for editing mass spectrometry data.
“Variables” in the last column are the aspects that were checked or scored for.
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activation/repression, c) functioning together with a steroid hormone
receptor or d) functioning specifically together with the AR. The
maximal protein property score for a protein could be 4. Three
databases were used for scoring the proteins: the Human Protein
Reference Database (www.hprd.org), GeneCards (www.genecards.
org) and PubMed (www.pubmed.com). Basically, when the protein
property scores were summed up for each protein, a protein property
score of 0 means that no information is available in the literature for
the protein. A protein property score of 1 indicates that the protein has
been found in the nucleus, but is not known to be involved in
transcription regulation of genes. A protein property score of 2
indicates a nuclear protein which is known to be involved in
transcription regulation of genes. A protein with protein property
score of 3 is a nuclear protein involved in transcription regulation of
genes, and also known to be involved in modulation of steroid
hormone receptor (SHR) signalling. These proteins have a high
potential to be AR interacting proteins, because of the high homology
between AR and the other SHRs. Proteins with a protein property
score of 4 have been described to act together with the AR in
transcription regulation of genes.
3.3. Identified proteins
After the second step, the number of proteins which were found in
both OBAs on at least 1 ARE1 oligonucleotide is 85. These 85 proteins
could be grouped into 7 categories: co-activating proteins, co-
repressing proteins, proteins possessing both co-activating and co-
repressing capabilities, other transcription regulating proteins, pro-
teins with a function related to RNA, nuclear proteins not involved in
transcription regulation, and proteins with an unknown function (see
Supplementary Tables 1–7).
These 85 proteins were checked for peptide counts. Peptide counts
of 1.5-fold or more for proteins bound to the ARE1 as compared with
the scrambled ARE1, revealed 7 proteins. These proteins were:
chromodomain helicase DNA binding protein 5 (CHD5), DEAD (Asp–
Glu–Ala–Asp) box polypeptide 17 (DDX17), DDX18, MYB binding
protein (P160) 1a (MYBBP1A), RecQ protein-like (RECQL), ribosomal
L1 domain containing 1 (RSL1D1), and zinc finger protein 384
(ZNF384; Table 2). All 7 proteins can be found in the nucleus.
RECQL and RSL1D1 are not known to be involved in transcription
regulation, but rather in DNA repair and regulation of replicative
senescence, respectively. CHD5, MYBBP1A and ZNF384 are involved in
transcription regulation and have a property score of 2. Studies have
shown that MYBBP1A can act as a co-activator as well as a co-
repressor. A function of DDX18 is not known yet, but from the same
protein family DDX17 is known to be a co-activator and a co-repressor
of ERα [33].
DDX17 seems to have the highest potential to be a co-factor of the
AR, compared to CHD5, DDX18, MYBBP1A, RECQL, RSL1D1, and
ZNF384. DDX17 has a protein property score of 3, and was found
enriched with only the ARE1 and not with the scrambled version in
both OBAs. DDX17 is an RNA helicase and has been shown to be
involved in both pre-mRNA and pre-rRNA processing [33]. But DDX17
possesses also both co-activating and co-repressing capabilities. The
repressing capabilities of DDX17 appear to be promoter-specific and
are achieved by recruiting histone deacetylase 1 (HDAC1) [33]. Co-
activation by DDX17 takes place with or without the recruitment of
any member of the SRC-1/TIF2 protein family [34]. These co-activating
and co-repressing capabilities of DDX17 are reported for the ERα, but
never for the AR [34].
4. Discussion
To identify possible novel AR co-factors which associate with the
AR in a hormone and DNA dependent fashion, an oligonucleotide-
based assay (OBA) was set up and applied in this study. The AR
together with interacting proteins was isolated via binding to
oligonucleotides containing either three ARE1s from the PSA gene
promoter in tandem or a scrambled version of the ARE1s. After careful
selection of the data obtained from twoOBAs, in total 85 proteinswere
identified, of which 7 proteins were shown to be enriched after
selection by peptide counting. DDX17 has been found to be a potential
AR co-factor based upon its function in presence of ERα and its
exclusive binding to the ARE1 oligonucleotide.
LNCaP cells were used in this study as a source for potential AR
interacting proteins, although these cells originate from a lymph node
carcinoma of prostate, and expresses the AR mutant T877A, the AR
mutant functions normally in the presence of androgens [35,36].
The difference between proteins isolated from the ARE1 oligonu-
cleotide and scrambled ARE1 oligonucleotide could not be shown by
SYPRO Ruby staining. Similarly in a study a difference could not be
shown by Coomassie Blue staining [37]. Most likely, DNA-bound AR
specific interacting proteins are in such a low concentration that they
were not visible by either staining.
Table 2
Protein selection by peptide counts
Protein Function Protein property score Mascot score a Peptide counts b
Nucleus Transcription SHR AR Total ARE Scr
CHD5/chromodomain helicase DNA binding protein 5 Transcription regulation, helicase 1 1 2 75 (2) x (1) 2
272 (6) 206 (4) 1.5
DDX17/DEAD (Asp–Glu–Ala–Asp) box polypeptide 17 Co-activator, co-repressor of ER 1 1 1 3 280 (5) x (1) 5
252 (4) x (1) 4
DDX18/DEAD (Asp–Glu–Ala–Asp) box polypeptide 18 Unknown 0 313 (5) x (1) 5
471 (7) 153 (2) 3.5
MYBBP1A/MYB binding protein (P160) 1a Co-activator, co-repressor 1 1 2 822 (16) 395 (7) 2.3
2254 (31) 1716 (21) 1.5
RECQL/RecQ protein-like /DNA helicase Q1-like DNA repair, helicase 1 1 95 (2) x (1) 2
486 (7) 252 (4) 1.75
RSL1D1/ribosomal L1 domain containing 1 Regulation of replicative senescence 1 1 285 (5) 46 (1) 5
443 (6) 244 (3) 2
ZNF384/Zinc finger protein 384 Transcription regulation 1 1 2 64 (2) x (1) 2
484 (4) 205 (2) 2
The names of the proteins and their abbreviations are from the HUGO Gene Nomenclature Committee (HGNC) database. Furthermore, the protein property scores are shown for
presence in the nucleus, involvement in transcription regulation, involvement in steroid hormone receptor function, andwhether the respective protein is known to act together with
the AR. Some alternative names, synonyms, aliases, and some common used names are also given.
a ARE=ARE1; Scr=scrambled ARE1. The first and second rows with the Mascot score for each protein represent the first and second OBA, respectively. The number of identified
peptides is given in brackets. x=Mascot score below the threshold of 45.
b Peptide counts are calculated by the ratio between the number of peptides found for the ARE1 and the scrambled ARE1 oligonucleotide.
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The AR was detected with immunoblotting in the eluents of both
the ARE1 oligonucleotide and, to a much lesser extent, of the
scrambled oligonucleotide. The AR protein itself was only detected
with mass spectrometry, unexpectedly, in the first OBA and on the
ARE1 oligonucleotide, but not in the second OBA. However, the
identification of the AR for the first OBAwas based on just one peptide
with a Mascot score of 52. This indicates that the identification of AR
by mass spectrometry might be very difficult. One possibility could be
that the abundance and the numbers of other proteins are too high as
compared to the AR protein level, which resulted in masking the AR.
Analysing the results, none of the 7 proteins which appear in both
OBAs are known to interact with DNA-bound AR. Available data
indicate that as many as 169 proteins can interact with the AR [5].
However, it has to be taken into account that these 169 AR interacting
proteins were identified by other methods, such as yeast two-hybrid
screening, mammalian two-hybrid screening, glutathione S-transfer-
ase (GST) pull-down assays, and co-immunoprecipitation assays. Most
of these AR interacting proteins are identified after an abundant
overexpression of proteins of interest, which might sometimes lead to
false positive results [38]. Therefore, additional experiments in
physiologically relevant cells lines are required with physiological
expression levels of these co-factors. In addition, AR DNA-binding was
not involved in these assays, whereas the oligonucleotides used in the
present experiments are part of an androgen responsive promoter.
Binding to response elements can cause conformational changes in
the AR, which in turn can influence co-factor recruitment and finally
transcription of genes. This might also explain that not all known AR
interacting proteins were identified in the present study.
In conclusion, with the oligonucleotide based assay (OBA) as
described herein, putative AR interacting proteins can be isolated.
Based on two selection methods, DDX17 appears to be the most
interesting putative AR co-factor identified in the present study. To
obtain more conclusive evidence that DDX17 is a functional DNA-
bound AR interacting protein, additional interaction and functional
assays need to follow. Interaction assays that would be informative
include pull-down, co-immunoprecipitation, and specific ChIP assays.
Functional reporter assays should preferably be performed for DDX17
in the presence of the AR and DNA.
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5.1 DISCUSSION AND CONCLUSIONS
hich can
d, three
In the following 
paragraph the conclusions regarding these questions are formulated. 
The main theme of this thesis is the study of factors and processes w
modulate androgen receptor (AR) transcriptional activity. To this en
main questions have been addressed (see Fig. 5-1).
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Figure 5-1 
A schematic overview of factors and processes which can modulate AR transcriptional
activity, studied in this thesis: AR phosphorylation, AR mutations, and AR co-factors. “AR 
phosphorylation” shows the known serine phosphorylation sites of the human AR. “AR
mutations” shows the number of AIS mutations found for each domain. “AR co-factors”
shows a part of the activating and repressing co-factors of the AR.
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Question 1: What is the influence of AR phosphorylation on AR isoforms and
AR transactivation?
luence of
ing to the
eased in
titutively
pattern
ted at a
tion site
mutational
residues
ion, NH2-
riptional
stingly, phosphorylation at
Ser-650 can be modulated by mutating Ser-515, another predicted 
on AR
XY DSD
that this
tation did
, protein
rast, this
teraction
raditional
complete
n might
currently used
functional assays. An alternative explanation for the severe penoscrotal 
hypospadias could be that the AR mutant recruits, in genital skin fibroblasts, a 
vely, an
recruitment of co-
repressor(s) other than N-CoR, present in specific androgen target cells. 
Question 3: Can existing and novel AR co-factors be isolated when 
complexed with the AR in an oligonucleotide-based in vitro assay?
When the present study of AR phosphorylation was started, the inf
phosphorylation on AR transactivation was largely unknown. Accord
present study it became clear that phosphorylation of serine 94 is incr
a ligand dependent way, and that serine 650 is being cons
phosphorylated (Chapter 2). With respect to the AR isoform
appearance, each isoform appears to be differentially phosphoryla
distinct set of phosphosites. However, not every phosphoryla
necessarily contributes to the isoform pattern, as was shown by
analysis (Chapter 2). Furthermore, AR phosphorylation at serine
does not appear to influence AR function directly, e.g. transactivat
/COOH-terminal domain interaction, and co-activation by transc
intermediary factor 2 (TIF2) are not affected. Intere
phosphorylation site (Chapter 2). 
Question 2: What is the effect of the novel mutation F826L
transactivation?
Initially, the AR LBD mutation F826L was found in the AR of a 46,
individual with a severe penoscrotal hypospadias, which suggested
phenotype could be caused by this mutation. However, the LBD mu
not affect AR transactivation, ligand binding, hormone response
stability, cellular localisation, and N-CoR co-repression. In cont
mutation resulted in a two-fold higher NH2-/COOH-terminal domain in
and TIF2 co-activation (Chapter 3). These effects are unlike the t
way in which a detected AR mutation from an AIS subject results in
or partial loss of AR transcriptional activation. The F826L mutatio
affect AR functioning in a way that is not detected with the
different repertoire of co-activators, not including TIF2. Alternati
altered LBD conformation may enhance a preferential
Discussion and conclusions
113
Many AR co-factors have been isolated via isolation procedure
absence of AR binding to specific DNA sequences. However, there
evidence that specific binding to DNA is essential for co-factor rec
Therefore, we used oligonucleotides containing the ARE1 of
promoter to study co-factor recruitment by the AR. Identified prote
scored for having one or more of the following known properties
localisation, involvement in transcription regulation, involvement i
hormone receptor (SHR) function, or specific involvement in AR fu
the so-called oligonucleotide-based assay (OBA), in total 85 prote
recruited by the AR in nuclear extracts obtained from LNCaP cells (C
Of the isolated proteins 11 were known to interact with the AR
influence AR transactivation. Five other bound proteins are known to
transactivation by other SHRs. In total 32 proteins with less AR in
potential were also found. These proteins are known to be in
transcription regulation of different genes. Furthermore, 25 protein
RNA binding or processing function, were isolated. Finally, for 4 pro
function is still unknown. Based on peptide counting, a more stric
criterion for specificity, we found enrichment of 7 proteins eluted
ARE1 oligonucleotide, compared to a scrambled oligonucleotide con
of these proteins, DDX17, is known to be a co-factor for estrogen re
(ERD), but has never been reported to
s in the
is ample
ruitment.
the PSA
ins were
: nuclear
n steroid
nction. In
ins were
hapter 4).
and to
influence
teracting
volved in
s with an
teins the
t slection
from the
trol. One
ceptor D
be associated with an AR function. In 
conclusion, the results indicate that the ARE1 of the oligonucleotide-based 
tion of known AR interacting proteins and of new 
ntified as
l., 2004).
,
sites by
y, a clear
n found.
e ER, GR, and PR,
h e Chapter
hormone
not been
detected for the AR. If such a site would be present, a hormone-induced AR 
phosphosite could influence the transactivation capacity of the AR. 
There are several explanations for the fact that a possible hormone-
induced phosphosite as well as other potential AR phosphosites could not be 
identified by peptide mapping and mass spectrometry. First: the phosphate 
assay allows the isola
potential DNA-bound AR interacting proteins. 
5.2 PHOSPHORYLATION 
In total, 7 serine residues in the human AR have now been ide
potential in vivo phosphorylation sites (Gioeli et al., 2002; Wong et a
These serine residues, Ser-16, Ser-81, Ser-94, Ser-256, Ser-308, Ser-424
and Ser-650, were all identified and confirmed as phospho
mutagenesis, peptide mapping and mass spectrometry. Unfortunatel
function for these phosphorylated serine residues has not bee
Phosphorylation of other steroid hormone receptors, like th
as an influence on transcriptional activation of these receptors (se
1). Some of these phosphosites are newly phosphorylated upon
binding, but such a change in phosphorylation has surprisingly
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group can be lost during the AR phosphopeptide isolation procedure.
phosphorylated peptides can be masked by unphosphorylated
during mass spectrometry analysis. Third: elution of large in-gel try
peptides containing
Second:
peptides
psinised
one or more potential phosphosites may face 
c
because
hosphate
and Qin,
oblem of
oserine
ons. The
reactive
ext steps
of the
ure does
selective
oproteins
titute for the loss of
p soon as
r several
t not be
s seldom
tides are
orylated
mount of
s during
hment of
via the
(IMAC).
ions via
on-affinity
hosphate
IMAC in
mentioned phosphate group
r masking.
antage of
biotinylation is that this also involves a general modification of other proteins, 
which can result in a considerable contamination. Therefore, other more 
specific chemical modifications are more appropriate. 
Concerning the third explanation for unidentified/missed phosphosites, in 
some phosphorylation studies antibodies were used for the precipitation of the 
onsiderable difficulties.
Until recently, the identification of phosphosites was complicated,
phosphoserine and phosphotyrosine residues can easily lose the p
group through ȕ-elimination reactions (Cantin et al., 2006; DeGnore
1998). However, newly developed methodology has solved the pr
phosphate group loss, for example by using biotinylation. Phosph
residues are chemically modified using strong alkaline conditi
peptides undergo a ȕ-elimination reaction, resulting in a
dehydroalanine moiety (Oda et al., 2001; Garcia et al., 2005). The n
include biotinylation enrichment after the above transformation
phosphate group to a thiol derivative with DTT or EDT. This proced
not only substitute for the loss of phosphate, but also enables
purification of the modified proteins resulting in enrichment of phosph
or phosphopeptides. The most effective way to subs
hosphate groups is to use the procedure on the phosphoproteins as
possible after protein extraction from cell lysates, rather than afte
other purification procedures (Oda et al., 2001; Tao et al., 2005). 
The second possible reason why some phosphosites migh
detected, is the fact that phosphorylation of a specific site in vivo i
stoichiometric. Consequently, most of the potential phosphopep
unphosphorylated, which results in only a small proportion of phosph
peptides (frequently less than 5%). In this way, a relatively large a
unphosphorylated peptides can mask the phosphorylated peptide
mass spectrometry analyses. A solution to this problem is the enric
phosphopeptides, which can be achieved by selective isolation
commonly used Immobilised Metal ion Affinity Chromatography
Phosphoproteins or -peptides can be bound to immobilised metal
their phosphate moiety and thereafter eluted from the metal i
columns (Neville et al., 1997). However, due to an easy loss of the p
group, IMAC alone is not the preferred method. In contrast,
combination with the use of a previously
eplacement by biotin is a more appropriate method to prevent the
Such enrichment would ease identification of phosphosites. A disadv
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phosphoprotein of interest (see also Chapter 2). SDS-PAGE puri
usually performed to avoid the overload of antibodies and to selective
the protein of interest, facilitating the mass spectrometric identi
phosphosites. However, the SDS-PAGE step is necessarily followed
gel digestion by a protease, which might become problematic w
peptides have to be extracted from the SDS-polyacrylamide gel. Bu
PAGE purification step can possibly be eliminated, because nowada
spectrometers are more sensitive, have an optimal liquid chroma
separation system and an optimal peptide fragmentation, thus seq
possibilities. These features facilitate protein identification marke
especially from a large mixture of proteins which in combina
alternatives of in-gel digestion can result in an even bette
identification. Some alternatives of in-gel digestion are just recen
developed. For instance, proteases immobilised on beads to which th
sample can be added, thus eliminating the use of SDS-PAGE (Lim et
Wu et al., 2006). However, such methods have not been tested on a
mixture of proteins. Another alternative, but still being studied, is the
of a protease to a purified mixture of proteins which are still attached
way to beads, the so-called on-bead digestion. This method is likely to work
well with proteins which are not isolated via antibody precipitation,
protein identification will likely be more difficult in the presence of an
overload. Although the excess of antibodies can be problematic, the
of antibodies might be decreased by competition between the bound
fication is
ly isolate
fication of
by an in-
hen large
t a SDS-
ys mass
tography
uencing
dly and
tion with
r protein
tly being
e protein
al., 2006;
complex
addition
in some
because
antibody
amount
proteins
a binds. If
ntification,
mpeting
using a
ate group
kind of group, followed by 2) enrichment of
p bably be
nclusion,
ion of the
nction of
tification
possible
function for phosphosites could also be rather limiting. Detection of a possible 
function for phosphosites is generally performed by the use of functional 
assays in which one or more phosphosites in transcription factors and also in 
nuclear receptors, like the AR, are mutated and tested for the ability to 
activate transcription of a reporter gene via interaction with an enhancer 
nd an excess of an exogenous peptide to which the antibody
necessary, when the excess of peptide interferes with the protein ide
it can be removed by the use of a tag or an isotope to discern the co
peptide from the original peptide of the protein of interest.
Most likely, an effective way to identify AR phosphosites is by
combination of the following methods: 1) replacement of the phosph
by biotin or by another
hosphopeptides. Even more or additional other phosphosites will pro
found if in the last method the SDS-PAGE-step is eliminated. In co
more AR phosphosites can likely be identified by using a combinat
three above-mentioned methods. 
As discussed above, one possible cause which leaves the fu
phosphorylation undetected could be a less optimal isolation and iden
of phosphosites. Besides this, the detection methodology for a
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and/or promoter. As concluded in Chapter 2, AR phosphorylation of
studied does not seem to have a function. Different gene promoters
lines have been used to study the AR in a more or less natural env
In most functional assays the AR with one mutated phosphosite
investigated. In addition, double phospho-mutants have been studie
function for AR phosphorylation could be revealed (Zhou et al., 1995;
al., 2002). Combinatorial phosphorylation could probably play a
keeping the AR function normal. It has been shown that mutation o
AR phosphosites results in phosphorylation or dephosphorylation o
site (Gioeli et al., 2002; Wong et al., 2004). Perhaps comb
phosphorylation can preserve AR function by phosphorylation of
amino acid residue. However, more research has to be perf
investigate the process of combinatorial phosphorylation. The
mutagenesis of more than 2 known AR phosphosites needs to be inv
too, as well as different combinations of mutated phosphosites. In
combinatorial phosphorylation might be prevented. Interestingly, ace
the AR seems to be important for the appearance of the hormone
and highly phosphorylated AR 114 kDa isoform (Fu et al., 2004). In a
has been shown that phosphorylation of ER Ser-305 blocks acetylatio
303, which results in an enhanced transac
the sites
and cell
ironment.
has been
d, but no
Gioeli et
role in
f certain
f another
inatorial
another
ormed to
effect of
estigated
this way,
tylation of
-induced
ddition, it
n of Lys-
tivation (Cui et al., 2004). Perhaps 
t influence
specific
nction of
s of AR
results in
pid, non-
ndrogens
d thereby
y (Migliaccio et al.,
2 -genomic
entioned
as to be
f protein
horylation
ntibodies
have not yet been used for elucidation of a function of AR phosphorylation.
However, two phosphosite-specific antibodies, each acting against one 
particular phosphosite of the GR, revealed that there are different GR 
phosphorylated isoforms and that each isoform is located at different regions
within the cell at the same time point (Lin et al., 2002). If this also occurs for 
he phosphorylation status of one or more sites in the AR can also
other types of AR modifications, or vice versa, which will make the
influence of phosphorylation even more complex. 
A second explanation why functional assays do not reveal the fu
phosphorylation, is a possible involvement in non-genomic action
phosphorylation. Apart from the known AR signaling pathway that
transcription regulation, there is evidence that the AR can exert a ra
genomic effect. In prostate cancer cells, it has been shown that a
can induce the association of both the AR and ERȕ with Src an
stimulating the Src/RAF1/ERK signal transduction pathwa
002; Migliaccio et al., 2000). If AR phosphorylation influences non
effects via this signal transduction pathway, then the use of the m
functional assays would not be suitable. Therefore, more research h
done also on possible non-genomic effects of AR phosphorylation.
An interesting approach is the use of antibodies for the study o
phosphorylation. Nowadays, antibodies against certain serine phosp
sites have proven to be quite specific. Phosphosite-specific AR a
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the AR, each phosphosite-specific antibody might be used to isolate
set of interacting proteins from which a certain function can be derive
or more phosphosites. Phosphosite-specific antibodies might also b
as semiq
a specific
d for one
e useful
uantitive indicator for the phosphorylation level of a certain
p
ur for the
n, 1995).
specific
is highly
ion of AR
al., 2006;
ortant for
e tyrosine
ition of 1
hest level
between
high level
cubation,
to serine
nd DHT-
f tyrosine
uction in
AR can
d (Guo et
criptional
., 2007).
ion of the
s study is
ith EGF,
point for
wo other
Mutation
and the
3F resulted in a 76%
d in AR
(Mahajan
sence of
a constitutive active ACK-1 kinase and the phosphorylation status was not
verified in the presence of hormone alone (Mahajan et al., 2007). 
Like tyrosine phosphorylation, it was thought that threonine 
phosphorylation does not occur for the AR (Kuiper et al., 1993; Gioeli et al., 
2002; Kuiper and Brinkmann, 1995). Recently, it was reported that threonine 
hosphosite.
Not until recently, tyrosine phosphorylation was thought not to occ
AR (Kuiper et al., 1993; Gioeli et al., 2002; Kuiper and Brinkman
However, this has been disapproved by the use of phospho-tyrosine
antibodies. It has been shown that AR tyrosine residue 534
phosphorylated (Guo et al., 2006; Kraus et al., 2006). Phosphorylat
Y534 is mainly induced by EGF via the activation of Src (Guo et
Kraus et al., 2006). Remarkably, Src has also been shown to be imp
the R1881-induced tyrosine phosphorylation (Kraus et al., 2006). Th
phosphorylation level is increasing from 10 min to 30 min after add
ng/ml EGF. However, when 10 or 100 ng/ml EGF was used, the hig
of phosphorylation was already reached within 5 min, but decreased
10 min and 30 min (Guo et al., 2006; Kraus et al., 2006). The same
of tyrosine phosphorylation is reached only after 30 min of R1881 in
which thereafter decreases (Kraus et al., 2006). In contrast
phosphorylation, tyrosine phosphorylation is involved in the EGF- a
induced transactivation of the AR, as was shown by the use o
mutants (Guo et al., 2006). The AR mutant Y534F has a 50% red
transcription activity. Remarkably however, a mutated tyrosine 534
still be fully active when a high concentration (10 nM) of DHT is use
al., 2006). In contrast, one research group has found that the trans
activity of AR mutant Y534F was minimally impaired (Mahajan et al
Furthermore, phosphorylation of Tyr-534 is involved in the translocat
AR to the nucleus (Guo et al., 2006). However, a weak point in thi
the large discrepancy between the incubation times (16 hours w
which is needed for the functional assays) and the time
phosphorylation (which occurs already within 10 to 30 minutes). T
tyrosine phosphorylation sites were identified, Tyr-267 and Tyr-363.
of Tyr-267 to phenylalanine abolished the AR transcriptional activity
binding to AREs (Mahajan et al., 2007). AR mutant Y36
ecrease of the overall AR tyrosine phosphorylation, a decrease
transcriptional activity by 65% and a reduced DNA binding of 50%
et al., 2007). However, these experiments were performed in the pre
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phosphorylation of the AR in human sperm cells could be demonstr
the use of a phosphothreonine specific antibody (Aquila et al., 2007).
the investigato
ated with
However,
rs have not determined the exact location of the threonine 
r
ations of
, did not
imicking
In many
tudied with
a wn that a
ity (Guo et al., 2006).
In conclusion, there might be still opportunities for finding a function for AR 
ggested experimental approaches. 
vent the
res and
human
ted with
e are an
tor structure-function
ides the
the AR
criptional
upled to
criptional
n F826L,
a clear
ll-length
wt AR.
wild-type
attern in
b-cellular
ever, the
ion were
increased two-fold as compared with the wt AR (see Chapter 3). These 
experiments included luciferase assays performed in CHO cells. An ideal
situation would be a functional study of the F826L AR mutant in a natural 
environment; such as GSFs from the AIS subject, because the recruitment of
tissue specific co-factors might be different from that in CHO cells. Recently, 
esidues involved.
The role of AR phosphorylation still remains unclear. Mut
individual phosphosites, or of five phosphosites in one AR protein
reveal an indication for function, nor does the phosphorylation m
mutation of six serine residues to aspartic acid (Yang et al., 2007).
studies the transcriptional activity of the AR has not been s
ndrogens in a dose-dependent manner, whereas it has been sho
high dose of androgens can result in a normal AR activ
phosphorylation with the su
5.3 AR MUTATIONS AND AIS 
It is generally accepted that defects in the androgen receptor can pre
normal development of both internal and external male structu
properties in 46,XY individuals, and information on the structure of the
AR gene has facilitated the study of molecular defects associa
androgen insensitivity. Naturally occurring mutations in the AR gen
interesting source for the investigation of recep
relationships. In addition, the variation in clinical phenotypes prov
opportunity to find a possible correlation between a mutation in
structure and an impairment of a specific physiological function. 
A mutation in the AR protein can result in an increased AR trans
activity or a broadened ligand specificity, which is most times co
prostate cancer. A mutation also can result in a decreased AR trans
activity or loss of ligand binding, which is coupled to AIS. The mutatio
found in a boy with severe penoscrotal hypospadias, did not show
functional difference compared with the wild-type (wt) AR. The fu
mutant F826L showed a similar transcriptional activity as the
Furthermore, this mutant appeared to be indistinguishable from the
with respect to ligand binding affinity and expression of an isoform p
genital skin fibroblasts (GSF), hormone responsivity, and su
distribution in transfected Chinese Hamster Ovary (CHO) cells. How
NH2-/COOH-terminal domain interaction and the TIF2 co-activat
Discussion and conclusions
119
Holterhus et al. (2005) managed to study the transactivation of w
mutant ARs in AR negative GSFs, by transfecting these cells with
AR or mutant AR, together with a reporter construct (Holterhus et a
The best way to study AR F826L, would be to transfect only a
construct in GSFs of the AIS subject and compare it to a panel
containing a wt AR, to eliminate the possible difference betwee
populations. However, the AR levels in GSFs is very low, and it
necessary to enhance the amount of reporter construct to detect a
but overexpression has to be prevented, to exclude perturbation of th
a difference is found between the wt and the mutant F826L AR in
the
t AR and
either wt
l., 2005).
reporter
of GSFs
n GSFs
might be
ny signal,
e cells. If
activating
reporter construct in GSFs, then the OBA can be applied to show a 
p d mutant
oly Gly)
ause the
an have
ublication
d genital
relatively
domain of
a A645D
says with
s) down-
ger poly
mutation,
found to
mbination
mutation
erestingly,
e A645D
is evident
that different lengths of the poly Gly and poly Gln repeats might have an 
influence on the activity of a mutant AR. However, it can be expected, based 
on the previous considerations, that the length of the repeats do not play a 
crucial role in the transcriptional activity of the AR mutant F826L, because the 
lengths are within the normal range (poly Gln: 22; poly Gly: 17; Chapter 3). 
ossible difference in the recruited co-factor repertoire between wt an
AR.
The lengths of the polyglutamine (poly Gln) and polyglycine (p
stretches in mutant ARs might also be relevant for AR activity, bec
length of the stretches in combination with an AR mutation c
pronounced influences on AR transactivation capacity. In a recent p
it was shown that two 46,XY individuals with undervirilisation an
malformations, have a short poly Gly repeat of 10 residues and a
long poly Gln repeat of 28 or 30 residues within the NH2-terminal
the AR. In addition, the AR harbours in these two individuals
mutation in the hinge region (Werner et al., 2006). Functional as
different plasmids showed that a shorter poly Gly repeat (10 residue
modulated AR activity to approximately 60-65% as compared to a lon
Gly repeat (16 residues). However, in combination with an A645D
the decrease in activity associated with the short poly Gly repeat was
be less. On the contrary, a short poly Gly repeat (10 residues) in co
with a long poly Gln repeat (28-30 residues) and the A645D
decreased the AR activity to less than 50% (Werner et al., 2006). Int
in the context of a short poly Gln and a short poly Gly repeat, th
mutation can even rescue AR activity to almost wild-type levels. It
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5.4 PROTEIN-PROTEIN INTERACTION
5.4. antages and disadvantages of the oligonucleotide-based 
assay
AR co-
sed with
. Beside
ral other
preferred
herefore
uences of
onsive elements
m ited by at
.
has also
ontaining
defined
rtain responsive elements, but co-
factors are recruited in vitro and the isolated proteins by OBA may not 
represent the total protein complexes which can be found on a regular
promoter in its native context in intact cell systems. 
cleotide-
nfirm the
ein. One
a DNA
promoter
roup has
linked to
es place
des of the
r of interest (Grosveld et al., 2005). However, disadvantages of this
experimental approach are some non-specific protein-protein and protein-
DNA cross-linking. Often the used cross-linking chemical is formaldehyde,
and this compound crosslinks proteins and protein-DNA within a radius of 
approx. 20 Å, which is beyond the closest distances between protein and DNA 
(5-10 Å).
1 Adv
The oligonucleotide-based assay (OBA) was performed to isolate
factors recruited by DNA-bound AR and which could be mis
conventional methods in which specific DNA binding is not an issue
the DNA-bound AR dependent recruitment, the OBA has seve
advantages. It is a straightforward, clearly defined method and the
responsive elements with their flanking sequences can be selected. T
specific binding of recruited proteins to the AR and the flanking seq
each ARE can be studied. The use of combinations of resp
ay reveal more proteins involved in a complex which are only recru
least two different DNA-bound AR molecules and/or bound co-factors
Besides the above-mentioned advantages OBA, this approach
some disadvantages. This method demands a large amount of AR c
cells to obtain sufficient quantities of AR protein. OBA is a clearly
method to study co-factor recruitment on ce
5.4.2 Methods to isolate in vivo recruited proteins 
After identification of possible AR interacting proteins via the oligonu
based assay, additional experiments have to be performed, to co
interaction between the AR and the identified AR interacting prot
approach which may represent more the in vivo situation, uses
construct with tags flanking the promoter of interest to isolate the
sequence and the attached proteins after fixation. A research g
isolated complexes, which were assembled in vivo and cross-
chromatin containing an inserted Tet-O binding site. The isolation tak
by using a Tet R tag and cleavage sites which are located on both si
promote
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In conclusion, crosslinking experiments can result in valuable in
on complex composition, alt
formation
hough this approach has its limitations due to non-
specific chemical modifications.
5.4.3 Conventional protein interaction methods 
own and
earching interacting proteins.
A dentifying
methods
terest is
ain. If an
activation
hich can
al., 1991).
teracting
teraction
be kept in
positives.
can be
k protein-
umber of
can also
t can be
ession of
hich can
the yeast
. These
l protein
on (Ito et al., 2000). 
H so-called
itoring of
Brent and
raction of
Another commonly used method to identify interactions is the glutathione 
S-transferase (GST) pull-down. Herein the protein (fragment) of interest, the 
bait, is expressed as a GST fusion protein and captured by a glutathione-
agarose column. Interacting proteins (the prey) are obtained by adding cellular 
extracts to the column. This method is also suitable for capturing a large 
Besides OBAs, yeast two-hybrid, mammalian two-hybrid, GST pull-d
co-immunoprecipitations are often used for s
lthough, these conventional methods are not very suitable for i
DNA-bound proteins, they have their own advantages. 
The yeast two-hybrid system is one of the most commonly used
to study protein-protein interaction. The protein (fragment) of in
expressed as a fusion protein containing a GAL4-DNA binding dom
interaction takes place with a possible partner containing a trans
domain, the complex may form a functional transcription factor w
activate transcription of a reporter gene (Chien et al., 1991; Dang et
This method is useful for identifying either a large amount of in
proteins or just a few specific proteins. It is suitable for studying in
between proteins which are unable to bind DNA. However, it has to
mind that several weak points of this method can lead to false
These are summarised below: 1. The number of false positives
increased by strong transcription activation domains in case of wea
protein interactions (Stephens and Banting, 2000); 2. The high n
copies of the upstream activation sequence in a promoter region
contribute to the increase of false positives; 3. The protein of interes
sticky or can bind unexpectedly directly to promoters; 4. Overexpr
proteins in yeast can lead to modifications in yeast permeability, w
result in more uptake of substrates (Serebriiskii et al., 2000). With
two-hybrid method, protein-protein interactions also can be missed
false negatives are due to a lack of cell-specific posttranslationa
modifications or processing (cleavage) prior to interacti
owever, this can be overcome by using mammalian cells, the
mammalian two-hybrid method. In addition, it allows the mon
modifications in the interaction in response to cell stimulation (
Finley, 1997). This system is frequently used to confirm the inte
known proteins or proteins found by the yeast two-hybrid method. 
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number of proteins. However, the following has to be kept in m
method involves the usual overexpression of both the bait and the
certain proteins are brought together which normally may not co-loca
cell. Beside these disadvantages, GST pull-down assay can result
background due to a-specific binding an
ind. This
prey and
lise in the
in a high
d in addition it may miss a relatively
h
in-protein
between
levels of
ctions, limited availability of 
s is often
teracting
tags are
tags can
However,
lls. This
not act
2006). In addition, during the
i eal with
isolation
between
ell lines.
ally high
ay cause loss of regulation that normally is
dependent on the cell cycle phase or on other cellular states. These events
can result in altered sub-cellular localisation and/or aberrant interactions,
leading to false positives. Furthermore, the detected protein interaction can 
s well as
be very
informative and has the preference over the conventional protein interaction 
identification methods. One of these recently developed methods is the
nowadays widely used fluorescence resonance energy transfer (FRET) 
analysis, in which the change of energy transfer from a fluorescent protein to 
another fluorescent protein is measured (Wallrabe and Periasamy, 2005). 
igh number of proteins (Edwards et al., 2002).
Co-immunoprecipitation is also frequently used to identify prote
interactions. It has the advantage that protein interactions take place
endogenous proteins from cells in culture (or from a tissue sample). However, 
co-immunoprecipitation is technically difficult, due to low expression
the protein of interest, weak affinity of the intera
pecific antibodies, and of suitable target epitopes. In addition, it
necessary to overexpress proteins in irrelevant cell lines.
Many tags are also fused to “bait” proteins for isolation of in
proteins as a complex (Chang, 2006; Terpe, 2003). Frequently used
FLAG, MYC, hexahis(tidine) and biotin. Proteins containing these
easily be isolated by either antibodies or for biotin by (strept)avidin.
these proteins need to be overexpressed or stably expressed in ce
might sometimes form a problem. Furthermore, tagged proteins may
similarly as their native counterparts (Chang,
solation of biotin tagged recombinant proteins one has to d
endogenous biotin modified proteins, which compete in the
procedure and increase the number of false positives. 
In general, most of the interactions in these methods are not
endogenous proteins or do not take place in physiological relevant c
In addition, the usual overexpression of proteins results in abnorm
physiological levels, which m
also be indirect via another protein. 
5.4.4 In-cell visualisation of protein-protein interactions
Determination of direct interactions between two known proteins a
studying these interactions in a more natural environment can
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This method can show the direct interaction between two prote
energy transfer only occurs if two fluorescent proteins are in close pro
each other. This method does not need overexpression of the flu
proteins. Only stable expression at physiological levels is sufficien
this advantage, the interaction can be visualised in real-time in living
this way complex formation and dissociation can by studied in
disadvantage of this method is related to the fluorescent tag. The
n
ins, since
ximity of 
orescent
t. Beside
cells. In
time. A
tag might
ompared
tion, has
ween two
sults in a
ig. 5-2).
antage is
ing from
thermore,
x, which
teraction
ular level and 
within a cellular population (Kerppola, 2006). However, like in the FRET 
approach, the fusion proteins used for the complementation method may not 
necessarily interact or behave in the same way as their native counterpart. 
egatively influence the interaction and action of a fusion protein as c
with its native counterpart. 
A new method based on protein fragmentation complementa
almost similar advantages as the FRET method. The interaction bet
proteins, fused to complementary fragments of a reporter protein, re
functional complementation and reporter activity (Kerppola, 2006; F
This method causes minimal cellular perturbation. However, a disadv
that the protein fragment association can have a time lag rang
minutes to 24 h depending on the character of the used protein. Fur
the association can also result in extra stabilisation of the comple
makes this method less suitable for studying protein-protein in
dynamics. The spatial resolution can be at the sub-cellular or cell
X X X YY
A A A BBB
Y
Figure 5-2 
Schematic representation of the principle of the protein complementation assay. Upon
interaction of proteins (or their fragments) X and Y, the fused fragments A and B are also 
brought to close proximity, thereby reconstituting the original function (e.g. proteolytic
activity or luminescence).
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Recently, the proximity ligation in situ assay (P-LISA), a method
direct interactions between endogenous proteins, has been d
(Soderberg et al., 2006). Proximity probes are oligonucleotides att
antibodies against two target proteins and they function by gu
formation of circular DNA strands if bound in close proximity. The DN
in turn serve as templates for localised rolling-circle amplificatio
allowing individual interacting pairs of protein molecules to be visua
counted. With P-LISA it is possible to study multiprotein complexes.
to study
escribed
ached to
iding the
A circles
n (RCA),
lised and 
However,
t eractions
ISA are
l protein-
interactions. More importantly, these methods are ideal in showing 
protein-protein interaction between a DNA-bound transcription factor and a 
identified
ect is to
d an AR
of an AR
uct, if the
he usual
r knock-
level of
c antigen
b-cellular
r, when
ind. Often
relevant
hich may
s. It may
red sub-
cificity of
substrates. Although most assays are performed with overexpressed
recombinant proteins, they are rather easy to perform and give at least an 
indication of a function. Very informative methods are knockout or knock-in 
approaches to remove or modify genes in mice. In this way proteins can be 
studied at a more physiological level and in a natural environment. However, 
he applied antibodies have to be very specific and the protein int
can only be studied in fixed cells and tissues. 
In conclusion, FRET, fragmentation complementation and P-L
good alternative ways to confirm or study in more detail potentia
protein
co-factor.
5.4.5 AR functional research 
Besides confirmation of an interaction between the AR and
candidate AR interacting partners, another more important asp
determine what the functional relationship is between the AR an
interacting protein. This can be achieved by studying the role
interacting protein in AR transactivation, first with a reporter constr
AR interacting protein can be easily expressed from a construct. T
procedure is either a gradual increase in protein expression level o
down of its expression using si-RNA, which might result in a changed
AR-induced transcription of a gene, such as the prostate specifi
(PSA) gene. Further research may involve the effect on AR su
localisation, the NH2-/COOH-terminal domain interaction assay, and the 
competition between co-repressors and co-activators. Howeve
performing these experiments, several aspects have to be kept in m
proteins of interest are overexpressed or constitutively expressed in ir
cell lines. The overexpression may result in the loss of regulation w
be dependent upon the phase of the cell cycle or other cellular state
also result in aberrant interactions with other proteins and/or alte
cellular localisation. Kinase overexpression may result in loss of spe
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the consequences of the observed changes in mice may not be
human situations, but the mouse models may help to decipher mec
step by step. However, the most informative indication for a func
human protein, is the experiment of nature, in which the
similar in
hanisms
tion of a
protein of interest
appears to be mutated in a human being with a changed phenotype. 
ns
fic DNA-
imates of
e protein
xpensive
unting of
unting is
the total
Liu et al.,
counted
a reliable
eful as a
nt in the
stigation,
uted from
e. One of
these proteins, DDX17, is known to be a co-factor for estrogen receptor Į
(ERĮ), but has never been shown to be associated with AR function. The 
present results indicate that the ARE oligonucleotide-based assay may allow 
enrichment of new candidate DNA-bound AR interacting proteins (Chapter 4). 
5.4.6 Peptide counting as selection criterion for isolated protei
For the present OBA, peptide counting was used to determine speci
bound AR interacting proteins. This method provides quantitative est
protein abundance and is therefore very useful to determin
enrichment, without requiring either the tagging of proteins or e
isotope labelling (Gao et al., 2005). Peptide counting is literally the co
peptides which are identified by mass spectrometry. Peptide co
based on the finding that protein abundance is correlated with
number of identified peptides for any given protein (Gao et al., 2003;
2004; States et al., 2006). The determination of the ratio between
peptides of the sample of interest and of the control sample, gives
quantitative estimation of protein enrichment. This method is us
selection criterion if a large number of identified proteins is prese
sample of interest and in the control sample. In the present inve
peptide counting revealed enrichment of 7 putative AR co-factors el
the ARE1 oligonucleotide, compared to the scrambled oligonucleotid
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SUMMARY
portant for
erentiation,
sis. These
r (AR), a
rs (SHRs).
androgen
enhancer
remodelling
ins of the
ited by the
factors can
sactivation,
acetylation,
ctivation. In
es for AR 
androgen insensitivity
influence of
ating processes and factors is still not clear. In Chapter 1, three
questions were formulated, which were addressed in detail in this thesis: 
Question 1: What is the influence of AR phosphorylation on AR isoforms and AR 
Q tivation?
plexed with 
eral steroid
e effect of
escribed in
reased in a
sphorylated.
With respect to the AR isoform pattern, each isoform appears to be differentially 
phosphorylated at a distinct set of phosphosites. However, not every
phosphorylation site necessarily contributes to the isoform pattern, as was shown by
mutational analysis. Furthermore, AR phosphorylation at serine residues does not
appear to influence AR function directly, e.g. transactivation, NH2-/COOH-terminal
domain interaction, and co-activation by transcriptional intermediary factor 2 (TIF2).
Androgens, testosterone (T) and 5D-dihydrotestosterone (DHT), are im
male and female physiology, in particular for male sexual diff
development of secondary male characteristics and spermatogene
hormones exert their actions by binding to the androgen recepto
transcription factor that belongs to the family of steroid hormone recepto
After ligand binding, the AR migrates to the nucleus and binds to
response elements (AREs), which are present in the promoter and
regions of androgen regulated genes. After DNA binding, chromatin
factors, other co-factors (co-activators or co-repressors) and prote
transcription initiation complex, including RNA polymerase II, are recru
AR to regulate gene transcription. Several modulating processes and
influence AR transactivation. Not only co-factors play a role in AR tran
but also post-translational modifications of the AR, such as
ubiquitylation, sumoylation and phosphorylation, can modify AR transa
addition, mutations in the AR gene can have dramatic consequenc
transactivation. In general, AR mutations result in the
syndrome, in which the male phenotype is affected. However, the exact
these modul
transactivation?
uestion 2: What is the effect of the novel mutation F826L on AR transac
Question 3: Can existing and novel AR co-factors be isolated when com
the AR in an oligonucleotide-based in vitro assay? 
Phosphorylation has been shown to influence the function of sev
hormone receptors. The AR is known to be phosphorylated, but th
phosphorylation on AR function is unknown. In the experiments d
Chapter 2, it became clear that phosphorylation of serine 94 can be inc
ligand dependent way, and that serine 650 is being constitutively pho
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Interestingly, dephosphorylation at Ser-650 occurred by mutating Ser-515, another 
p
pment and 
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ein stability, 
is mutation 
d a two-fold 
tioning in a 
alternative
 AR mutant 
nital skin fibroblasts, a different repertoire of co-activators, not 
i enhance a 
target cells, 
tors. Many 
ence of AR 
cific binding 
onucleotide 
ion of this 
pter 4).
ing known 
involvement
R function. 
85 proteins 
 associated 
re known to 
roteins are 
ith less AR 
 involved in 
ith an RNA 
binding or processing function, were isolated. Finally, from 4 proteins the function is 
still unknown. When peptide counting was applied as a more strict selection criterion 
for specificity, we found enrichment of 7 proteins eluted from the ARE1 
oligonucleotide, compared to the scrambled oligonucleotide. One of these proteins, 
DDX17, is known to be a co-factor for estrogen receptor Į (ERĮ). The present study 
is the first report in which DDX17 is being associated with an AR function. In 
otential phosphorylation site. 
Androgen signalling is important in particular for male develo
physiology. A defective signalling in an individual can result in the
insensitivity syndrome (AIS), which belongs to the group of disord
development (DSD), and which is predominantly caused by mutations
gene. In Chapter 3, the study of the newly identified F826L mutation 
described. This mutation was found in the AR gene of a boy wit
penoscrotal hypospadias (classified as 46,XY DSD). Remarkably, this LB
did not affect AR transactivation, ligand binding, hormone response, prot
sub-cellular localisation, and N-CoR co-repression. In contrast, th
resulted in a two-fold higher NH2-/COOH-terminal domain interaction, an
increase in TIF2 co-activation. The F826L mutation might affect AR func
way that is not detected with the currently used functional assays. An 
explanation for the severe penoscrotal hypospadias could be that the
recruits, in ge
ncluding TIF2. Alternatively, an altered LBD conformation may 
preferential recruitment of co-repressor(s), present in specific androgen 
other than N-CoR. 
Transcription regulation of genes involves a large numbers of co-fac
AR co-factors have been isolated via isolation procedures in the abs
binding to specific DNA sequences. However, there is evidence that spe
to DNA is important for co-factor recruitment. Therefore, we used an olig
containing the ARE1 of the PSA promoter, and a scrambled vers
oligonucleotide as control, to study co-factor recruitment by the AR (Cha
Identified proteins were scored for having one or more of the follow
properties: nuclear localisation, involvement in transcription regulation, 
in steroid hormone receptor (SHR) function, or specific involvement in A
With the so-called oligonucleotide-based assay (OBA), a selection of 
from AR containing nuclear extracts from LNCaP cells were found to be
with the AR bound to the ARE1. Of the bound proteins, 11 proteins we
interact with the AR and to influence AR transactivation. 5 other bound p
known to influence transactivation of other SHRs. In total 32 proteins w
interacting potential were also found. These proteins are known to be
transcription regulation of different genes. Furthermore, 25 proteins w
Summary
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ows the isolation of 
k s.
s 2, 3 and 4
tudies on a
use of the
the F826L
mutation in the AR and on a possible function for the identified co-factors are also 
discussed.
conclusion, the results indicate that the ARE1 in the OBA all
nown AR interacting proteins and of new potential AR interacting protein
In Chapter 5, the results obtained from studies described in Chapter
are discussed in a broader perspective. Future directions for additional s
relationship between phosphorylation and AR function, a possible ca
severe penoscrotal hypospadias of the 46,XY DSD individual with
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ngrijk voor
mannelijke
mannelijke
efenen hun
e-factor die
inding is de 
esponsieve
e enhancer
chromatine
ssoren) en
merase II, 
odulerende
t alleen co-
ties van de
kunnen de
dramatische
tivatie. In het algemeen, resulteren AR 
mutaties in het androgeen-ongevoeligheidssyndroom (AIS), waarbij het mannelijke 
processen
is nog niet duidelijk. In Hoofdstuk 1 worden er 3 vragen geformuleerd 
die in dit proefschrift in detail worden behandeld.
Vraag 1: en op AR
V atie?
onucleotide
an enkele
sforyleerd,
perimenten
van serine
94 verhoogd kan worden in een hormoon afhankelijke manier en dat serine 650 
constitutief is gefosforyleerd. Met betrekking tot het AR isovorm patroon werd 
gevonden dat elke isovorm verschillend is gefosforyleerd op een aantal 
fosforyleringsplaatsen. Echter, niet elk gefosforyleeerd aminozuur draagt 
noodzakelijkerwijze bij aan het isovorm patroon zoals werd aangetoond met mutatie
analyses. Bovendien, modulatie van AR fosforylering van serine residuen lijkt niet 
De androgenen testosteron (T) en 5D-dihydrotestosteron (DHT) zijn bela
de mannelijke en vrouwelijke fysiologie, met name voor de
geslachtsdifferentiatie, voor de ontwikkeling van de secundaire
geslachtskenmerken en voor de spermatogenese. Deze hormonen o
werking uit door binding aan de androgeenreceptor (AR), een transcripti
tot de familie van steroidhormoonreceptoren (SHR) behoort. Na ligand b
AR in de celkern aanwezig en bindt daar o.a. aan androgeen r
elementen (ARE), die gelokaliseerd zijn in de promoter en zogenaamd
regio’s van androgeen gereguleerde genen. Na DNA binding, worden
modulerende factoren, andere co-factoren (co-activatoren en co-repre
eiwitten van het transcriptie initiatie complex, inclusief RNA poly
gerekruteerd door de AR om gentranscriptie te reguleren. Diverse m
processen en factoren kunnen de AR transactivatie beïnvloeden. Nie
factoren spelen een rol in AR transactivatie, ook post-translatie modifica
AR, zoals acetylering, ubiquitilering, sumoylering en fosforylering
transactivatie beïnvloeden. Bovendien kunnen mutaties in het AR gen
gevolgen hebben voor de AR transac
fenotype is aangetast. Echter, de exacte invloed van deze modulerende
en factoren
Wat is de invloed van AR fosforylering op AR isovormen
transactivatie ? 
raag 2: Wat is het effect van de nieuwe mutatie F826L op AR transactiv
Vraag 3: Kunnen bestaande en nieuwe AR co-factoren met een olig
bindingsmethode worden geïsoleerd uit AR complexen.
Er zijn voldoende aanwijzingen dat fosforylering de functie v
steroidhormoonreceptoren beïnvloedt. Bekend is dat de AR wordt gefo
maar het effect van fosforylering op AR functies is onbekend. In de ex
beschreven in Hoofdstuk 2 werd duidelijk gemaakt dat de fosforylering
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direct de transcriptie activatie, NH2-/COOH-terminale domein interactie
activatie door transcriptional intermediary factor 2 (TIF2) te beïnvloeden.
is dat de-fosforylering van serine 650 wo
en de co-
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van deze
ectie van in
den uit een
n al bekend
atie kunnen
beïnvloeden. Van 5 andere gebonden eiwitten was bekend dat ze de transactivatie
van andere steroidhormoonreceptoren beïnvloeden. Daarnaast werden er 32 
eiwitten gevonden waarvan bekend was dat ze betrokken zijn bij transcriptie 
regulatie van verschillende genen, echter niet specifiek van AR gereguleerde genen.
Bovendien zijn er 25 eiwitten geïsoleerd met een RNA bindende of “RNA-
processing” functie. Tot slot, van 4 eiwitten is de functie onbekend. Wanneer een
ndere potentiële fosforyleringsplaats (serine 515). 
Androgeen signaaltransductie is belangrijk voor de
geslachtsontwikkeling tijdens de embryogenese. Een defecte androg
transductie in een individu kan leiden tot AIS, dat behoort tot de stoorn
geslachtsontwikkeling, en hoofdzakelijk wordt veroorzaakt door mutatie
gen. In Hoofdstuk 3 is de studie van de nieuw geïdentificeerde F826L m
AR beschreven. Deze mutatie werd gevonden in het AR gen van een
een ernstige penoscrotale hypospadie (geclassificeerd als 46,XY DSD).
is dat de LBD mutatie geen invloed heeft op de AR transactivatie, de liga
de AR eiwit stabiliteit, de kinetiek van de subcellulaire AR localisatie en
co-repressie. Echter, deze mutatie resulteerde wel in een tweemaal ho
/COOH-terminale domein interactie en ook in een verhoogde TIF2 co-a
F826L mutatie kan mogelijk het AR functioneren negatief beïnvloe
manier die niet detecteerbaar is met de gebruikte functionele te
alternatieve verklaring voor de ernstige penoscrotale hypospadie zou k
at de AR mutant, in genitale huidfibroblasten, een ander reperto
activatoren, exclusief TIF2, rekruteert. Een andere mogelijkheid is d
veranderde LBD conformatie, een preferentiële binding van co-re
exclusief N-CoR, plaatsvindt in specifieke androgeen doelwitcellen.
Bij de transcriptie regulatie van genen is een groot aantal co-factoren
Veel AR co-factoren zijn geïsoleerd door middel van isolatie-procedures
binding aan specifieke DNA sequenties ontbreekt. Echter, er zijn
aanwijzingen dat specifieke binding aan DNA belangrijk is voor co-factor
Om de co-factor rekrutering door de AR te onderzoeken is gebruik ge
oligonucleotiden die de ARE1 van de PSA promoter bevat of een nie
versie van de ARE1 (Hoofdstuk 4). Geïdentificeerde eiwitten werden ge
het bezit van één of meer van de volgende bekende eigenschappen
localisatie, betrokkenheid bij transcriptie regulatie, betrokkenheid bij ster
functie of specifieke betrokkenheid bij AR functie. De toepassing
zogenaamde “oligonucleotide-based assay” (OBA) resulteerde in de sel
totaal 85 eiwitten die met de AR in combinate met DNA werden gebon
kernextract van LNCaP-cellen. Hiertoe behoorden 11 eiwitten, waarva
was dat ze kunnen interacteren met de AR en tevens AR transactiv
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strictere selectie op basis van het aantal unieke peptiden werd toegep
we, in vergelijking met de scrambled oligonucleotide, een specifieke ver
eiwitten met de ARE1 olignucleotide. Eén van deze eiwitten, DDX17, is
als een co-factor voor de oestrogeenreceptor Į (ERĮ). Deze studie i
waarin DDX17 wordt geassocieerd met een AR functie. Geconcludeerd
d
ast, vonden
rijking van 7
beschreven
s de eerste
kan worden
eiwitten en
ven in de
Er worden
fosforylering
enoscrotale
iscussieerd.
Tevens wordt aangegeven welke studies er kunnen worden uitgevoerd om de 
functies van de nieuw geïdentificeerde co-factoren in het werkingsmechanisme van 
androgenen te onderzoeken. 
at de ARE in de OBA de isolatie van bekende AR interacterende
nieuwe potentieel AR interacterende eiwitten mogelijk maakt. 
In Hoofdstuk 5 worden de resultaten van de studies, beschre
Hoofdstukken 2, 3 en 4, bediscussieerd in een breder perspectief.
mogelijkheden geopperd voor nieuwe studies naar een relatie tussen
en AR functie. Nieuwe studies naar de mogelijke oorzaak voor de p
hypospadie van het 46,XY individu met de F826L mutatie wordt ook bed
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Gert, Marja, Esther, Willy, Jan (Vreeburg), Joost, Iris en Eveline. Ik was vaak aan
jullie kant te vinden doordat veel van de door mij gebruikte apparatuur aan jullie kant
stonden en ik geen zin had om heen en weer te lopen. Maar ik was daar ook omdat 
daar de meest hilarische dingen gebeurden en daar was ook de vrijdagse whiskey
Eindelijk, het laatste stukje tekst. Het promotieonderzoek ging niet van ee
De eerste paar maanden waren er al apparatuur problemen. Collega
zelfs in de kou staan al die jaren, letterlijk nog wel, voor 1-2 uren per w
koelcel van 4° C……om experimenten uit te voeren. Door mijn out
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ou toch draaglijk en gelukkig heb ik van hen nog veel hulp gek
uiteenlopende zaken.
Maar eerst wil ik mijn promotor Anton en copromotor Albert bedank
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Jeroen Demmers, Karel Bezstarosti, Ka Wan Li, Henk Dekker, Luitze
Esther Schippers, Sten Drop, Dennis Dooijes, Wim Kleijer en Katja Wolff
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Dennis en Michel aan hoofdstuk 3 waren meer dan welkom. 
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Raymond, Kakuan, Yee Ling, Danny, Huiqiong, Haylie, Tom, Tri, vele
heb ik al die jaren vaak moeten teleurstellen, omdat mijn werk voor p
Maar de keren dat ik jullie zag, was het een ontzettende vrolijke boel. D
kon ik af en toe goed gebruiken. De komende periode zal ik wat meer ti
hebben. Hopelijk gaan jullie dat niet vervelend vinden. Het zal wel even
voor jullie :p. Olá Sílvia, surpresa! You probably expected a thank you
way I wanted to thank you for the support year in year out for my stud
since 2000. I still want to visit you in Portugal, if I’m welcome and if I ca
friends to join me. Last but not least Chi-
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Mocht ik nog iemand vergeten te bedanken, mijn excuses daarvoor. Jullie ook
b
া㽕໩䱑⛵
ed: As long as the sunset is infinitely
beautiful, why melancholy about the coming dusk.
Tot slot, wens ik iedereen het allerbeste en veel succes met allerlei plannen! 
Hao Yun
௯ႆ
“Life is not the amount of breaths you take, it's the moments that take your breath 
away” (Hitch). 
edankt, natuurlijk.
De periode als promovendus beschouw ik als het volgende gezegde:
䰤དΤԩ䷜ᚚᚉ䖥咗ᯣǄFreely translat

